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CHAPTER 1
Cellular & Molecular Aspects of Bone Regeneration
1.1 Bone
Bone is a rigid organ, constituting the human skeleton that supports and
protects various organs of the body to maintain their function as a universal
system. Bone tissue is connective tissue, which is composed of mineralized
extracellular matrix in which different cell types, i.e. osteoblasts, osteoclasts,
and osteocytes, are embedded for reconstruction, remodeling, resorption and
mineralization processes of bone tissue. Bone defects can be caused due
to various reasons, e.g. trauma, skeletal abnormalities, tumor resection and
congenital disorders. In response to injury, bone has an intrinsic ability
for regeneration, remodeling and repair. Although bone possesses these re-
markable self-healing and regeneration capacities, in many clinical cases the
regeneration of bone defects, especially those that exceed the critical size
dimensions, this self-healing potential is insufficient to completely heal the
defect. Consequently, critical size bone defects cannot be healed without
surgical intervention [1] and represent a clinical challenge for surgeons that
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is related to finding an appropriate method for bone defect healing [2]. Cur-
rently, the general treatment for bone defects is the use of autologous bone
grafts (from the patient) or allograft (from a donor), the former which has
become established as the ”gold standard” in bone reconstructive surgery.
However, these approaches have many limitations, including size limitation
of available tissue, second surgery, donor site morbidity, risk of rejection and
disease transmission (latter only when using allograft). Alternative treat-
ment options for bone grafting are the use of alloplastic or allogenic materi-
als, either or not in combination with adult stem cells (mesenchymal stromal
cells [MSCs]) and/or signaling molecules (e.g. growth factors) [3]. In view of
the promises of tissue engineering, regenerative medicine and adult stem cell
technology, bone regenerative research is heavily focused on strategies that
combine scaffolds, cells and signaling molecules. To achieve an advance level
in tissue engineering strategies, it is important to understand the influence
of scaffold properties (stiffness, topography), signaling factors (hormones,
growth factors), metabolic (oxygen, Ca2+) and inflammatory factors on cel-
lular behaviour and osteogenic differentiation (Figure 1.1). This thesis is
mainly focused on cell-cell and cell-biomaterial based aspects of bone regen-
eration involving adult stem cell-based approaches for (future) application in
bone regenerative research and therapy.
1.2 Cell-based strategies in bone regenera-
tive approaches
Among various cell types used in tissue engineering approaches, mesenchy-
mal stromal cells (MSCs) have received major attention, because of their
proliferation and multipotent differentiation potential, including differentia-
tion into the osteogenic lineage. MSCs can be harvested from various tissues,
including adipose tissue (AT), bone marrow (BM), cord blood, dental pulp,
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skin, and placenta. However, the yield of MSCs isolated from these diverse
tissues is different [5]. In view of this and because of apparent osteogenic
potential, BM-MSCs and AT-MSCs are the most frequently used adult stem
cells in bone regeneration research [6, 7, 8]. Still, the easy accessibility, low
morbidity and relatively high yield make AT the most logical choice as the
source for MSCs compared to other tissue sources [6, 9].
Figure 1.1: Factors involved in mesenchymal stromal cell differentiation [4].
A. Cellular components and cell-cell interaction, B. Secreted signaling factors and signal
transduction,C. Inflammation and influence on osteogenic differentiation,D. Extracellular
matrix formation, E. Influence of physical factors, F. Metabolic factors.
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1.3 Cell-cell interaction & crosstalk
To develop cell-based bone regenerative strategies, it is necessary to un-
derstand natural bone regeneration, remodeling and fracture healing pro-
cesses. All of these are complex physiological processes, involving multiple
cell types (e.g. MSCs, angiogenic cells, immune cells) and multiple factors
(acting through different signaling pathways), which coordinate cell migra-
tion, proliferation, osteogenic differentiation and extracellular matrix for-
mation [10]. Bone is a highly vascularized tissue and vascularization is an
essential process during bone fracture healing and regeneration (Figure 1.2)
[11].
Figure 1.2: Cellular crosstalk and bone formation [4].
Representative schema for the illustration of cellular composition during bone formation.
Communication between the cells functioning either direct or indirect contact. Direct
contact: cell-cell adhesion, receptor interaction and subsequent signal activation. Indi-
rect contact: cell-cell interaction via secreted factors and subsequent signaling pathway
activation.
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To mimic the natural bone micro-environment, co-culture systems have been
introduced, in which MSCs (from different origin) were cultured together
with endothelial cells or macrophages. These research efforts have shown
that the co-culture of MSCs with endothelial cells promotes mineralization of
MSCs in vitro and bone formation in vivo [12, 13, 14]. Several studies suggest
that macrophages also play a crucial role in bone regeneration, because they
are involved in the early responses of wound healing, extracellular matrix
formation [15, 16, 17], and secrete a plethora of signaling molecules that are
linked to multiple processes during osteogenesis [18, 19].
1.4 Importance of Signaling Mechanisms in
Osteogenic Differentiation
In the natural bone regeneration processes, signaling molecules, secreted by
cells into the extracellular matrix, act in an autocrine, paracrine, or en-
docrine manner to affect cell proliferation and osteogenic differentiation of
MSCs. Signaling pathways are downstream effectors of these external stim-
uli and responsible for cell-cell interactions and osteogenic differentiation
via specific signal transduction [20]. It has been proven that specific ex-
tracellular signaling molecules (i.e. bone morphogenetic proteins (BMPs),
transforming growth factor-betas (TGFβs), Wnts, fibroblast growth factors
(FGFs), platelet-derived growth factors (PDGF), and insulin-like growth fac-
tors (IGFs)), and their activated signaling pathways are directly involved in
osteogenic differentiation and bone formation [21]. Understanding molecular
mechanisms of bone regeneration (i.e. signaling pathways that are involved in
bone regeneration) will help to control cellular responses in cell-based bone
tissue regenerative strategies and optimize the efficacy thereof.
6 Chapter 1: Cellular & Molecular Aspects
1.5 Scaffolds for bone tissue regenerative treat-
ment
In addition to cells, the choice of a biomaterial as a scaffolding structure,
is critical for the achievement of successful regeneration. To mimic the 3D
micro-environment of bone, several scaffold systems (either from natural or
synthetic origin) have been introduced in bone regenerative research. Among
these, ceramic-based biomaterials, including calcium phosphates (CaPs; e.g.
hydroxyapatite and tricalciumphosphate), and polymer-based organic ma-
terials, including collagen and gelatin, are being widely used in the clinic
[22, 23, 24]. However, the ideal scaffold system should possess several proper-
ties, including biocompatibility, osteoinductive & osteoconductive capacities,
ability of fluid transport, delivery of bioactive molecules, surface topography
(recognized by cells), degradability and ability to induce signal transduction
in cells [25]. So far, none of the developed scaffolds can pass all necessary
requirements. Some studies indicate that physical properties of scaffolds (e.g.
topography, stiffness) can enhance the osteogenic differentiation of MSCs in
vitro [26], because cell-biomaterial interactions can promote the activation
of specific intracellular pathways and appropriate signal transduction. For
example, matrix stiffness can activate the intracellular signaling of MSCs,
by help of mechano-transducers: focal adhesion kinase (FAK) and Rho ki-
nase (ROCK), which affect the osteogenic phenotype of MSCs [27]. In view
of the promises of tissue engineering, future generation biomaterials should
provide controllable signals to loaded MSCs for subsequent osteogenic dif-
ferentiation. Next, the chemical properties of biomaterials have shown to
influence MSC proliferation and osteogenic differentiation [28]. For example,
CaP-based biomaterials have high potential to affect osteogenic differenti-
ation of MSCs, because CaP-based biomaterials can absorb osteoinductive
proteins and release Ca2+ irons [29].
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1.6 The objective of this thesis
The research described in this thesis aimed to study cellular and molecular
aspects of cell-cell and cell-biomaterial interactions, with emphasis on MSCs
and their interaction with both biomaterials and other cell types. More spe-
cifically, the following research questions were addressed:
1. Which signaling pathways are involved in osteogenesis and how can
the knowledge on these signaling pathways be applied to improve the
success of bone regenerative medicine?
2. To what extent do cell culture supplements (with their signaling molecules)
affect osteogenic differentiation of human BM-MSCs and AT-MSCs?
3. How does co-culture of human AT-MSCs with endothelial or hematopoi-
etic cells affect the osteogenic signalling and differentiation of MSCs?
4. To what extent does the amount of CaP nanoparticles in a composite
collagen/CaP gel system affect MSCs behavior and osteogenic differ-
entiation?
5. Do surface features of CaP-based ceramics affect cellular organization
and osteogenic differentiation of AT-MSCs?
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CHAPTER 2
Signaling pathways involved in osteogenesis & their
application for bone regenerative medicine
2.1 Introduction
One of the challenges for bone regeneration research is to identify proper
strategies for defect repair and regeneration. For orthopedic surgery, the most
important problem is how to repair large (segmental) skeletal bone defects
originating from various pathological problems, including postmenopausal
osteoporosis, resection of metastases due to breast and prostate cancer, and
several metabolic diseases [1, 2]. Only in Europe, annually about one million
patients need a bone reconstructive surgery and this number is increasing
every year [3]. In the US, over sixty million people are expected to be diag-
nosed with osteoporosis or low bone mass by the year 2020 [4, 5].
So far, bone autografts (i.e. patient’s own bone) remain the gold standard for
bone regenerative treatments because of the efficacy, safety and immunocom-
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patibility of autografts. However, the harvest of autologous bone is associated
with several disadvantages, including fracture potential, second surgery at
the ’donor’ site, size and shape differences, and limitations in volume (max.
about 20 cm3) and quality [2, 6]. An alternative option for bone regener-
ative treatments is to use bone allograft (donor bone from another human
being), but this may lead to transfer of diseases and immunological rejec-
tion [7]. Because of the increasing number of bone regenerative treatments
and hence demand for reliable grafting material, it is imperative that the
multidisciplinary field of biomaterials, in collaboration with the medical de-
vice industry, develops bone substitutes (i.e. alloplasts) that meet the clinical
and commercial requirements and fully exploit the potential of these bone
substitutes to harness the body’s own healing capacity for defect healing [5].
2.2 Bone & bone regenerative treatment
Bone is a mineralized tissue rich with inorganic calcium phosphates (i.e.
biological apatite), in which the mineralized extracellular matrix provides a
natural scaffold for native cells and homeostasis. Bone regeneration involves
a series of biological processes, in which multiple cell types (e.g. osteoblasts,
osteocytes, osteoclasts, and osteoprogenitors) and multiple extracellular and
intracellular signaling networks are involved. Finally, bone tissue possesses
an intrinsic regeneration capacity during skeletal development and during
bone remodeling throughout the entire life to respond to injury and trauma
[3, 8, 9].
Current strategies in bone regenerative medicine are focused particularly on
the biomaterial characteristics for the generation of material- and cell-based
bone substitutes (alloplasts) that trigger the endogenous healing capacity of
the human body [2, 5]. A critical aspect of bone regenerative medicine is
to design three-dimensional (3D) scaffolds, in which different cell types (os-
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teoblasts, endothelial cells, etc.) can grow and generate the complex struc-
ture of bone tissue [5]. Furthermore, new generation of 3D scaffold systems
should meet several criteria, such as osteogenic activity, fast integration with
surrounding tissue, and biocompatibility in order to provide successful tissue
regeneration. To develop an advanced bone substitute, it is necessary to un-
derstand the osteogenesis and bone regeneration/remodeling processes in na-
ture. Full understanding of signaling mechanisms responsible for osteogenesis
will help to optimize current strategies and create new approaches in bone re-
generative medicine. In view of this, it is of utmost importance for the field of
regenerative medicine to understand the function of bioactive molecules (e.g.
growth factors, cytokines and hormones) and their interplay with endogenous
signals, which are driving the cells into osteogenic differentiation. Addition-
ally, the question whether biomaterial properties contribute to cell signaling
toward osteogenesis requires attention. Various proteins/growth factors are
already being explored in bone regeneration research because of their high
therapeutic potential [10]. Although many studies show that such molecules
can have a direct and crucial role, their exact molecular mechanisms have not
been fully unraveled [11], or these mechanisms are not very well known in the
regenerative medicine community. Consequently, the aim of this review is to
provide an overview of the molecular mechanisms and complexity of actions
of osteogenic molecules and their signaling cascades, which are important for
bone regeneration and tissue engineering strategies. The understanding of
cross-activation and complex signaling of these molecules will lead in the near
future to the design of advanced bone substitute materials. Furthermore, de-
tailed knowledge about regulation of signaling mechanisms in different cell
types and molecular consequences of cell-biomaterial interactions will help
to control the regeneration of bone defects inside the body.
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2.3 Mesenchymal stromal cells for bone re-
generative treatment
An adequate supply of bone precursor cells in designed scaffolds is important
for efficient bone regeneration. Current approaches using mesenchymal stro-
mal cells (MSCs) in bone regenerative research have received considerable
attention, because of the potential of MSCs to differentiate into adipocytes,
chondrocytes, osteocytes and several other cell types [12]. It is also known
that many tissues, including bone marrow, adipose tissue, periodontal liga-
ments, dental pulp, muscle tissue, blood vessels and others, contain tissue-
specific MSCs [13]. Therefore, the differentiation potential and quality of
MSCs from all of these sources needs to be examined before considering these
cells as effective cell types for tissue regeneration purposes [10]. In general,
the characterization of MSC is based on the expression of surface antigens,
such as CD44, CD73 CD90 (Thy1), CD105, CD106, CD166 [14, 15]. Based
on this surface antigen specificity, the International Society for Cellular Ther-
apy (ISCT) has defined characterization criteria for MSCs, which include that
MSCs require to be positive at least for CD73, CD90, and CD105 and neg-
ative to CD45, CD34, CD14, (< 2%) [16]. In addition, MSCs need to have
several other characteristics, such as adherence to plastic and multilineage
differentiation capacity [14, 15, 17].
Because of their high osteogenic potential, MSCs isolated from bone marrow
(BM-MSCs) are the most popular cell population in bone tissue regeneration
research [18]. Despite the fact that BM-MSCs meet all of the criteria, as indi-
cated above, several disadvantages related to the isolation of BM-MSCs (es-
pecially the invasive harvesting methods) have stimulated scientists to search
for alternative sources of MSCs. Recently, research efforts have focused on
MSCs isolated from adipose tissue (AT-MSCs) because of their multi-lineage
differentiation capacity and large similarity to BM-MSCs in terms of surface
antigen expression, osteogenic differentiation, and adherence to the plastic
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[16]. However, in contrast to BM-MSCs, AT-MSCs are much easier to ob-
tain, donor morbidity is very low and large numbers of cells can be harvested
from relatively small volumes of adipose tissue. AT-MSCs are also more
stable after expansion and after cryopreservation compared to BM-MSCs
[12]. Further, it has been proven that AT-MSCs are able to secrete many
growth factors, most of which have angiogenic as well as osteogenic capacities
[14, 19]. For instance, it is known that AT-MSCs produce fibroblast growth
factor-2 (FGF-2) and vascular endothelial growth factor (VEGF), which are
crucial for angiogenic stimulation, but the same growth factors have also os-
teogenic activity [20]. Finally, AT-MSCs have shown several other features
such as self-renewal ability, high proliferation capacity and potential of os-
teogenic differentiation [15]. In view of this, it becomes significant to study
first the key signaling pathways, which lead osteoprogenitor cells to differ-
entiate into osteoblasts, in order to understand the potential of other MSCs
(from different origin) to pass complete osteogenic differentiation [21].
2.4 Growth factors, hormones & their signal-
ing activity
Growth factors (e.g. cytokines, hormones) are proteins, which regulate a
large variety of cellular processes. They act as signaling molecules between
cell-cell interactions and usually interact with their specific receptors on the
surface of the target cell. Growth factors are secreted by cells into the extra-
cellular matrix and act in an autocrine, paracrine, or endocrine manner to
affect cell proliferation, differentiation and maturation. Thus, growth factors
regulate cell signaling from an extracellular level until target gene expression
and protein synthesis in cells [5]. Every signaling molecule is responsible for
a particular signaling pathway activation and signal transduction. There are
two general signaling mechanisms that can transfer external signals to the
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nucleus. The first mechanism is typical for exogenous lipophilic signaling
molecules, which are able to penetrate cellular membrane and interact di-
rectly with transcriptional regulators. The second mechanism is typical for
hydrophilic molecules (i.e. growth factors and cytokines), which are not able
to penetrate the cell membrane. However, these molecules are intercepted
by trans-membrane receptors, and transmit a second message or secondary
reaction into the cytoplasm. At the intracellular level, this second message
stimulates transcription factors (second messenger molecules) to be activated
via mechanism of posttranslational modification, e.g. phosphorylation [22].
Within the nucleus, the active (phosphorylated) factors (ee.g. transcription
factors, co-activators, co-repressors) interact with regulatory DNA motives
(i.e. with promoter, enhancer or silencer regions) giving rise to transcription
(more detailed description of signal transduction mechanism see reference
[22]). The mechanism of many growth factors/cytokines from extracellular
level until target gene transcription has been already unraveled and it has
been proven that many of them (i.e. bone morphogenetic proteins (BMPs),
transforming growth factor-betas (TGFβs), Wnts, fibroblast growth factors
(FGFs), platelet-derived growth factors (PDGF), and insulin-like growth fac-
tors (IGFs)), are directly involved in osteoblast activity and local bone for-
mation [23].
2.5 Molecular pathways & osteogenesis
2.5.1 BMP/TGF-β pathway
BMP/TGF-β pathways are major signaling cascades responsible for osteo-
genesis [24, 25]. BMP/TGF-β signaling is involved in the vast majority of
cellular processes that are responsible for bone formation during mammalian
development [26, 27]. The disruption of BMP/TGF-β signaling causes mul-
tiple bone disorders such as tumor metastasis, brachydactyl type A2, and
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osteoarthritis (Table 2.1, Table 2.2) [28].
BMPs and TGF-βs are cytokines that belong to the TGF-β superfamily,
which includes approximately 40 members divided in several subgroups: BMPs,
TGF-βs, Nodal and Activins [29, 30]. In order to start signaling, BMP/TGF-
βs interact with BMP or TGF-β specific type 1 and type 2 serine/threonine
kinase receptors [31, 33]. Accordingly, the BMP/TGF-β regulated cascade
is transmitting the signal into the cytoplasm via both canonical (i.e. Smad-
dependent pathways; BMP/TGF-β ligands, receptors and Smads) and non-
canonical pathways (i.e. Smad-independent signaling pathways; e.g. p38,
mitogen-activated protein kinase: MAPK (Figure 2.1) [24].
In canonical pathways, 8 different types of Smad proteins are involved. Ac-
cording to their function Smads are divided in three classes. The first class
is the receptor-regulated Smad family or R-Smad (Smad 1, 2, 3, 5 and 8;
Figure 2.1). Smad 1, and 5 are usually activated by BMP extracellular sig-
nals, and Smad 2 and 3 are activated by TGF-β extracellular signals [37].
The second class is common-mediator Smad (co-Smad), which includes only
Smad 4. Smad 4 forms a complex with co-Smads, penetrates into the nu-
cleus, then interacts with DNA promoter region and as a transcriptional co-
activator participates in transcription. The third functional class of Smads
is the inhibitory Smad family or I-Smads (Smad 6 and 7), which are negative
regulators for BMP/TGF-β-Smad signaling cascade. I-Smads also mediate
receptor inactivation of other Smad classes (class 1, 2) [38]. Non-canonical
TGF-β signaling also participates in osteoblast differentiation, osteoprogen-
itor cell proliferation and bone formation [41]. This pathway includes many
signaling molecules, which mainly belong to mitogen-activated protein kinase
family, MAPKs (for a more detailed description of MAPK cascades see ref-
erences [38, 41]). The MAPK cascade is a widely studied signaling pathway,
which has been shown to be involved in important cellular programs, such as
cell differentiation, movement, division and death [39]. In the context of bone
regeneration, the P38/MAPK activation cascade has a crucial function for an
efficient induction of osteoblast differentiation. This cascade (P38/MAPK)
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is involved in alkaline phosphatase (ALP) and osteocalcin (OC) expression in
osteoblastic cells, providing evidence that these MAPKs have distinct roles
in regulating osteoblast differentiation (Figure 2.1 , Figure 2.2) [42].
Figure 2.1: Canonical/non Canonical TGFβ/BMP2 Pathways
TGFβ regulate heteromeric complex formation between TGFβ specific type I and type II
serine/threonine kinase receptors [31, 32, 33]. BMPs start signaling via the activation of
two types of serine/threonine kinase receptors (BMP type I and BMP type II) [34, 35, 36].
This complex formation is important and sufficient for Smad and other non-Smad signaling
activation, because this complex leads to the phosphorylation and activation of the type
I receptors in cytoplasmatic site [31]. The signal transduction regulated by BMP/TGFβ
is directed to both canonical (Smad-dependent pathways; BMP/TGFβ ligands, receptors
and Smads) and non-canonical signaling pathways (Smad-independent signaling pathway;
e.g. p38, mitogen-activated protein kinase (MAPK) pathway) to the cytoplasm [24]. The
canonical BMP/TGFβ pathway starts signaling in the cell surface via the interaction with
specific receptors. In the cytoplasm activated receptors are interacting with R-Smads
(Smad 1, 5 and 8). With the same mechanism the TGFβ extracellular signals can be
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activated with Smad 2 and 3 [37]. Prior to phosphorylation, R-Smads (Smad 1, 2, 3,
5, 8) form heteromeric complexes with Smad 4 (common mediator Smad class or co-
Smads). After complex formation the entire complex is translocated into the nucleus and
accumulated there prior to regulate the transcription of target genes in combination with
other transcription factors [37, 38]. The Smad 6 and 7 (inhibitory Smads or I-Smads) are
negative regulators of BMP/TGFβ - Smad signaling and mediate receptor inactivation of
other two other Smads classes [37, 38]. In non canonical signaling pathways, the TGFβ
activation kinase 1 (TAK1) and TAK1 binding protein 1 (TAB1) play a crucial role for
upstream signal activation followed by MKK3/6 and P38/MAPK. TAK1 regulates MKK3
and p38/MAPK protein levels in the entire MAPK cascades [24, 39]. Therefore, the TGFβ
induction in either Smad dependent or independent pathways translocates the signal into
the nucleus, leading to Runx2 transcriptional gene control [40].
Figure 2.2: Ca2a+ signaling and Wnt signaling.
Ca2a+ signaling: Runx2 mediates ATP-dependent Ca2a+ influx via the calcium channels
with the help of protein kinase C (PKC), Src family kinase, protein kinase A (PKA), and
further via the phosphorylation of focal adhesion kinase (FAK) and proline-rich tyrosine
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kinase 2 (PYK2) [43]. The cytoplasmic Ca2a+ promotes phospholipase C (PLC) activ-
ity and inositol-1,4,5-trisphosphate (IP3) signaling [44]. The increase of cytoplasmatic
Ca2a+ promotes subsequent PKC and Ras activity, which are involved in activation of
the MAPK pathway via the ERK1/2, JNK activation and upregulation of c-fos and c-Jun
expression [45]. The c-fos gene product together with c-Jun protein forms the activator
protein-1 (AP-1). AP-1 is a transcription factor that binds to the promoter region of
mechano-sensitive genes [44]. This mechanical stimulation leads to upregulation of sev-
eral growth factors, such as insulin-like growth factor (IGF I and II), vascular endothelial
growth factor (VEGF), TGFβ, and BMP2 and BMP4, which start signaling on the cell
surface [44, 46, 47]. On the cell surface, Ca2a+ interacts with G-protein coupled recep-
tors (GPCRs) and activates this machinery. The most widely described GPCR pathway
involving Ca2a+ is the calcium sensing receptor machinery (CaSR). Also PLC can be ac-
tivated by GPCRs, resulting in synthesis of IP3 and its signaling activation [48]. The
PKA signaling activated by Ca2a+ can induce FGF-2 gene expression (identification in
cementoblasts) [49]. In osteoblasts, Ca2a+ induces phosphorylation of ERK1/2. This
phosphorylation is significantly reduced in the presence of a CaSR antagonist [50].
Wnt molecules activate at least three distinct intracellular signaling cascades: Wnt/β-
catenin pathway (canonical), Wnt/Ca2a+ pathway (non canonical), and Wnt/planar po-
larity pathway. The ligands (Wnts) of canonical pathway first form a complex with FZD
and low density lipoprotein (LDL) related protein 5 (LRP5) or LRP6 receptors that lead
to signal initiation, and translocate the signal into the cytoplasm. Within the cytoplasm,
this complex inhibits the activity of glycogen synthase kinase 3 (GSK-3) with the help
of several proteins (i.e. Disheveled, Axin, and Frat-1). Wnt pathway-dependent/GSK3
inhibition helps to stabilize β-catenin level in the cytoplasm [51]. GSK-3 inactivity blocks
the phosphorylation of β-catenin, which prevents degradation of β-catenin in the cyto-
plasm leading to its translocation into the nucleus. In the nucleus, β-catenin first forms a
complex with Tcf/Lef transcription factors (T-cell/lymphoid enhancer transcription factor
family) and activates target gene transcription [25, 51]. The Wnt/planar polarity pathway
activates Rho/Rac GTPases and Jun N-terminal kinase (JNK) to modulate cytoskeletal
organization and gene expression [52].
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Table 2.1: Most Important BMP Family Members.
Name Synonyms Main Function
BMP1 None Metaloprotease activity Acts on pro-collagen type I, II, III; Car-
tilage development ; BMP1 does not belong to the TGFβ family
of proteins
BMP2 BMP 2A Induces bone and cartilage formation, osteoblast differentiation.
Plays a role in cardiac morphogenesis
BMP3A Osteogenin Induces bone and cartilage formation.
BMP3B GDF-10 Unknown biological function, it may play a role in osteoblast dif-
ferentiation, augmenting BMP 2 activity.
BMP4 BMP2B;
BMP2-B1,
BMP2-B2,
BMP2-RS1
Induces bone and cartilage formation, involved in regulation of
teeth formation, limbs and bone formation in mesoderm, fracture
repair.
BMP5 None Induces bone and cartilage formation.
BMP6 Vgr-1, Vgr-1
related pro-
tein
Induces bone and cartilage formation and involved in iron home-
ostasis control.
BMP7 OP-
1(osteogenic
protein 1)
Induces bone and cartilage formation, involved in calcium regula-
tion and bone homeostasis, key role in osteoblast differentiation.
Induces the production of Smads. May act as an osteo-inductive
factor responsible for epithelial osteogenesis. Key role in renal
development and repair.
BMP8A OP-
2(osteogenic
protein 2)
Induces bone and cartilage formation, involved in calcium regula-
tion and bone homeostasis. May act as an osteo-inductive factor
responsible for epithelial osteogenesis.
BMP8B OP-
2(osteogenic
protein 2)
Stimulates cartilage and bone formation, implicates in calcium
regulation and bone homeostasis.
BMP9 GDF-2 May be involved in bone formation, involved in chondiriogenesis
BMP10 None Plays a crucial role in trabeculation of embryonic heart
BMP11 GDF-11 Involved in patterning of both mesodermal and neural tissues and
establishing the skeletal muscle. Act globally to specific positional
identity along the anterior/posterior axis.
BMP12 GDF- 7 Induces the formation of tendon and ligament tissues.
BMP13 GDF-6 Plays a role in cartilage homeostasis, involved in the embryonic
skeletal development, and formation if tendon-like tissue.
BMP14 GDF-5 Essential for limb cartilage and limb-joint formation. Involved in
embryonic skeletal development.
BMP15 None Role in oocyte and follicular development.
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Table 2.2: Most Important TGFβ BMP Family Members.
Name Synonyms Main Function
TGFβ1 None Cell growth, proliferation, differentiation apoptosis
TGFβ2 None Regulates cell proliferation, growth, differentiation, and motility.
Involved in adipogenesis, chondrogenesis, embryogenesis, tissue
remodeling, wound healing and tumor formation.
TGFβ3 None Regulates cell proliferation, growth, differentiation, and motility.
Involved in adipogenesis, chondrogenesis, embryogenesis, tissue
remodeling, wound healing and tumor formation Cellular adhe-
sion, extracellular matrix formation.
TGFβ4 None Essential for left-right asymmetry determination of organ systems.
2.5.2 Ca2a+ signaling
Ca2+ signaling plays an important role in the osteoblast differentiation pro-
cess. Via diverse signaling pathways, Runx2 plays the role as a mediator for
ATP-dependent Ca2+ influx through calcium channels. The increasing level
of cytoplasmic Ca2+ promotes phospholipase C (PLC) activity and inositol-
1,4,5-trisphosphate (IP3) signaling. The increasing level of cytoplasmic Ca2+
promotes phospholipase C (PLC) activity and inositol-1,4,5-trisphosphate
(IP3) signaling (39). This signaling leads to a release of Ca2+ from intracel-
lular stores (mainly from the endoplasmatic reticulum) [53]. The increased
cytoplasmatic Ca2+ further promotes upregulation of the transcription factor
AP-1, which binds to the promoter region of mechano-sensitive genes. This
leads to upregulation of several growth factors, such as insulin-like growth
factor (IGF 1 and 2), vascular endothelial growth factor (VEGF), TGFβ,
BMP2, and BMP4 (for more details on mechanism of Ca2+ signaling see
reference [44]). These growth factors (i.e. VEGF, TGFβ and BMPs) start
signaling on the cell surface via autocrine and paracrine mechanisms (i.e. cell-
cell communication and signaling) [46, 47]. Full screening of the mechanism
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of Ca2+ signaling will help to improve the understanding of the biological pro-
cess of osteogenesis and bone regeneration. The mechanism of Ca2+ signaling
may also explain how CaP particles can enhance osteoblastic activation and
high mineralization capacity of osteoprogenitor cells [54]. Moreover, it is
proven that CaP crystals fail to induce expression of an osteoblast character-
istic set of genes when upstream activators of ERKs (MAPK signaling) are
blocked (identification in mouse embryonic fibroblasts), which provides an
evidence about the relation between Ca2+ and MAPK signaling (Figure 2.2)
[55].
It is also known that Ca2+ channels can be activated by CaP crystals (identi-
fication in a mouse embryonic fibroblast cell line) and by free Ca2+, dissolved
from hydroxyapatite, which leads to an increase of osteopontin (OP), bone
sialoprotein (BSP) and ALP expression [56]. It is proven that Ca2+ is a lig-
and for G-protein coupled receptors (GPCRs) [48]. These GPCRs have been
identified in both osteoblasts and MSCs [57]. Several other receptors, which
are responding to Ca2+ fluctuations, belong to this GPCR family. Members
of this family are metabotropic glutamate receptors and their activity has
been correlated with osteoblast function [58]. Ca2+ can also enter to the
cytoplasm via the gap junction, hemi-channels or via the activation of Notch
signaling pathway [59].
2.5.3 Wnt pathway
Wnts (for wingless) are a large family of ligands for the membrane-spanning
frizzled (FZD) receptors. Frizzled receptors belong to G protein coupled re-
ceptor family that are activating only with Wnt ligands. Wnt pathways are
involved in various cell activities, such as proliferation, growth, differentia-
tion, fate determination, polarity, migration, and cell death. Wnt signaling
plays an important role in osteoblast differentiation and mineralization pro-
cesses. Wnts activate at least three distinct intracellular signaling cascades:
Wnt/β-catenin pathway (canonical), Wnt/Ca2+ pathway (non-canonical),
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and Wnt/planar polarity pathway (Figure 2.2 and 2.3) [60, 61]. There are
several studies, which indicate that canonical Wnt pathways play a criti-
cal role in bone formation, because of their involvement in the expression
of osteoblast-specific gene markers [25]. The Wnt/planar polarity pathway
modulates cytoskeletal organization via the activation of osteoblast-specific
gene expression [51, 52].
Figure 2.3: Signaling networks involved in osteoblast differentiation and
molecular crosstalk between signaling pathways.
FGF signaling: The members of fibroblast growth factors (FGFs) family can bind to seven
different isoforms of FGF tyrosine kinase receptors (FGFRs).
IGF signaling: It is known that IGFs can activate the signaling via the activation of
ERK or phosphatidylinositol 3-kinase (PI3K) pathways. IGFs involved also in osterix
upregulation via the BMP independent pathway, which is followed by PKC activated
pathway and RUNX2 indirect activation [25].
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2.5.4 FGF pathway
The FGF pathway has been shown to be involved in osteogenesis as well
as several other cellular processes, such as angiogenesis and wound healing
[62]. In osteoprogenitor cells, the role of the FGF pathway is critical in
the controlling process of endochondral and intramembranous signaling [63].
Normally, the FGF pathway stimulates osteoblast differentiation and inhibits
osteocyte differentiation. Therefore, in osteoblast maturation process, FGF
signaling has stage-specific effects [64]. To date, a total of 23 FGF family
members are known that are able to interact with 4 different tyrosine kinase
receptors. It has been shown that Runx2 is phosphorylated and activated by
FGF2 via the MAPK pathway, which suggests an important role for FGF2 in
the regulation of Runx2 function and bone formation (Figure 2.3) [65]. Fur-
ther, it is known that FGF2 is secreted by AT-MSCs [25]. The expression of
FGF9 and FGF18 plays a predominant role during embryonic skeletogenesis
[51]. Several studies indicate that FGFR2 (fibroblast growth factor receptor
2) positively regulates bone growth and the anabolic function of osteoblasts
[66, 67]. The FGF pathway activation via FGFR3 regulates cell growth
and differentiation of proliferating chondrocytes, whereas in differentiated
osteoblasts it regulates bone density and cortical thickness [25].
2.5.5 Insulin-like growth factor (IGF) & signaling
IGF signaling is one of the important signaling pathways involved in prolifer-
ation and differentiation of osteoblasts (Figure 2.3). The IGF family consists
of two members, namely IGF1 and IGF2. IGF2 is the most abundant growth
factor in the bone [68]. Both IGFs are expressed in osteoblasts and have sim-
ilar biological characters. They are responsible for stimulation of osteoblast
differentiation and bone matrix deposition. Their function is crucial in ex-
pression of collagens and non-collagenous proteins [25]. However, in contrast
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to IGF2, IGF1 does not influence the proliferation and differentiation of
MSCs toward osteoblasts, but it is an important molecule for longitudinal
bone growth and the maintenance of bone mass [69].
2.5.6 Platelet derived growth factor (PDGF) & signal-
ing
PDGF is an extracellular signaling factor, from which five biologically active
isoforms are known. One of the members of this PDGF family is the VEGFA
subfamily [70]. Several studies indicate that PDGF signaling plays an impor-
tant role in the control of various cell functions in skeleton [71, 72]. However,
the network of PDGF signaling in MSCs has not been fully investigated
yet.The depletion of the β-PDGFR gene in MSCs increases ALP activity
and the expression of osteocalcin, BMP2, Runx2 and osterix at the mRNA
level [73]. More recent studies indicate that the pharmacological inhibition
of PDGFR decreases MSC proliferation, but does not affect osteoblastic dif-
ferentiation [74].
2.5.7 Notch pathway, cellular crosstalk & signaling
Notch pathway is traditionally known for its ability to facilitate short-range
signaling between neighboring cells (cellular communication), coordinating
spatial and temporal regulation of cell fate during embryonic development of
tissues and organisms. Notch pathway is involved in osteoblast differentia-
tion via canonical (BMP/Smads) as well as non-canonical (TGFβ/MAPKs)
pathways [75]. Notch signaling regulates distinct cellular programs in differ-
ent cell types. Notch signaling directly inhibits osteoblast differentiation and
indirectly influences osteoclast differentiation [76]. This pathway is an im-
portant sign for osteoclast maturation and function. There is experimental
evidence, which shows that Notch signaling prevents the differentiation of os-
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teoclast precursors into mature osteoclasts [76, 75]. For the Notch signaling
cascade, cell-cell interactions are required. At the nuclear level, Notch sig-
naling is involved in up-regulation of bone related genes. Notch signaling can
also induce severe osteosclerosis, because it can inhibit Runx2 transactivation
[25].
2.6 Transcription factors
Runx2 (also called Core-binding factor alpha, Cbfa1) is an essential tran-
scription factor for osteoblast differentiation, matrix production and min-
eralization during bone formation [77, 78], because Runx2 regulates down-
stream genes that determine the osteoblast phenotype and function during
skeletogenesis [79]. Runx2 is the key transcription factor in the nuclear mi-
croenvironment that controls the expression of osteogenic genes in response
to physiological signals [5, 25]. In particular, the Runx2 is the master regu-
lator for expression levels of osteogenic marker genes such as alkaline phos-
phatase (ALP), osteopontin (OPN), type I collagen, bone sialoprotein (BSP),
and osteocalcin (OC) [79, 81]. Runx2 regulates the expression of Osterix
(OX), which is a key transcription factor for osteoblast differentiation [43].
In the nucleus, Runx2 binds to osteoblast-specific cis-acting element (OSE2),
which is present in the promoter region of several osteoblast-specific genes
[69, 79, 82]. Runx2 regulates BMP signaling from the cell surface until the
target gene expression (BSP, ALP, OC, etc.) in the nucleus [78, 83]. There-
fore, an appropriate mRNA dosage of Runx2 is crucial for normal bone devel-
opment [84]. However, in mature osteoblasts, Runx2 needs to be suppressed
in order to form mature bone [78].
Runx2 expression is controlled by various extracellular signals including
BMP and fibroblast growth factor (FGFs) pathways [78]. Transcription-
ally, Runx2 is upregulated by BMP2 via the transduction of Smad 1, 3, 5 [5].
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Overexpression of Runx2 may cause several disorders. It has been shown that
overexpression of Runx2 can inhibit adipogenesis and reduce lipid droplet
formation in AT-MSCs. This phenomena result in early osteoblast differen-
tiation and osteoblastic gene expression (ALP and mineral deposition) ac-
tivity in AT-MSCs [84]. A forced expression of Runx2 in non-osteoblastic
cells can also promote expression of the major osteoblast specific genes [79].
BMP/TGF-β pathway is also involved in Runx2 stabilization via the activa-
tion of Smad 5. The Erk activated pathway promotes Smad-induced Runx2
acetylation and stabilization. All these results indicate that Erk signaling
(from BMP/TGF-β) increases Runx2 stability and transcriptional activity
[78].
Osterix (OX) is a transcriptional regulator for the final stages of bone for-
mation. Osterix is a zinc finger protein, which contains specific domains
responsible for osteocalcin and collagen type 1 gene activation. OX-null
osteoblast precursors can express only chondrocyte markers, such as Sox9
and Col2a1, which means that OX-null osteoblast precursors can neither be
differentiated into osteoblasts nor deposit bone matrix. Thus, without OX
bone formation cannot occur [69]. These data prove that OX is a down-
stream regulator for Runx2 able to induce osteoblastic differentiation in
osteo-progenitor cells [43]. However, OX can be induced by other signal-
ing pathways, which are acting in parallel and independent of Runx2. It has
been shown that Runx2 is not sufficient for the BMP-2 mediated OX induc-
tion, because MAPK signaling pathways serve as points where the BMP-2
can effect directly on OX expression [25].
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2.7 The application & future perspective of
signaling pathways in bone regenerative
medicine
The induction of osteogenic differentiation is the basis of bone regeneration,
which is only possible via the activation of responsible signaling mechanisms.
To be able to develop advanced bone substitute materials, it becomes im-
perative to implement the initiation of those signaling mechanisms in the
strategies of bone regenerative research and therapy. Therefore, in bone
regenerative medicine, the involvement of knowledge about cell signaling be-
comes an important concept.
The natural matrix of bone, which is rich with several signaling molecules se-
creted by different cell types (Figure 4a), is able to promote osteogenesis [85].
These molecules activate entire signaling cascades inside cells as described in
the previous sections. An effective implementation of cell signaling knowl-
edge for the improvement of bone regenerative treatments might rely on one
or more of the following possible strategies:
• incorporating signaling molecules via loading or genetic modification of
stromal cells
• exploiting cell-cell interactions
• optimization of material surface properties
• utilization of material degradation products
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2.7.1 Incorporation of signaling molecules or genetic
modification of stromal cells
From the BMP family members, the most appealing osteoinductivity was
observed for BMP2 and BMP7. These particular growth factors already have
become a modulating tool for bone regenerative research, aimed to develop
therapeutic concepts for the restoration and treatment of skeletal defects.
Furthermore, BMP2 and BMP7 are commercially available for clinical use as
human recombinant proteins, manufactured via mammalian cell expression
systems [85]. However, the disadvantage of using BMPs in bone regeneration
is the required high dosage and the related clinical side-effects [86]. The
perspective of bone regeneration via the help of signaling molecules should be
directed to the improvement of expression quality of these proteins inside the
body, preferably via material-based release systems with optimized control
on the release of loaded BMPs.
Alternatively, with the help of advanced gene transfer technologies in the
near future, it will become possible to control MSCs to express an appro-
priate dosage of signaling molecules during the regeneration process [85, 87].
Despite the fact that several studies already show the benefit of gene trans-
fer technologies as a powerful strategy in bone regeneration therapy, the step
from experimental research to clinical practice still requires hurdles from a
scientific, industrial, and ethical perspective.
Genetic engineering technologies have another potential to be involved in
bone regenerative research and therapy. For example, it will be beneficial to
identify and knock out genes, which are negatively regulating osteogenesis.
Recently, because of direct effect on MSCs differentiation into osteoblasts,
Wnt signaling has attracted interest for applications in bone regenerative
research. Therefore, the identification of target molecules from Wnt path-
way could help to promote MSCs into osteoblast differentiation. Several
studies show that pharmacological inhibition of Src (Sarcoma rous cellular
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oncogene homolog) signaling (Src is a molecule from Wnt signaling networks)
increases Wnt canonical signal and early osteoblast differentiation in MSCs.
This observation makes Src a potential target for the control of MSC differen-
tiation processes [88]. Osteocytes can control bone mass via the production
of negative regulators of Wnt/β-catenin pathway, such as Dkk1 and Scle-
rostin (SOST). SOST is an inhibitor of osteoblast activity. Based on this
observation, it would be possible to control osteoblast activity during bone
regeneration using Dkk1 and SOST as target molecules. Several preclinical
trials have focused on targeting Dkk1 and SOST for the treatment of post-
menopausal osteoporosis and for clinical trials an antibody against to SOST
is already commercially available [89].
Still, the field of gene transfer technologies and gene therapy requires more re-
search to avoid possible complications, including previously observed patient
death [90].
2.7.2 Cell-cell interactions
Angiogenesis and vascularization are crucial for bone regeneration and frac-
ture healing, because the blood supply delivers oxygen and nutrients into a
defect site. Vascularization is one of the main issues in the fields of bone
regenerative research [91]. In bone regeneration processes, endothelial cells
plays an important role, because they (endothelial cells) also produce os-
teoinductive molecules, such as BMPs, which are directly involved in MSCs
osteogenic differentiation [92, 93]. A recent in vivo study (in a BMP2 reporter
transgenic mice model) showed that the high expression level of BMPs was
generated by endothelial cells [94]. This observation and numerous other
in vitro co-culture studies proved that osteogenic differentiation of MSCs
significantly increases in the presence of endothelial cells, which is a result
of cellular crosstalk and substantial signaling activation [95, 96]. The per-
spective of these observations will lead to an advanced design of co-culture
(cell combination) systems with improved osteogenic as well as angiogenic
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capacities [91, 97]. However, the concept of cell-cell interactions is not only
based on endothelial cell and MSC combinations, because in the natural bone
micro-environment many other cell types are present (Figure 2.4a) [98].
Figure 2.4: a. Cellular composition in defect site of bone b. Cell-cell inter-
action and intracellular signaling.
(a) The cellular composition in the defect site of bone during wound healing process. The
cellular micro-environment allows cells to communicate via expressed bioactive molecules
(cellular crosstalk). (b) These bioactive molecules can be involved in activation of signaling
networks of other cell types (such as crosstalk between endothelial and bone progenitors)
[93].
Recently, it has been found that monocytic exosomes, co-cultured with MSCs,
can stimulate upregulation of osteogenesis-related genes (Runx2, BMP2, os-
teocalcin) via cellular crosstalk [99].This particular study did not describe
the pathways that are responsible for molecular crosstalk and osteogenic sig-
naling. The future perspective of this field (i.e. co-culture between different
cell types) will be the improvement of detailed molecular screening of cel-
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lular crosstalk (Figure 2.4b). Further, thorough testing of such co-culture
approaches needs to be carried out and the influence of reliable biocompati-
ble scaffolds needs to be evaluated.
2.7.3 Optimization of material surface properties
Molecular screening of cell behavior/osteoinductivity, in applications with
synthetic biomaterials, becomes also very important in the field of bone re-
generative research. To mimic bone microenvironment, synthetic biomate-
rials need to meet several criteria, such as porosity (similar to bone), in-
terconnectivity, biocompatibility, mechanical properties and chemical sta-
bility [100, 101]. Several studies indicate that synthetic biomaterials can
improve the extent of MSC proliferation, differentiation and mineralization
[102, 103, 104]. However, only a few studies report about molecular mecha-
nisms of cell-biomaterial interaction and signaling [105, 106, 107]. Neverthe-
less, the molecular screening of cellular response to material properties will
contribute to determine the efficacy of biomaterials for eventual clinical use.
One of the most commonly used biomaterials in bone implantology is ti-
tanium, because of its biocompatibility and reliable mechanical properties.
Despite the fact that titanium is in clinical use already for quite a long time,
the mechanism of cellular osteointegration and molecular response of cells
remains largely unclear [108]. Furthermore, several studies indicate that
topographical cues on the surface of biomaterials affect cell behavior and
osteogenic activities, a topic that has also been explored for titanium sur-
face topography can increase osteoinductivity of contacting cells [109, 111].
More particularly, it was shown that a rough titanium surface enhances the
secretion of osteoblastic phenotype related proteins, e.g. ALP, osteocalcin,
osteoprotegrin and TGF-β [105, 106]. Finally, it was demonstrated that the
roughened titanium surface (sandblasting with grits of 0.25-0.5mm) induces
an upregulation of genes responsible for osteogenesis (BMPs and Smad fam-
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ily), for transcriptional regulation (NF-kB), for angiogenesis (VEGFs), for
extracellular matrix formation (collagen and surface markers) and several
other genes including IGF1R, IGF2, FGF2 [108]. This observation and fur-
ther fundamental investigation of osteogenesis-related gene expression pro-
files will help to increase the quality of newly designed biomaterials with
superior performance in terms of osteoinductivity and osteogenicity.
2.7.4 Material degradation products
Calcium phosphates (CaP) are a very popular family of bioactive materi-
als, which are used in bone tissue regenerative research. As an appropriate
scaffold material and cell carrier, CaP biomaterials have been applied in
numerous in vitro and in vivo studies [112]. Several clinical trials showed
that CaP scaffolds in combination with pre-cultured MSCs have substantial
healing capacity for bone defects [7, 113]. In order to understand the biolog-
ical interaction and osteoinduction of MSCs in contact with CaP, molecular
screening of cell/CaP biomaterial interaction effects has been performed.
This screening showed that Ca2+ ions released from scaffolds might be re-
sponsible for inducing osteogenic differentiation in MSCs, as demonstrated by
increased ALP and BMP2 expression [48]. Additionally, β-calcium silicates
(β-CS) recently received major attention in the field of bone regenerative
research, because it was demonstrated that a composite scaffold, consisting
of β-CS and PDLGA (poly-L-lactic-co-glycolic acid), was able to upregulate
the osteogenic differentiation of MSCs by help of ionic extracts released from
the scaffold. In particular, it was shown that bioactive ions (released from
β-CS/PDLGA scaffold) were able to enhance cell viability, ALP activity,
and calcium mineral deposition. Finally, at mRNA level, an upregulation of
MAPKs, Erkl/2 (from TGF-β pathway), and Runx2 was observed. These
data suggest that β-CS/PDLGA composite material can promote bone re-
generation [114]. Future characterization and evaluation of these materials in
cell-biomaterial concepts, together with detailed knowledge about the molec-
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ular response of cells, will bring those materials more closely to preclinical
and clinical bone regenerative applications.
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CHAPTER 3
Osteogenic signaling of human BM-MSCs & AT-MSCs
cultured in PL- or FBS- supplemented media
3.1 Introduction
Due to the continuously aging population, with an increasing incidence of
bone-related problems (i.e. osteoporosis, bone tumors and skeletal injuries),
new strategies for the treatment of bone defects become of utmost impor-
tance. Over the last decades, bone tissue regenerative approaches increas-
ingly focused on cell-based strategies, which are based on in vitro expansion
of mesenchymal stromal cells (MSCs), steering them into the osteogenic lin-
eage and their subsequent seeding on a scaffold for in vivo application [1, 2].
MSCs isolated from different tissues, including bone marrow (BM) and adi-
pose tissue (AT), have been characterized and pre-clinically applied in several
studies [3, 4]. Many studies reported that BM-MSCs are able to differenti-
ate into osteoblasts in vitro and in vivo [5, 6, 7]. However, the harvest of
bone marrow cells is an invasive procedure with high risk of complications.
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Moreover, the amount of harvested cells is often relatively limited [8].
Recently, AT-MSCs have become more popular in bone regenerative research,
because of their easy accessibility and relatively large yield [4, 9, 10]. In order
to apply AT-MSCs in bone regenerative research, a characterization based
on proliferation and osteogenic differentiation capacity is recommendable.
Several studies have indicated that AT-MSCs proliferate much faster than
BM-MSCs, and show substantial osteogenic differentiation capacity in vitro
[11, 12, 13]. Although the osteogenic potential of AT-MSCs is proven by
aforementioned studies, the underlying molecular mechanisms of osteogenic
differentiation seem to be different from BM-MSCs [14]. For example, AT-
MSCs do not respond well to bone morphogenetic protein 2 (BMP2) [15, 16],
while BMP2 is known to be the most powerful growth factor involved in the
osteogenic differentiation of BM-MSCs [17]. In addition, it is proven that the
expression level of some of the receptors involved in BMP/TGF-β pathways
are downregulated or even not expressed in AT-MSCs [18]. This indicates
that molecular mechanisms of osteogenic differentiation of AT-MSCs and
BM-MSCs are different [9, 19]. In view of this, it seems logical to study
the osteogenic differentiation of MSCs (i.e. AT-MSCs and BM-MSCs) at
a molecular level, focusing on the osteogenic signaling pathways (e.g. the
BMP/TGF-β and Wnt-pathways), and the natural bone regeneration process
[14].
BMPs and TGF-βs are known as the most potent osteogenic growth factor
that activate the BMP/TGF-β (transforming growth factor beta) signaling
pathway [20, 21]. In this BMP/TGF-β pathway, many intracellular signaling
molecules are involved, amongst which Smads, which transmit the extracellu-
lar signal through the cytoplasm into the nucleus. The BMP activated signal
initiates phosphorylation of Smads1/5/8, while the TGF-β activated signal
initiates phosphorylation of Smad2/3 [22]. Phosphorylated Smads subse-
quently form a complex with Smad4, which is responsible for signal translo-
cation into the nucleus, where the Smad-complex initiates a transcriptional
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response with Runx2 activation [21, 23]. Runx2 is the key transcription fac-
tor for transcriptional activation of osteogenic gene expression [24, 25]. In
addition, Runx2 is the key regulator of the genes that determine osteoblast
phenotype, and for Runx2 activity osterix (transcriptional regulator) plays
a crucial role [18, 26].
Alternative signaling is possible via the Wnt pathway, which recently received
large attention in the field of bone regenerative research due to several studies
that indicated the involvement of this pathway in osteogenic differentiation
of MSCs [27, 28]. Wnt signaling increases bone mass via diverse mechanisms,
including renewal of stromal cells, stimulation of pre-osteoblast replication,
and enhancement of osteoblast activity [29]. So far, 19 Wnt family members
have been identified. Wnt1 is one of those family members directly involved
in upregulation of Runx2 expression [28] and osteogenesis via the activation
of Dkk2 expression [30]. In the cytoplasm, the Wnt-transmitted signal sta-
bilizes β-catenin activity [27, 31]. Subsequently, β-catenin translocates into
the nucleus, where it induces osteogenic gene expression via activation of
transcription factors, i.e. Runx2 and osterix [32, 33, 34, 35, 36]. Many stud-
ies demonstrated that Wnt/β-catenin pathway is important in the context of
osteogenic differentiation, as the loss of Wnt/β-catenin signaling leads MSCs
differentiation into adipocytes [37, 38].
The culture conditions and nutritional supplement source have direct effect
on the osteogenic differentiation of MSCs [39, 40, 41], because these sup-
plements are rich in various growth factors and signaling molecules. The
most common nutritional supplement used for in vitro cell culture is fetal
bovine serum (FBS) because of its availability, acceptable costs, and famil-
iarity. However, FBS is not applicable for subsequent pre-clinical and clini-
cal trials, because of potential immunological issues and pathogen transmis-
sion [42, 43]. As an alternative, autologous/allogeneic human serum-derived
products (e.g. blood plasma, cord blood serum, and platelet lysate) have
been explored [39, 40, 41, 44]. Regarding human platelet lysate (PL), sev-
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eral studies have demonstrated its decreasing effects on BM-MSCs osteogenic
differentiation compared to FBS-supplemented media [11, 45, 46, 47]. Inter-
estingly, AT-MSCs showed opposite results with low osteogenic differenti-
ation in FBS-supplemented medium and high osteogenic differentiation in
PL-supplemented medium [48, 49].
This study aimed to evaluate the gene expression profile of components in-
volved in signaling pathways (i.e. BMP/TGFβ and Wnt pathways) related to
osteogenic differentiation of different MSCs (i.e. BM-MSCs and AT-MSCs),
which were cultured in a medium with different nutritional supplements (ei-
ther FBS or PL).
We hypothesized that the osteogenic signaling and gene expression profile
is dependent on (i) the origin of the MSCs, and (ii) the nutritional supple-
ments (i.e. FBS or PL), which differently affects cell signaling pathways and
related osteogenic differentiation. Experimentally, cell proliferation (DNA
content), differentiation (ALP activity) and mineralization (calcium depo-
sition) of both AT-MSCs and BM-MSCs cultured in a medium with either
of two different nutritional supplements (i.e. FBS or PL) were analyzed.
Additionally, the gene expression of osteogenic signaling molecules from the
BMP/TGFβ and Wnt pathways (i.e. BMP2, BMP4, TGF-β1, Smad4, Wnt1,
β-catenin, Runx2, and osterix) were analyzed.
3.2 Material & Methods
3.2.1 Isolation, expansion & characterization of the cells
AT-MSCs were isolated from fat tissue of healthy humans. The fat tissue was
obtained from the Department of Plastic Surgery (Radboudumc, the Nether-
lands) after written informed consent. BM-MSCs were isolated from human
3.2 Material & Methods 57
iliac bone chips, obtained from patients undergoing maxillofacial surgery at
the Department of Oral and Craniofacial Surgery (Radboudumc, the Nether-
lands) after written informed consent. This study was performed according
to the principles of the Declaration of Helsinki. The AT-MSCs and BM-MSCs
isolation procedure is described in detail elsewhere [3, 11, 21, 30]. Harvested
cells were cultured in corresponding proliferation media consisting of alpha
Minimal Essential Medium, (α-MEM; Gibco R©, Life Technologies, Grand
Island, USA) supplemented with either 5% PL (Sanquin Blood Bank, the
Netherlands) [11], or 15% fetal bovine serum (FBS; Lonza, Basel, Switzer-
land) at 37oC in humid atmosphere with 5% CO2 (the complete composition
of proliferation media is given in Table 3.1).
Table 3.1: Composition of the proliferation (PM) and osteogenic media (OM)
FBS-supplemented (PM-FBS) PL-Supplemented (PM-PL)
Minimal Essential Medium (α-MEM)
15% fetal bovin serum (FBS)
0.2 mM L-ascorbic acide 2-phosphate
(Vit C)
2 mM L-glutamine
100 U/ml penicillin
10 µg/ ml streptomycin
Minimal Essential Medium (α-MEM)
5% platelet lysate (PL)
10U/ml heparin
100 U/ml penicillin
10 µg/ ml streptomycin
FBS-supplemented (OM-FBS) PL-Supplemented (OM-PL)
Minimal Essential Medium (α-MEM)
15% fetal bovin serum (FBS)
0.2mM L-ascorbic acide 2-phosphate
(Vit C)
2 mM L-glutamine
100 U/ml penicillin
10 µg/ ml streptomycin
10-8 M dexamethasone
0.01 M β-glycerophosphate
Minimal Essential Medium (α-MEM)
5% platelet lysate (PL)
0.2 mM L-ascorbic acide 2-phosphate
(Vit C)
2 mM L-glutamine
100 U/ml penicillin
10 µg/ ml streptomycin
10-8 M dexamethasone
0.01 M β-glycerophosphate
0.02 10U/ml heparin
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Medium was changed twice a week. Cells were passaged upon reaching 80%
confluency using 0.25% w/v trypsin/0.02% EDTA (Gibco R©). Cells were
examined by fluorescence-activated cell sorting (FACS) for positive expres-
sion of CD73, CD90 and CD105 (eBioscience, San Diego, USA) and negative
expression of CD45 (R&D system, Abingdon, United Kingdom).
3.2.2 Experimental groups & cell seeding
AT-MSCs and BM-MSCs (passage 4) were cultured in either PL- or FBS-
supplemented osteogenic media for 28 days (Table 3.1). The samples for
biochemical assays were prepared with 5,000 cells/cm2 seeding density (n=3).
The samples for RNA extraction/Q-PCR analysis were prepared with 10,000
cells/cm2 seeding density (n=3). The culture medium was changed twice
a week and samples were collected at 7 day intervals (days 7, 14, 21 &
28). During the entire culture period, cell morphology was monitored via an
inverted light microscope (Leica DM-IL, 5W LED illumination, Rijswijk, the
Netherlands).
3.2.3 Cell behavior
Sample preparation for biochemical assays, to determine cell behavior in
terms of cellular DNA content, alkaline phosphatase (ALP) activity and cal-
cium deposition, was performed by washing the cell layer twice with PBS,
adding 1 ml MilliQ, repetitive freeze/thaw cycles (two times), and finally
storage at -80oC till analysis of the DNA and ALP content. Afterwards, the
wells were incubated overnight at room temperature with 1 ml 0.5N acetic
acid for analysis of Ca deposition.
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3.2.3.1 Cellular DNA content
Cellular DNA content was measured using the Quant-iTTM PicoGreen R© ds-
DNA assay kit (Invitrogen; Breda, the Netherlands) according to the man-
ufacturer’s instruction. For the standard curve, serial dilutions of dsDNA
stock (range: 0-2000 ng/ml) were prepared. Next, 100 µl of either sample
or standard solution was added into the wells, followed by 100 µl of working
solution. The plate was incubated at room temperature for 5 min, and then
the fluorescence of samples/standards was measured with acceptable wave-
length range, (excitation at 475-505 nm and emission at 520-550 nm) using
a fluorescence microplate reader (FL600, BioTek, Canada).
3.2.3.2 Alkaline phosphatase (ALP) activity
ALP activity was measured using a 5 nM p-nitrophenyl phosphate (4-NP)
colorimetric assay. According to the manufacturer’s instruction (Sigma-
Aldrich, St. Louis, MO, USA), 80 µl of sample solution was combined with
20 µl of buffer (0.5 M 2-amino-2methyl-1-propanol). For the standard curve,
serial dilutions of 4-NP (range: 0-25 nmol) were used. Next, 100 µl substrate
solution (5 nM p-nitrophenyl phosphate) was added to the samples/standards
and incubated for 60 min at 37oC. The reaction was stopped by adding in
each well 50 µl 0.3M NaOH. The absorbance of samples was measured at
405 nm using an ELISA microplate reader (EL800, BioTek, Abcoude, the
Netherlands). The ALP content was normalized using corresponding cellu-
lar dsDNA amount.
3.2.3.3 Calcium deposition
Calcium deposition was measured using the orthocresolphtalein complexone
assay (OCPC; Sigma Aldrich, St. Louis, MO, USA), which is based on
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a colorimetric reaction between o-cresolphthalein complexone and calcium.
According to the manufacturer’s instruction, serial dilutions of calcium stock
(CaCl2) were prepared (range: 0-100 mg/ml) for the standard curve. For the
assay, 10 µl of sample or standard was used, to which 300 µl OCPC solution
was added to complete the reaction. After the incubation of plate for 10
min at room temperature, the absorbance was measured at 570 nm using an
ELISA microplate reader (EL800, BioTek, Canada).
3.2.4 Gene expression
3.2.4.1 RNA isolation & reverse transcription
To analyze the gene expression profile of selected molecules, RNA was iso-
lated using Genelute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich).
According to the manufacturer’s instruction, the samples (days 0, 7, 14,
21 and 28) were collected by adding 500 µl ’RNA’ lysis buffer and sub-
sequent storage at -80oC. After extraction, the RNA was quantified using
a spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). For
the reverse transcription (cDNA synthesis), an iScriptTM cDNA kit was used
(Bio-Rad, Hercules, CA, USA), and for each cDNA reaction 1 µg of mRNA
was used. The samples were stored at -20oC until use.
3.2.4.2 Real-Time Polymerase Chain Reaction
For real-time polymerase chain reaction (RT-PCR), qPCR Master Mix Plus
/SYBR Green I (Eurogentec; Seraing, Belgium)was used according to the
manufacturer’s instruction. For each reaction, 1 µg cDNA was used. RT-
PCR was completed with 40 amplification cycles. The sequence of applied
primers is given in Table 3.2. The raw data were normalized to the expression
of RPLP0 (housekeeping gene) within the same sample/mRNA. The gene
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expression and fold changes were calculated according to Livak & Schmittgen
(2−∆∆Ct) method, relative to BM-PL at the day 0 (50).
Table 3.2: Primer sequences
Gene name Sequences
RPLP0 Forward- TTCTTCTTTGGGCTGGTCAT
Reverse- TTGGGTAGCCAATCTGCAGA
RUNX2 Forward- TCTGGCCTTCCACTCTCAGT
Reverse- GACTGGCGGGGTGTAAGTAA
BMP-2 Forward- CCCAGCGTGAAAAGAGAGAC
Reverse- GAGACCGCAGTCCGTCTAAG
Wnt-1 Forward- TTCTCCGGGTCCTCCTAAGT
Reverse- ATGGCTCCACGACAGAGACT
β-catenin Forward- GAAACGGCTTTCAGTTGAGC
Reverse- CTGGCCATATCCACCAGAGT
TGF-β1 Forward- CAATTCCTGGCGATACCTCAG
Reverse- GCACAACTCCGGTGACATCAA
Osterix Forward- CCTCTGCGGGACTCAACAAC
Reverse- AGCCCATTAGTGCTTGTAAAGG
Smad4 Forward- CTCATGTGATCTATGCCCGTC
Reverse- AGGTGATACAACTCGTTCGTAGT
BMP4 Forward- TAGCAAGAGTGCCGTCATTCC
Reverse- GCGCTCAGGATACTCAAGACC
3.2.5 Statistical analysis
Data are presented as mean ± standard deviation. Statistical analysis was
performed based on N=3 (for all experimental groups) with Graphpad Prism
R©5.03 software (Graphpad Software Inc, San Diego, CA, USA). Quantitative
results were analyzed using a one-way ANOVA with a posthoc Dunnett test
(control - BM-PL at day 0). Differences were considered as significant at the
p< 0.05 value. All experimental cultures were repeated three times.
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3.3 Results
3.3.1 Characterization & morphology of MSCs
The results of FACS analysis showed that both cell types (AT-MSCs and
BM-MSCs) were 99% positive for expression of surface markers CD73, CD90
and CD105, whereas both these cell types were completely negative for CD45
expression (data not shown).
Figure 3.1: Cell morphology monitored with inverted light microscopy, at
selected intervals time points, for AT-MSCs and BM-MSCs cultured in PL-
or FBS-supplemented media. Black colorization indicates mineralization.
Light microscopy analyses showed that both AT-MSCs and BM-MSCs had an
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elongated, spindle-shaped morphology in osteogenic culture condition (Fig-
ure 3.1), but after 3 days of culture AT-MSCs appeared smaller with higher
cell density than BM-MSCs. After 14 days of culture period, mineralization
of the extracellular matrix (black spots) was clearly observed for AT-PL and
BM-FBS, and to a lesser extent for BM-PL. After 28 days of culture, sub-
stantial mineralization was observed for all experimental groups, except for
AT-FBS.
3.3.2 Cell behavior
3.3.2.1 Cellular DNA content
Figure 3.2: Cellular DNA contant of BM-MSCs and AT-MSCs under different
culture conditions. The ”a” indicates significantly different compared to day 0 (p-
values: a p<0.05, aa p<0.01, aaa p<0.001). The ”*” indicates significantly different
compared to BM-PL value at the same time point (p-values: **p < 0.05, **p < 0.01 and
***p < 0.001.)
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Analysis of DNA content (Figure 3.2) showed a gradual increase of cell pro-
liferation until day 28 for BM-PL and BM-FBS.The proliferation pattern of
AT-PL and AT-FBS was different, with a maximum proliferation at day 14.
The level of proliferation of AT-PL (p< 0.001) and AT-FBS (p< 0.001) was
significantly higher compared to both BM-PL and BM-FBS.
3.3.2.2 ALP activity
Figure 3.3: ALP activity, of BM-MSCs and AT-MSCs under different culture
conditions. The ”a” indicates significantly different compared to day 0 (p-values: a
p<0.05, aa p<0.01, aaa p<0.001). The ”*” indicates significantly different compared to
BM-PL value at the same time point (p-values: **p < 0.05, **p < 0.01 and ***p < 0.001.)
For both cell types, ALP-activity (early marker for osteogenic differentiation)
was high when cells were cultured in PL-supplemented medium (Figure 3.3).
With culture time till day 28, a significant increase of ALP-activity was
observed for BM-PL and BM-FBS relative to day 0 (p< 0.001). In contrast
to BM-PL and BM-FBS, the ALP-activity peak for AT-PL and AT-FBS was
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at day 21, followed by a decrease till day 28. In AT-PL and AT-FBS, the
ALP-activity was significantly increased at all time points relative to day 0
(p< 0.05).
3.3.2.3 Calcium deposition
Figure 3.4: Ca deposition in BM-MSCs and AT-MSCs under different culture
conditions. The ”a” indicates significantly different compared to day 0 (p-values: a
p<0.05, aa p<0.01, aaa p<0.001). The ”*” indicates significantly different compared to
BM-PL value at the same time point (p-values: **p < 0.05, **p < 0.01 and ***p < 0.001.)
The results of cellular mineralization, measured by Ca deposition, showed
significant differences for cell types as well as for nutritional supplement
types (Figure 3.4). Both cell types showed highest mineralization at day 28,
but AT-MSCs started to mineralize already from day 14 (in both PL and
FBS condition), whereas for BM-MSCs mineralization started from day 21.
Moreover, BM-MSCs showed high mineralization in FBS-supplemented and
AT-MSCs in PL-supplemented cultures. Significantly increased mineraliza-
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tion was observed (relative to day 0 in the same group) for BM-PL at day
28 (p< 0.001), for BM-FBS at day 21 and 28 (p< 0.001), for AT-PL at
days 21 and 28 (p< 0.001), and for AT-FBS at days 21 and 28 (p< 0.001).
Moreover, BM-MSCs showed high mineralization in FBS-supplemented and
AT-MSCs in PL-supplemented cultures. Significantly increased mineraliza-
tion was observed (relative to day 0 in the same group) for BM-PL at day
28 (p< 0.001), for BM-FBS at day 21 and 28 (p< 0.001), for AT-PL at days
21 and 28 (p< 0.001), and for AT-FBS at days 21 and 28 (p< 0.001).
3.3.3 Gene expression profile of selected genes
To determine gene expression profiles of selected genes, RT-PCR analysis was
performed. The results for each experimental group are described separately.
Figure 3.5: Gene expression profile of BMP2. The ”a” indicates significantly
different compared to day 0 (p-values: a p<0.05, aa p<0.01, aaa p<0.001). The ”*”
indicates significantly different compared to BM-PL value at the same time point (p-
values: **p < 0.05, **p < 0.01 and ***p < 0.001.)
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Figure 3.6: Gene expression profile of BMP4. The ”a” indicates significantly
different compared to day 0 (p-values: a p<0.05, aa p<0.01, aaa p<0.001). The ”*”
indicates significantly different compared to BM-PL value at the same time point (p-
values: **p < 0.05, **p < 0.01 and ***p < 0.001.)
BM-PL: BM-PL showed relatively high gene expression levels for the molecules
BMP2 and BMP4, as well as for the transcription factors Runx2 and osterix.
BMP2 showed an >10-fold upregulation, starting from the first week until
third week of culture (Figure 3.5). Similarly, gene expression of BMP4 was
upregulated up to 2.5-fold (Figure 3.6). The expression profiles of BMP2 and
BMP4 were similar, but the amount of BMP4 was relatively low compared to
BMP2. In contrast to BMPs, the expression of TGF-β1 was downregulated
over the entire culture period, except for day 7 (Figure 3.7). Smad4 expres-
sion was upregulated especially at 14 days of culture (Figure 3.8). Wnt1
was upregulated during the first 21 days of culture. The expression pattern
of Wnt1 was similar to BMP2 and BMP4 expression (Figure 3.9). At the
same time β-catenin (from Wnt pathway) was downregulated (Figure 3.10).
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Finally, gene expression of transcription factors Runx2 and osterix was up-
regulated during first three weeks of culture (Figure 3.9), Figure 3.10).
Figure 3.7: Gene expression profile of TGFβ. The ”a” indicates significantly
different compared to day 0 (p-values: a p<0.05, aa p<0.01, aaa p<0.001). The ”*”
indicates significantly different compared to BM-PL value at the same time point (p-
values: **p < 0.05, **p < 0.01 and ***p < 0.001.)
BM-FBS: For BM-FBS, BMP2 expression was relatively high ( 4.5 fold) al-
ready in proliferation media (day 0). In osteogenic conditions, the expression
of BMP2 was not stable, showing variations during 28 days of culture period
(Figure 3.5). BMP4 expression was upregulated (up to 2.5 fold) during the
first two weeks of culture, and afterwards it was downregulated until day
28 (Figure 3.6). During the entire culture period, TGF-β1 expression was
downregulated (Figure 3.7). For BM-FBS, the expression pattern of Smad4
was similar to BM-PL, with an upregulation (up to 6.5 fold) in the second
week of culture (Figure 3.8).
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Figure 3.8: Gene expression profile of Smad4. The ”a” indicates significantly
different compared to day 0 (p-values: a p<0.05, aa p<0.01, aaa p<0.001). The ”*”
indicates significantly different compared to BM-PL value at the same time point (p-
values: **p < 0.05, **p < 0.01 and ***p < 0.001.)
The expression of Wnt1 was upregulated (up to 5.5 fold) in the second and
third weeks (Figure 3.9). The expression of β-catenin was downregulated
during the entire culture period (Figure 3.10). For osteogenic transcription
factors, an upregulation of Runx2 (up to 2 fold) was observed in the first,
second and fourth week of culture (Figure 3.11). For BM-FBS, the level of
Runx2 was substantially lower than for BM-PL. Finally, an upregulation of
osterix was observed already in proliferation media, but after the first week
of its gene expression was downregulated, and on day 28 no expression of
osterix was detectable anymore (Figure 3.12).
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Figure 3.9: Gene expression profile of Wnt1. The ”a” indicates significantly
different compared to day 0 (p-values: a p<0.05, aa p<0.01, aaa p<0.001). The ”*”
indicates significantly different compared to BM-PL value at the same time point (p-
values: **p < 0.05, **p < 0.01 and ***p < 0.001.)
AT-PL: In contrast to BM-PL and BM-FBS, the expression of BMP2 was
very low (up to 3 fold) in AT-PL. A small upregulation of BMP2 was ob-
served only in the first week of culture (Figure 3.5). BMP4 was upregulated
(up to 1.7 fold) in the second week of culture (Figure 3.6). TGF-β1 was
downregulated during the entire culture period (Figure 3.7). An upregula-
tion of Smad4 (up to 6.5 fold) was detected again in the second week of
culture (Figure 3.8). In contrast to BM-PL and BM-FBS, for AT-PL the ex-
pression of Wnt1 and β-catenin was downregulated during the entire culture
time (Figure 3.9), (Figure 3.10) but in proliferation media (day 0) the level
of β-catenin was relatively high (up to 1.5 fold). For transcription factors,
Runx2 was upregulated (up to 5 fold) in the second and third week of cul-
ture (Figure 3.11), and osterix was downregulated during the entire culture
3.3 Results 71
period (Figure 3.12).
Figure 3.10: Gene expression profile of β-catenin. The ”a” indicates significantly
different compared to day 0 (p-values: a p<0.05, aa p<0.01, aaa p<0.001). The ”*”
indicates significantly different compared to BM-PL value at the same time point (p-
values: **p < 0.05, **p < 0.01 and ***p < 0.001.)
AT-FBS: The expression of BMP2 for AT-FBS was upregulated (up to 13
fold) in the first week of culture (Figure 3.5); afterwards it decreased to
baseline values. For AT-FBS, the expression of BMP4, Wnt-1 and osterix
was similar to BMP2 showing an upregulation only at day 7 (Figure 3.6,
Figure 3.9, Figure 3.10). TGF-β1 was upregulated (up to 1.7 fold) in the
second week of culture (Figure 3.7). An upregulation of Smad4 (up to 4
fold) was observed again in the second week of culture (Figure 3.8). The
expression of β-catenin was downregulated during the entire culture period
(Figure 3.10). For transcription factors, Runx2 was upregulated in the second
and third weeks of culture and the expression pattern of osterix was similar
to BMP2, showing an upregulation in the first week of culture (Figure 3.11,
3.12).
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Figure 3.11: Gene expression profile of RUNX2. The ”a” indicates significantly
different compared to day 0 (p-values: a p<0.05, aa p<0.01, aaa p<0.001). The ”*”
indicates significantly different compared to BM-PL value at the same time point (p-
values: **p < 0.05, **p < 0.01 and ***p < 0.001.)
3.4 Discussion
This study aimed to evaluate the gene expression profile of components in-
volved in signaling pathways (i.e. BMP/TGFβ and Wnt pathways) related to
osteogenic differentiation of different MSCs (i.e. BM-MSCs and AT-MSCs),
which were cultured in a medium with different nutritional supplements (ei-
ther FBS or PL).
We hypothesized that the osteogenic signaling and gene expression profile is
dependent on (i) the origin of the MSCs, and (ii) the nutritional supplements
(i.e. FBS or PL), which differently affect cell signaling pathways and related
osteogenic differentiation. The main findings of this study showed that BM-
MSCs show a more pronounced mineralization in FBS-supplemented media,
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Figure 3.12: Gene expression profile of Osterix. The ”a” indicates significantly
different compared to day 0 (p-values: a p<0.05, aa p<0.01, aaa p<0.001). The ”*”
indicates significantly different compared to BM-PL value at the same time point (p-
values: **p < 0.05, **p < 0.01 and ***p < 0.001.)
while AT-MSCs do so in PL-supplemented media. Remarkably, BM-MSCs in
PL-supplemented media highly express several osteogenic genes (i.e. BMP2,
BMP4, Wnt1, Runx2, and osterix) in contrast to AT-MSCs, which only
highly express Runx2. Furthermore, a high level of parallelism in BMP2,
BMP4 and Wnt1 gene expression was observed, irrespective of MSC origin
or nutritional supplement.
The data of biochemical assays showed remarkable differences between cell
types and supplement types. Both cell types showed high proliferation (DNA
content) and differentiation (ALP activity) capacity in PL-supplemented me-
dia. However, calcium deposition showed opposite results, with for BM-
MSCs highest mineralization in FBS-supplemented media, while for AT-
MSCs in PL-supplemented media. A similar observation was recently re-
ported in [11]. This observation indicates that although BM-MSCs and AT-
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MSCs are morphologically similar, the gene expression profiles of several os-
teogenic genes are different, which differently affect osteogenic differentiation
of cells.
BM-MSCs in PL-supplemented culture highly expressed the most potent
osteogenic molecules i.e. BMP2, BMP4, Wnt1, Runx2 and osterix. However,
the mineralization pattern of BM-PL did not correlate with the level of the
aforementioned gene expression profiles. An upregulation of BMP2 and ALP
expression by BM-MSCs cultured in PL-supplemented media was reported
previously [45]. These data suggest that BMP2, BMP4, Wnt1, Runx2 and
osterix have high potential to be involved in early stage differentiation of
BM-PL. However, at later stages of osteogenic differentiation of BM-PL,
those molecules seem not to be crucial. Moreover, gene expression profiles
for BM-MSCs in FBS-supplemented media also showed an upregulation of
BMP2, BMP4, Wnt1, Runx2 and osterix, which correlated with high levels
of mineralization. These results confirm our hypothesis that osteogenic gene
expression profiles are dependent on the nutritional supplement (i.e. FBS or
PL), which differently affects cell signaling pathways and related osteogenic
differentiation.
The molecular mechanisms of proliferation and osteogenic differentiation of
AT-MSCs are different from those of BM-MSCs, because the gene expression
of most osteogenic molecules (i.e. BMP2, BMP4, Wnt1, osterix; not Runx2)
was downregulated in AT-MSCs or expressed at rather low levels. These
remarkable differences in expression levels of osteogenic signaling molecules
between these two cell types confirm our hypothesis that the gene expres-
sion profile is dependent on the origin of the MSCs. Runx2 was one of few
molecules, which was upregulated for AT-MSCs, in both PL- and FBS- sup-
plemented cultures. Interestingly, AT-MSCs showed high levels of calcium
deposition (for both AT-PL and AT-FBS conditions), which is an indication
about a possible correlation between Runx2 expression and AT-MSC min-
eralization. It is known that calcium can accumulate in intracellular stores,
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mainly via calcium channels by help of Runx2 [50], which could be linked
to the high mineralization of AT-MSCs. Osterix is considered as a down-
stream regulator of Runx2 [24]. However, in our observations, the expression
of osterix was not in accordance with Runx2; osterix expression profiles were
rather similar to those of BMP2 and BMP4, which implies that BMP expres-
sion is osterix-dependent or BMP-signaling induces the osterix expression [2].
Interestingly, Wnt1 expression profiles were also similar to BMP2 and BMP4
in each separate group. It seems that BMPs control Wnt1 expression or
Wnt1 induces BMP expression. A recent report about the correlation of
BMP2 and Wnt signaling showed that BMP2-mediated extracellular matrix
mineralization is involved in activation of Wnt signaling [51]. To fully elu-
cidate a possible correlation between Wnt signaling and mineralization of
MSCs (AT-MSCs or BM-MSCs), more genes from the Wnt pathway need to
be analyzed.
The results of gene expression of TGF-β1, Smad4 and β-catenin indicate
that these molecules are not directly involved in osteogenic differentiation
of MSCs, as TGF-β1 and β-catenin were downregulated at almost all cul-
ture periods for both cell types. An upregulation of Smad4 was detected
only in the second week of culture for all experimental groups, which after-
wards decreased back to baseline values again. This observation suggests
that the expression of Smad4 is not cell type-specific or supplement-specific,
because the expression profile for all experimental groups was similar. How-
ever, Smad4 is known to be a crucial element for the transmission of BMP-
as well as TGF-β-activated signals into the nucleus [52]. An upregulation
of Smad4 in the second week could indicate its temporary involvement in
turning on during osteogenic differentiation.
The phenomenon of maximized mineralization capacity of AT-MSCs in PL-
supplemented and BM-MSCs in FBS-supplemented media still remains elu-
sive. PL contains many signaling molecules (growth factors), which can acti-
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vate osteogenic signaling mechanisms for AT-MSCs, but less for BM-MSCs.
Possible explanations for this phenomenon include the concentration of PL
in the media (5%), which was probably sufficient to promote BM-MSCs pro-
liferation, but not mineralization. It is known that an appropriate dosage of
proteins is crucial for normal bone development [24], and overexpression of
osteogenic proteins may cause unexpected disorders [52].
The fact that AT-MSCs have high osteogenic activity in PL-supplemented
media is appealing for their use in subsequent (pre-)clinical applications.
Together with the rapid proliferation and the knowledge that in vitro expan-
sion of MSCs requires a safe nutritional component in the culture medium
(e.g. autologous PL), AT-MSCs seem more appropriate for this purpose than
BM-MSCs. Comparative evaluations of both cell types regarding their (pre-)
clinical efficacy are required to address this issue.
3.5 Conclusions
Our data showed that the cellular behavior and molecular mechanisms of
osteogenic differentiation of BM-MSCs and AT-MSCs are rather different,
which confirms dependency of the osteogenic gene expression profile on the
origin of the MSCs. Different nutritional supplements stimulated alterna-
tive signaling pathways for controlling the proliferation and osteogenic dif-
ferentiation of BM-MSCs and AT-MSCs. BMP/TGF-β and Wnt signaling
seem to be involved in proliferation and early differentiation of BM-MSCs,
whereas Runx2 is potentially involved in osteogenic differentiation and min-
eralization of AT-MSCs. These observations confirm that osteogenic gene
expression profiles are dependent on the nutritional supplement (i.e. FBS or
PL), which differently affects cell signaling pathways and related osteogenic
differentiation. The fact that AT-MSCs showed rapid proliferation and high
mineralization capacity, especially in PL-supplemented media, is appealing
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for their application in subsequent (pre-) clinical research, as an alternative
cell source for BM-MSCs.
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CHAPTER 4
Osteogenic capacity of human adipose tissue-derived
mesenchymal stromal cells in co-culture with endothelial
cells or macrophages
4.1 Introduction
One of the challenges confronted by orthopedic surgeons is to repair large
segmental bone defects caused by trauma, infection, tumor resection, skeletal
bone abnormalities or other bone disorders. So far, such clinical challenges
have been predominantly approached using autologous bone grafts. However,
this approach is accompanied by multiple limitations, e.g. quantity and qual-
ity issues of autologous donor bone and issues related to a second surgery site
[1]. Alternative treatment options have been explored using the toolbox of
tissue engineering (i.e. scaffolds, biologicals and cells). In view of cell-based
strategies, major emphasis has focused on mesenchymal stromal cells (MSCs)
[2]. These MSCs can be obtained from various tissues, including bone mar-
row (BM), skin, muscle and adipose tissue (AT). However, the yield of MSCs
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usually varies within these different tissues [3]. In contrast to other donor
tissues, substantial numbers of MSCs can be harvested from AT, with less
morbidity and easy accessibility compared to other tissue sources [4]. More-
over, AT-MSCs have shown high potential for osteogenic differentiation and
mineralization in vitro [4, 5, 6].
To develop cell-based bone tissue regenerative strategies, it is necessary to
understand natural bone regeneration and fracture healing processes. Bone
is a highly vascularized tissue with self healing, regeneration and remodel-
ing ability, representing biological processes that involve many cell types [7].
Vascularization is an essential process during bone fracture healing, regener-
ation and remodeling. Fracture healing starts with an inflammatory phase,
followed by reparative and remodeling phases. During inflammation, white
blood cells (i.e. monocytes, macrophages, neutrophils, and lymphocytes) ac-
cumulate at the defect site, where they form granulation tissue [8]. Next,
MSCs and endothelial cells migrate to the defect site, where they promote
vascularization and bone repair. In this phase, many signaling mechanisms
evoke subsequent differentiation of MSCs into osteoblast and formation of os-
teoclasts from hematopoietic precursor cells. Fracture healing is completed
with a bone remodeling phase, during which bone retains its original shape,
structure, and mechanical strength [8]. Consequently, bone regeneration and
fracture healing are complex physiological processes, in which many cell types
(i.e. MSCs, endothelial cells, macrophages) and multiple factors (signaling
pathways) are involved, which coordinate cell migration, cell proliferation,
osteogenic differentiation and extracellular matrix formation [9]. MSCs from
different origin co-cultured with endothelial cells already received huge in-
terest in bone regenerative research, and it was proven that endothelial cells
promote mineralization of MSCs in vitro and bone formation in vivo [10, 11].
Moreover, cellular crosstalk between MSCs and endothelial cells activates
adequate osteogenic signals aided by the expression of signaling factors [12]
(e.g. vascular endothelial growth factor; VEGF), which is shown to be es-
sential for bone repair [13]. Several studies indicate that macrophages play a
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crucial role in bone regeneration, because they are involved in extracellular
matrix formation [14, 15] and secrete a plethora of signaling molecules that
are linked to multiple processes during osteogenesis [16, 17]. In view of this,
it is straightforward to study the behavior of AT-MSCs in in vitro culture
conditions based on co-culture with endothelial cells or macrophages [12].
Different studies, which focused on cell-cell interactions in a direct or in-
direct co-culture set-up [18, 19, 20] , showed that direct cell-cell contact
has different effects on cellular communication compared to indirect contact
[21, 22]. This indicates that cell co-culture set-up plays an important role in
cellular communication [18]. MSCs in direct contact with endothelial cells
showed positive effects regarding osteogenic differentiation in comparison to
indirect contact [10]. It has been proven that direct cellular contact be-
tween MSCs and adult cardiomyocytes promotes MSC differentiation into
cardiomyocytes, in contrast to indirect contact. Moreover, in an indirect
co-culture set-up, signaling molecules (growth factors), which were secreted
in the culture medium, showed no effect on MSC differentiation [21]. Con-
sequently, it is important to understand what mechanisms are involved in
direct and indirect cell-cell communication [23, 24].
This study aimed to evaluate the osteogenic differentiation of AT-MSCs
upon co-culture with endothelial cells or macrophages in a direct or indi-
rect co-culture set-up. Our hypotheses were that (i) endothelial cells and
macrophages stimulate AT-MSCs proliferation and osteogenic differentiation,
and that (ii) these two cell types will more profoundly affect osteogenic differ-
entiation of AT-MSCs in a direct compared to an indirect co-culture set-up,
because of the possibility for both cell-cell interactions and effects of secreted
soluble factors.
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4.2 Materials & Methods
4.2.1 Cell-culture
AT-MSCs were isolated from fat tissue of three different healthy human
donors. Fat tissue was obtained from the Department of Plastic Surgery
(Radboudumc, Nijmegen, the Netherlands) after written informed consent.
This study was performed according to the principles of the Declaration of
Helsinki. The procedure of AT-MSCs isolation is described in detail else-
where [4, 10, 25, 26].
Table 4.1: Composition of the proliferation and osteogenic media
Proliferation Media (PM) Osteogenic Media (OM)
Minimal Essential Medium (a-MEM) Minimal Essential Medium (a-MEM)
5% platelet lysate (PL) 5% platelet lysate (PL)
10U/ml heparin 0.2 mM L-ascorbic acide 2-phosphate
(Vit C)
100 U/ml penicillin 2 mM L-glutamine
10 µg/ ml streptomycin 100 U/ml penicillin
10 µg/ ml streptomycin
10-8 M dexamethasone
0.01M β-glycerophosphate
10U/ml heparin
Harvested cells were expanded in proliferation medium, consisting of alpha
minimal essential medium, (α-MEM; Gibco R©, Life Technologies, Grand Is-
land, USA) supplemented with 5% platelet lysate (PL, Sanquin Blood Bank,
Nijmegen, the Netherlands), pooled from 5 different donors, 100 U/ml peni-
cillin (Gibco R©), 10 µg/ml streptomycin (Gibco R©), and 10 U/ml heparin
(LEO Pharma, Amsterdam, the Netherlands) at 37◦C in a humid atmosphere
with 5% CO2. Medium was changed twice a week. Cells were passaged upon
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reaching 80% confluency using 0.25% w/v trypsin/0.02% EDTA (Gibco R©)
(Table 4.1). AT-MSCs, before using them in experimental work, were exam-
ined by fluorescence-activated cell sorting (FACS) for positive expression of
stem cell markers CD73, CD90 and CD105 (eBioscience, San Diego, USA)
and negative expression of CD45 (R&D system, Abingdon, United King-
dom). All donors were checked via biochemical assays for their osteogenic
potential, i.e. ALP activity and calcium deposition.
As endothelial cells, Human Umbilical Vein Endothelial Cells (HUVECs)
were obtained from a commercial source (Becton Dickinson Biosciences, BD,
Breda, the Netherlands). Cells were expanded at 37◦C in proliferation medium
consisting of Medium 200 (Gibco R©), supplemented with low serum growth
supplement kit (LSGS; Gibco R©), in humid atmosphere with 5% CO2. Medium
was changed twice a week. Cells were passaged upon reaching 80% conflu-
ency using 0.25% w/v trypsin/0.02% EDTA.
As a monocyte/macrophage cell type, RAW 264.7 cells were used, which
were obtained from a commercial source (Sigma-Aldrich, St. Louis, MO,
USA). RAW 264.7 cells were expanded in proliferation medium consisting of
Dulbecco’s Modified Eagle Medium (D-MEM Gibco R©), supplemented 2 mM
L-glutamine and 10% fetal bovine serum (FBS, Lonza, Basel, Switzerland).
Medium was refreshed twice a week and cells were passaged upon reaching
80% confluency.
4.2.2 Experimental co-cultures
For the direct co-culture set-up, AT-MSCs were cultured with either HU-
VECs or RAW264.7 cells in a 1:1 cell ratio, with total number of 10.000
cells/cm2 (24 well plates /n=3). As a control, AT-MSC monoculture (10.000
cells/cm2) was used (Table 4.2). The experimental groups were following:
direct AT-AT (AT-MSCs in monoculture as a control), AT-HU (AT-MCSs
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co-cultured with HUVECs) and AT-RAW (AT-MCSs co-cultured with Raw
264.7 cells).
Table 4.2: Overview of co-culture systems of AT-MSCs
AT-MSCs HUVECs RAW 264,7
Cell culture in 
cell specific
proliferation
media
Co-culture in non 
specific osteogenic 
media
AT-HU AT-RAWAT-AT (control)
Direct Indirect Direct Indirect Direct Indirect 
For the indirect co-culture set-up, AT-MSCs were cultured in 24 well plates,
which were combined with transwell inserts (Greiner Bio-One, Kremmnster,
Austria), into which HUVECs or RAW264.7 cells were cultured. The cell
seeding density in 24 well plates was 10.000 cells/cm2 (n=3) and in tran-
swells, the same number of cells were seeded to maintain a 1:1 cell ratio.
As a control, AT-MSCs were co-cultured with AT-MSCs in transwells. Ex-
perimental groups were following: indirect AT-AT (AT-MSCs co-cultured
with AT-MSCs), AT-HU and AT-RAW. For all co-culture groups, the same
osteogenic medium was used consisting of α-MEM supplemented with 5%
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PL, 100 U/ml penicillin, 10 µg/ml streptomycin, 10 U/ml heparin, 0.2 mM
L-ascorbic acid-2-phosphate (Sigma-Aldrich, St. Louis, MO, USA), 2mM
L-glutamine (Gibco R©), 10-8M dexamethasone (Sigma-Aldrich) and 0.01 M
β-glycerophosphate (Sigma-Aldrich), at 37◦C in a humid atmosphere with
5% CO2 (Table 4.2).
4.2.3 Cell morphology
During the entire culture period, cell morphology was monitored with an
inverted light microscope (Leica DM-IL, 5W LED Illumination, Rijswijk,
the Netherlands) for both direct and indirect co-cultures. Additionally, cell
morphology was monitored with scanning electron microscopy (SEM; JOEL
6330F, Peabody, USA), for which samples were prepared at selected time
points by washing twice with PBS, fixing with 2% glutaraldehyde for 10
minutes, and washing with 0.1M Na-cacodylate buffer for 10 minutes. For
dehydration, samples were treated with a graded series of ethanol, each for
5 minutes. Finally, samples were incubated in air flow overnight by adding
one drop of tetramethylsilan to each sample for complete dehydration. Prior
to observation using a SEM, samples were coated with a gold layer.
4.2.4 Cell behavior
Cell behavior was analyzed with different biochemical assays, which were
used as described previously [10]. Cellular DNA content was used as a mea-
sure for cell proliferation and quantified with the QuantiFluor R© dsDNA
kit (Promega, Madison, Wisconsin, USA). To determine early osteogenic
differentiation, alkaline phosphatase (ALP) activity was measured using a
colorimetric assay (Sigma-Aldrich, St. Louis, MO, USA) and normalized
to cellular DNA content. Finally, for late stage osteogenic differentiation,
calcium deposition was measured using a p-nitrophenyl phosphate (4-NP)
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colorimetric assay (Sigma-Aldrich, St. Louis, MO, USA).
Samples from cell culture experiments were taken at the days 7, 14, 21, 28
and 35. For sampling, cell layers were washed twice with PBS, and stored
with 1 ml MilliQ at −80◦C. After two repetitive freeze/thaw cycles, samples
were used as per instructions of the manufacturer of the assay kits. Sam-
pling for calcium deposition, measurements was performed by incubating the
remaining extracellular matrix in the 24 well plates overnight at room tem-
perature with 1 ml 0.5N acidic acid on a shaking plate. For direct co-culture,
the ALP and calcium deposition data were normalized with initial AT-MSCs
cell seeding number.
4.2.5 Statistical analysis
The data was statistically analyzed using Graphpad Prism software (Graph-
Pad Software INC.7825 Fay Avenue, Suite 230 La Jolla, CA 92037, USA).
An one-way ANOVA with post-hoc Dunett’s comparisons test was used to
analyze the effect of different cell types on proliferation, differentiation and
mineralization. An unpaired t-test was used to analyze the data between
different co-culture set-up, i.e. direct versus indirect. Differences were con-
sidered as significant at p < 0.05.
4.3 Results
This study is based on results using AT-MSCs of three different human
donors. All donor cells were first characterized with FACS for expression
of stem cell markers (CD73, CD90, and CD105). The results of FACS analy-
sis showed that AT-MSCs (all three donors) were 99% positive for expression
of these markers and completely negative for CD45 expression (data not
shown). All donor cells further showed positive results for differentiation
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and mineralization (based on ALP activity and Ca deposition results). A
comparative overview of co-culture results compared to simultaneous respec-
tive AT-MSCs mono-culture controls is presented in Table 4.3. Similarly, a
comparative overview of direct versus indirect co-culture results is presented
in Table 4.4.
Table 4.3: Overview of co-culture results of AT-MSCs from 3 donors com-
pared to respective AT-MSCs mono-cultures.
AT-HU AT-HU AT-RAW AT-RAW
Direct Indirect Direct Indirect
Proliferation
Donor 1 01 0 + 0
Donor 2 0 0 + 2 0
Donor 3 0 0 + 0
Differentiation
Donor 1 + + -3 +
Donor 2 + ±4 - -
Donor 3 + ± - -
Mineralization
Donor 1 + + - +
Donor 2 + - - -
Donor 3 + 0 - 0
1 no differences in proliferation, differentiation or mineralization of experimental groups
compared to AT-MSCs mono-culture
2 increased proliferation, differentiation or mineralization of experimental groups com-
pared to AT-MSCs mono-culture control
3decreased proliferation, differentiation or mineralization of experimental groups com-
pared to AT-MSCs mono-culture control
4 variable proliferation, differentiation or mineralization in experimental groups com-
pared to AT-MSCs mono-culture control
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Table 4.4: Overview of direct versus indirect co-culture results with AT-
MSCs from 3 human donors.
AT-HU AT-RAW
Direct vs indirect co-culture Direct vs indirect co-culture
Proliferation
Donor 1 0 -
Donor 2 + -
Donor 3 + -
Differentiation
Donor 1 + +
Donor 2 - +
Donor 3 - +
Mineralization
Donor 1 - +
Donor 2 - +
Donor 3 - +
4.3.1 Cell morphology
With inverted light microscopy, it was possible to monitor the cell morphol-
ogy of all experimental groups. The results at days 7 and 35 for both direct
and indirect culture set-up are presented in (Figure 4.1 and 4.2).
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Figure 4.1: Cell morphology at day 7 (inverted light microscopy). The
groups: AT-AT (control), AT-HU, AT-RAW in direct or indirect culture
set-up
Already at day 7, cells completely covered the culture area of 24 well plates in
both direct and indirect culture set-up. Detectable morphological differences
were observed also in inserts (indirect culture set-up), especially for AT-
MSCs versus RAW264.7 cells. AT-MSCs showed an elongated and spindle
shape morphology, whereas RAW 264.7 cells appeared round shape. At day
35, dense cellular accumulations were observed for all groups, in which min-
eral depositions (black spots; highlighted with red arrows) were detectable
(Figure 4.1 and 4.2).
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Figure 4.2: Cell morphology at day 35 (inverted light microscopy). The
groups: AT-AT (control), AT-HU, AT-RAW in direct or indirect culture
set-up.
Scanning electron microscopy showed that AT-MSCs (AT-AT) had a similar
morphology in both direct and indirect co-culture where cellular multilayers
covered globular deposits (Figure 4.3). In contrast, the direct and indirect
co-cultures of AT-HU, as well as AT-RAW showed different morphologies. In
direct AT-HU, many globular deposits were observed to which cells attached,
but in indirect AT-HU only few globular deposits were detectable, which were
covered by cellular multilayers. In direct AT-RAW, few cellular accumula-
tions were observed and the culture surface appeared not completely covered
with cells. In indirect AT-RAW, cells created very dense cellular multilayers
with few globular deposits.
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Figure 4.3: Cell morphology at day 35 (SEM). The groups: AT-AT (control),
AT-HU, AT- RAW in direct or indirect culture set-up.
4.3.2 Effect of HU & RAW cells on AT-MSC prolifer-
ation
Based on results of cellular DNA content, a significantly increased prolifer-
ation was observed for direct AT-RAW (p< 0.001) during the entire culture
period (Figure 4.4). The proliferation pattern for direct and indirect AT-
HU, as well as for indirect AT-RAW was similar to AT-MSC monoculture,
where proliferation increased till day 21 and day 28, after which proliferation
decreased to day 35. Remarkably, in these groups (direct/indirect AT-AT, di-
rect/indirect AT-HU, indirect AT-RAW) the proliferation was decreased also
at day 14 (results of Donor 1). Table 4.3 presents an overview of co-culture
results from 3 different donors, which shows similar proliferation patterns
for all donors. Comparing direct versus indirect co-cultures (Table 4.4), an
increased proliferation was generally observed for indirect AT-HU (Donor 2
and 3), and direct AT-RAW (all donors).
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Figure 4.4: DNA content of AT-MSCs (Donor 1) at day 7, 14, 21, 28 and 35.
The groups: AT-AT (control), AT-HU, AT-RAW in direct or indirect culture
set-up. *p < 0.05, **p < 0.01 and ***p < 0.001 indicate the significant differences of
AT-HU and AT-RAW compared to AT-AT control, in direct and indirect culture set-up.
#p < 0.05, ## p< 0.01 and ###p< 0.001 indicate the significant difference between direct
and indirect co-culture.
4.3.3 Effect of HU & RAW cells on AT-MSCs differ-
entiation
Early osteogenic differentiation of AT-MSCs was measured by ALP-activity
for both direct and indirect culture set-up (Figure 4.5). The results indicated
a positive effect of HUVECs on the osteogenic differentiation of AT-MSCs in
both direct and indirect culture set-up, where the ALP level was significantly
increased during the entire culture period (direct co-culture → p < 0.01 at
day 7, 14, 28; p< 0.001 at day 21 and 35; indirect co-culture → p < 0.01 at
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day 14; p< 0.05 at day 28). RAW264.7 cells also positively affected AT-MSCs
osteogenic differentiation, but not during the entire culture period.
Figure 4.5: ALP activity of AT-MSCs (Donor 1) at day 7, 14, 21, 28 and 35.
The groups: AT-AT (control), AT-HU, AT-RAW in direct or indirect culture
set-up. *p < 0.05, **p < 0.01 and ***p < 0.001 indicate the significant differences of
AT-HU and AT-RAW compared to AT-AT control, in direct and indirect culture set-up.
#p < 0.05, ###p < 0.01 and ###p < 0.001 indicate the significant difference between
direct and indirect co-culture.
A significantly increased ALP-activity was observed for direct AT-RAW at
day 28 (p< 0.001) and for indirect AT-RAW at day 35 (p< 0.05). Next,
a decreased osteogenic differentiation was observed during the first three
weeks for direct AT-RAW (p< 0.001 → day 7; p< 0.05 → day 14 and 21).
At the same time points, no significant differences were observed for indirect
AT-RAW. ALP-activity was similar for the three different donors in direct
AT-HU and direct AT-RAW, but varied for indirect AT-HU and indirect
AT-RAW (Table 4.3). For direct versus indirect co-cultures, an increased
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differentiation was observed for indirect AT-RAW (for all donors), and direct
AT-HU (Donor 2, Donor 3).
4.3.4 Effect of HU & RAW cells on AT-MSCs miner-
alization
Ca deposition was measured to monitor the late stage osteogenic differenti-
ation and mineralization of AT-MSCs.
Figure 4.6: Ca content of AT-MSCs (Donor 1) at day 7, 14, 21, 28 and 35.
The groups: AT-AT (control), AT-HU, AT-RAW in direct or indirect culture
set-up. *p < 0.05, **p < 0.01 and ***p < 0.001 indicate the significant differences of
AT-HU and AT-RAW compared to AT-AT control, in direct and indirect culture set-up.
#p < 0.05, ##p < 0.01 and ###p < 0.001 indicate the significant difference between
direct and indirect co-culture.
Results of Ca deposition were normalized for initial cell seeding number (Fig-
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ure 4.6), which showed that HUVECs positively affected AT-MSCs miner-
alization in both direct and indirect culture set-up. For direct AT-HU, a
significantly increased mineralization was observed at days 14, 21, 28 and 35
(p< 0.001). For indirect AT-HU, an increased mineralization was observed
at days 21 (p< 0.05), 28 and 35 (p< 0.01). The mineralization patterns were
similar for all three donors in the direct culture set-up, but varied in the
indirect culture set-up (Table 4.3). Direct versus indirect co-cultures showed
an increased mineralization for direct AT-HU for all three donors(Table 4.4).
RAW 264.7 cells had a positive effect on AT-MSCs mineralization only in
an indirect culture set-up (Donor1), in which a significantly increased min-
eralization was observed at days 14 (p< 0.05), 28 and 35 (p< 0.01). For
direct AT-RAW, however, mineralization was significantly decreased at days
14, 21, 28 and day 35 (p< 0.001). The mineralization pattern of AT-RAW
varied among the three donors (Table 4.3). Direct versus indirect co-culture
showed an increased mineralization for all three donors (Table 4.4).
4.4 Discussion & Conclusion
The aim of this study was to evaluate the osteogenic differentiation of AT-
MSCs upon co-culture with endothelial cells or macrophages in a direct or
indirect culture set-up. Our hypotheses were that (i) endothelial cells and
macrophages stimulate AT-MSCs proliferation and osteogenic differentiation,
and that (ii) these two cell types will more profoundly affect on osteogenic
differentiation of AT-MSCs in a direct compared to an indirect culture set-
up, because of the possibility for both cell-cell interactions and effects of
secreted soluble factors. We observed that HUVECs had a positive effect
on osteogenic differentiation and mineralization of AT-MSCs, especially in
a direct culture set-up, whereas the same HUVECs had no effect on AT-
MSCs proliferation for neither direct nor indirect culture set-ups. Finally, we
observed that RAW264.7 cells had a variable effect on AT-MSCs osteogenic
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differentiation and mineralization.
An important concept in cell-based bone regenerative strategies is to under-
stand cell-cell interactions between different cell types, which are involved
in fracture healing, bone regeneration, remodeling and wound healing pro-
cesses. This will help to investigate new approaches in bone regenerative
research. To understand cellular communication between different cell types,
this study used endothelial (HUVECs) and immune cells (RAW 264.7) as
co-culture partners for AT-MSCs from three different donors. The results
showed that HUVECs have a positive effect on AT-MSC osteogenic differen-
tiation and mineralization, which was consistent for all three donors in direct
co-culture set-up. A positive effect of AT-MSC osteogenic differentiation and
mineralization was observed also for indirect AT-HU, but results were not
consistent for all donors. This finding indicates that HUVECs can interact
with AT-MSCs in vitro and promote osteogenic differentiation via direct and
indirect cellular cross-talk [27, 28]. Moreover, in direct co-culture set-up,
HUVECs more efficiently affected AT-MSCs osteogenic differentiation and
mineralization compared to indirect set-up, likely because of simultaneous
direct cell-cell contact and actions of secreted soluble molecules.
In contrast, HUVECs showed no effect on AT-MSC proliferation, neither
in direct nor in indirect co-culture set-up. However, opposite results have
been reported for MSCs isolated from bone tissue, for which HUVECs were
able to increase the proliferation, especially in direct co-culture set-up [29].
These results suggest that MSCs from different tissue origins in co-culture
with HUVECs may exert different behavior.
RAW264.7 cells showed a negative effect on AT-MSCs osteogenic differen-
tiation and mineralization, especially in a direct co-culture set-up. Based
on morphological evaluation of the co-culture, the number of AT-MSCs ap-
peared very low for direct AT-RAW during the entire culture period. This
could explain the low levels of ALP activity and Ca deposition in the direct
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AT-RAW group. It is known that RAW264.7 cells are a type of macrophages,
whose main function is to digest any substance recognized as foreign (cellu-
lar debris, pathogenic factors such as pathogen bacteria, viruses, cancer cells,
etc.) in blood or in tissues [30]. Because AT-MSCs and RAW264.7 cells de-
rive from different species, AT-MSCs might have been recognized as a foreign
cell type and digested by RAW264.7 cells [31], which would explain survival
issues of AT-MSCs in direct co-culture with RAW 264.7 cells. RAW264.7
cells further are able to differentiate into osteoclasts in vitro upon stimu-
lation with RANKL. Osteoclasts are bone resorbing cells and generally in
balance with osteoblasts. In direct contact with AT-MSCs, RAW264.7 cells
might show osteoclastic behavior and affect AT-MSCs proliferation and dif-
ferentiation into osteoblasts [32]. Although in the present study no proof was
obtained for osteoclastogenesis of RAW264.7 cells, the occurrence of osteo-
clastic differentiation cannot be excluded, particularly in view of the used
human platelet lysate during cell cultures, which is rich in many signaling
molecules and growth factors.
For some AT-MSC donors, RAW264.7 cells showed a positive effect on os-
teogenic differentiation and mineralization in indirect co-culture set-up. Pre-
viously, a positive effect of macrophages on osteogenic differentiation of MSCs
was shown by several studies. Few studies indicated that resident tissue
macrophages (OsteoMacs) impact bone formation [33, 34]. Therefore, it
becomes more interesting to investigate how macrophages (from the same
species) can affect osteogenic differentiation of AT-MSCs in vitro. From all
experimental groups, only direct AT-RAW showed an increased prolifera-
tion. Based on morphological appearance, however, this was likely a result
of the fast growth of RAW264.7 cells rather than a stimulatory effect of
macrophages on AT-MSCs proliferation.
The results of this study contribute to continuing and improving future in
cell-based bone regenerative strategies, especially related to novel co-culture
based strategies. The clinical relevance of this study is that AT-MSCs show
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high potential for bone tissue regeneration, because AT-MSCs even at half
the number of control mono-cultures, in co-culture with other cell types can
achieve equal levels of in vitro mineralization compared to AT-MSC mono-
cultures. Stimulated osteogenic differentiation and mineralization of AT-
MSCs was observed especially for co-cultures with endothelial cells, where
AT-HU 50%-50% ratio showed equal mineralization as AT-MSC monocul-
ture. The fact that endothelial cells promote AT-MSCs differentiation into
osteoblasts makes co-culture system attractive for future preclinical and clin-
ical trials. This effective cellular communication gives an idea about cellu-
lar behavior in natural bone micro-environment. However, further research
needs to be performed in co-culture systems and a variation of parameters
must be investigated to mimic the natural bone micro-environment and en-
tire regeneration cascade. By the help of dedicated scaffold systems, a 3D
cellular interaction needs to be analyzed and more cell types need to be in-
cluded in the same scaffold system. With successful in vitro results next, in
vivo research need to be performed, where more parameters can be examined
in a natural micro-environment.
In conclusion, endothelial cells showed a positive effect on AT-MSC os-
teogenic differentiation and mineralization. Interestingly, AT-MSCs in AT-
HU co-culture set-up, where AT-MSCs were only 50% of total amount, com-
pared to monoculture controls (100% AT-MSCs), achieved equal levels of
mineralization. Direct co-culture of AT-MSCs with HUVECs appeared more
effective for osteogenic differentiation and mineralization compared to indi-
rect. This proved our hypothesis that direct co-cultures more profoundly
affect osteogenic differentiation and mineralization of AT-MSCs because of
direct cell-cell contact. Macrophages, for indirect co-cultures, affect on os-
teogenic differentiation and mineralization of AT-MSCs variably, whereas for
direct co-cultures they decrease the osteogenic differentiation of AT-MSCs,
which probably related to species differences in the used cell types. The re-
sults of this study demonstrate the potential of cell combination strategies
in bone regenerative research.
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4.5 Supplementary materials
Figure 4.7: DNA content of AT-MSCs (Donor 2) at day 7, 14, 21, 28 and 35.
Figure 4.8: ALP activity of AT-MSCs (Donor 2) at day 7, 14, 21, 28 and 35.
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Figure 4.9: Ca content of AT-MSCs (Donor 2) at day 7, 14, 21, 28 and 35.
Figure 4.10: DNA content of AT-MSCs (Donor 3) at day 7, 14, 21, 28 and
35.
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Figure 4.11: ALP activity of AT-MSCs (Donor 3) at day 7, 14, 21, 28 and
35.
Figure 4.12: Ca content of AT-MSCs (Donor 3) at day 7, 14, 21, 28 and 35.
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CHAPTER 5
Effect of nano-HA/Collagen Composite Hydrogels on
Osteogenic Behavior of Mesenchymal Stromal Cells
5.1 Introduction
Bone loss, caused by trauma, tumor resection or congenital disorders, is an
increasingly serious health problem, for which current treatment remains a
clinical challenge, especially for critical size bone defects [1]. Structurally,
bone tissue forms the human skeleton, which consists of multiple cell types
and a largely mineralized extracellular matrix (ECM). The organic part of
ECM is composed of protein fibers (mainly type 1 collagen), which repre-
sents about 30 wt% of bone. The inorganic part of bone is composed of
minerals (∼70 wt% of bone), with hydroxyapatite (HA; Ca10(PO4)6(OH)2)
as the major component [2, 3]. As such, the ratio between collagen and HA
is approximately 1:2. These HA crystals, embedded within the extracellular
matrix, are very small, measuring approximately 200A˚ (in the largest di-
mension, i.e. nano-sized HA, nHA). In a synergistic manner, the strands of
collagen provide bone with tensile strength and the interspersed nHA crystals
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provide compressional strength [4].
Nowadays in bone regenerative research, the use of scaffold systems receives
remarkable attention, because of the increasing demand to replace autologous
bone for grafting purposes. For an appropriate cell attachment, proliferation
and osteogenic differentiation, scaffolds need to pass several properties, e.g.
biocompatibility, ability of fluid transport, delivery of bioactive molecules,
surface topographical cues, degradability and ability to induce signal trans-
duction [5].
In view of biomimicry, it seems appealing to develop scaffolds that combine
structural properties of bone ECM. Among the different materials available
for scaffold preparation, hydrogels represent a highly versatile group of bio-
materials with appealing properties for 3D scaffolding. Hydrogels are hy-
drophilic networks (water content ≥ 30% by weight) of natural or synthetic
polymer chains, which approximate the viscoelastic properties of native tissue
[6]. Because of distinctive features, such as biocompatibility, cell-controlled
degradability, injectability, ability to release drugs or bioactive molecules,
hydrogels are considered as reliable biomaterials for the regeneration of a
wide range of tissues, including cartilage and bone [5, 7]. Natural hydrogels
(i.e. collagen, fibrin) have more advantages, because they demonstrate non
antigenic and intrinsic cellular interaction capacities [8]. Moreover, collagen
based hydrogels support the expression of an osteogenic phenotype of (differ-
entiating) MSCs in vivo [9]. However, the mechanical properties of collagen
are relatively low (E∼100MPa) in comparison to bone (E ∼ 2−50GPa) [10].
To obtain more biomimetic scaffold systems for bone regeneration, several
attempts have focused on the combination of a hydrogel and HA to study
effects of cell behavior (mainly mesenchymal stromal cells, MSCs) in vitro
and bone regeneration in vivo [11, 12, 13]. These studies have shown that
HA/collagen based composite hydrogels can have potential to enhance MSC
osteogenic differentiation [7, 14].
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From a cellular perspective, hydrogels provide a 3D micro-environment to
which cells can attach, attain a specific morphology, have 3D cell-cell/cell-
biomaterial interactions and subsequently proliferate and differentiate [15].
Moreover, for bone regeneration, the use of cell-based constructs provides
osteoinductive properties [16, 17] in comparison to bare scaffolds [18, 19].
Since in the developmental and regenerative processes of bone BM-MSCs are
involved, they have become the main cell source for bone tissue engineering
[20]. However, MSCs can be extracted from different tissues, such as skin,
muscle, periodontal ligament, blood, adipose tissue (AT) and the yield of
extracted cells is dependent of cell source. The easiest harvesting of MSCs
(less invasive) with substantial yield is from adipose tissue [21, 22]. Moreover,
at the same 2D culture condition (using platelet lysate [PL] or fetal bovine
serum [FBS] as nutritional supplement), AT-MSCs showed higher prolifer-
ation and osteogenic differentiation capacities compared to BM-MSCs, and
AT-MCSs showed their highest proliferation and osteogenic differentiation
capacities in PL supplemented media, whereas BM-MSCs did in FBS sup-
plemented media [21, 23]. In view of this, the major challenge remains to
understand the complexity of cellular responses of different MSCs to different
scaffold systems.
The aim of this study was to comparatively evaluate the in vitro effect of
biomimetic nHA/collagen based composite hydrogels (with different ratios
of nHA) on the behavior of human MSCs, isolated from adipose tissue (AT-
MSCs) or bone marrow (BM-MSCs). We hypothesized that (i) nHA/collagen
based hydrogels will promote the osteogenic differentiation of MSCs in an
nHA concentration dependent manner, (ii) AT-MSCs will show higher os-
teogenic potential compared to BM-MSCs, because of their intrinsic higher
proliferation and osteogenic differentiation potential in in vitro 2D cultures.
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5.2 Materials & Methods
5.2.1 Cell culture
AT-MSCs were isolated from fat tissue of healthy human donors. The fat
tissue was obtained from the Department of Plastic Surgery (Radboudumc,
the Netherlands) after written informed consent.
Table 5.1: Composition of the proliferation media (PM) and osteogenic media
(OM).
BM-MSCs AT-MSCs
FBS-supplemented (PM-FBS) PL-Supplemented (PM-PL)
Minimal Essential Medium (α-MEM)
15% fetal bovin serum (FBS)
0.2 mM L-ascorbic acide 2-phosphate
(Vit C)
2 mM L-glutamine
100 U/ml penicillin
10 µg/ ml streptomycin
Minimal Essential Medium (α-MEM)
5% platelet lysate (PL)
10U/ml heparin
100 U/ml penicillin
10 µg/ ml streptomycin
FBS-supplemented (OM-FBS) PL-Supplemented (OM-PL)
Minimal Essential Medium (α-MEM)
15% fetal bovin serum (FBS)
0.2mM L-ascorbic acide 2-phosphate
(Vit C)
2 mM L-glutamine
100 U/ml penicillin
10 µg/ ml streptomycin
10-8 M dexamethasone
0.01 M β-glycerophosphate
Minimal Essential Medium (α-MEM)
5% platelet lysate (PL)
0.2 mM L-ascorbic acide 2-phosphate
(Vit C)
2 mM L-glutamine
100 U/ml penicillin
10 µg/ ml streptomycin
10-8 M dexamethasone
0.01 M β-glycerophosphate
0.02 10U/ml heparin
BM-MSCs were isolated from human iliac bone chips, obtained from patients
undergoing maxillofacial surgery at the Department of Oral and Craniofa-
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cial Surgery (Radboudumc, the Netherlands) after written informed consent.
MSC extraction was performed according to the principles of the Declara-
tion of Helsinki. The isolation procedure of AT-MSCs and BM-MSCs is
described in detail elsewhere [21, 24, 25, 26]. Harvested cells were exam-
ined by fluorescence-activated cell sorting (FACS) for positive expression of
CD73, CD90 and CD105 (eBioscience, San Diego, USA) and negative expres-
sion of CD45 (R&D system, Abingdon, United Kingdom). Next, both cell
types were examined (via biochemical assays) for their osteogenic potential,
i.e. ALP activity and calcium deposition. Upon usage, MSCs were cultured
in corresponding proliferation media consisting of alpha Minimal Essential
Medium, (α-MEM; Gibco R©, Life Technologies, Grand Island, USA) sup-
plemented either with 5% PL (Sanquin Blood Bank, the Netherlands) for
AT-MSCs or with 15% fetal bovine serum (FBS; Lonza, Basel, Switzerland)
for BM-MSCs [21], at 37◦C in humid atmosphere with 5% CO2 (the com-
plete composition of proliferation media is given in Table 5.1). Medium was
changed twice a week. Cells were passaged upon reaching ∼ 80% confluency
using 0.25% w/v trypsin/0.02% EDTA (Gibco R©).
5.2.2 Preparation of hydrogels & experimental groups
Prior to the preparation of hydrogel scaffolds, nHA crystals (size: 20-500 nm;
Berkeley Advanced Biomaterials, Berkeley, CA, USA) were suspended in PBS
(10x concentrated) with a final concentration of 150 mg/ml. The suspension
was homogenized by sonication for 20 min. Before addition to hydrogels
(see in Table 5.2), each time the suspension was vortexed for 1 min. For
the preparation of hydrogels, collagen type 1 (COL; rat tail; BD Bioscience,
Bedford MA, USA) was used with various amounts of nHA (Table 5.2). The
procedure of hydrogel preparation was according to manufacturer’s instruc-
tion (Table 5.2), and composite nHA/COL hydrogels were prepared with an
nHA/COL ratio (wt/wt) of 0/1, 1/1, and 2/1. MSCs were added during
hydrogel preparation (Table 5.2).
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Table 5.2: Reagents for scaffold preparation and cell encapsulation.
Groups A. Without cells B. With the cells
CaP/ Collagen
0:1 (control)
Collagen 2610 µl
PBS(10x) 300µl
CaP susp. 0
NaOH 1N 60µl
H2O/α-MEM 30µl
Cell susp. 0
Total 3000 µl
Collagen 2610 µl
PBS(10x) 300µl
CaP susp. 0
NaOH 1N 60µl
H2O/α-MEM 0µl
Cell susp. 30µl
Total 3000 µl
CaP/ Collagen 1:1 Collagen 2610 µl
PBS(10x) 240µl
CaP susp. 60µl (150 mg/ml)
NaOH 1N 60µl
H2O/α-MEM 30µl
Cell susp. 0
Total 3000 µl
Collagen 2610 µl
PBS(10x) 240µl
CaP susp. 60µl (150 mg/ml)
NaOH 1N 60µl
H2O/α-MEM 0µl
Cell susp. 30µl
Total 3000 µl
CaP/ Collagen 2:1 Collagen 2610 µl
PBS(10x) 180µl
CaP susp. 120µl (150 mg/ml)
NaOH 1N 60µl
H2O/α-MEM 30µl
Cell susp. 0
Total 3000 µl
Collagen 2610 µl
PBS(10x) 180µl
CaP susp. 120µl (150 mg/ml)
NaOH 1N 60µl
H2O/α-MEM 0µl
Cell susp. 30µl
Total 3000 µl
Cell seeding density of AT-MSCs and BM-MSCs in all experimental groups
was 1x106 per 1 ml of hydrogels. For the analysis of cellular behavior (DNA
content, ALP activity and calcium [Ca] deposition) and histological analysis
(HE staining, Von Kossa staining and immunohistochemistry [IHC]) hydro-
gels were injected in 48 well plates, with the total hydrogel volume of 200 µl
(200.000 cells; n=3). To obtain sufficient RNA, hydrogels for RNA extrac-
tion were injected in 24 well plates, with the total volume of 400 µl (400.000
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cells; n=3). All samples were incubated in corresponding osteogenic media
(Table 5.1), supplemented with either 5% PL for AT-MSCs or 15% FBS for
BM-MSCs and incubated for 35 days at 37◦C in a humid atmosphere with
5% CO2. To monitor the behavior of pure hydrogels (without cells) as a neg-
ative control nHA/COL=0/1, nHA/COL=1/1, nHA/COL=2/1 constructs
were prepared and cultured either in PL or in FBS supplemented media.
Cell morphology was monitored with an inverted light microscope (Leica
DM-IL, 5W LED illumination, Rijswijk, the Netherlands).
5.2.3 Cell behavior
To monitor cellular behavior, cellular DNA content, alkaline phosphatase
(ALP) activity and calcium deposition were analyzed [21]. Samples were
collected (at days 1, 14, 28 and 35) in 1 ml MilliQ and subsequently stored
at −80◦C until use. The same samples were used for all biochemical as-
says. For extraction of cells from hydrogels, scaffolds were digested first
using Collagenase A (Roche Diagnostics Penzberg, Germany). According
to the manufacturer’s instruction, a digestion buffer was prepared in a con-
centration of 1 mg/ml. Before digestion, the constructs were washed 2 times
with PBS, incubated with 1 ml digestion buffer overnight at 37◦C on a rotary
shaker. After complete digestion and two repetitive freeze/defroze cycles at
−80◦C/ + 20◦C, samples were ready for the analysis of DNA content, ALP
activity and Ca deposition [21, 27]. After analyzing DNA content and ALP
activity, samples were doubled in volume using 1N acetic acid (to dissolve
mineral deposits) and incubated at room temperature overnight. Ca deposi-
tion was measured as described previously [28].
5.2.3.1 Cellular DNA content
Cellular DNA content was measured using a QuantiFluor R© dsDNA System
Kit (Promega, Madison, Wisconsin, USA). For the standard curve, serial
dilutions of dsDNA stock (range: 0-2000 ng/ml) were prepared. 100 µl of
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either sample of standard solution was added into the wells, followed by 100
µl of working solution. The plate was incubated at room temperature for
5 min, and then the absorbance of samples/standards was measured at 504
nm excitation and 541nm emission, using a fluorescence microplate reader
(FL600, BioTek, Canada).
5.2.3.2 Alkaline phosphatase (ALP) activity
ALP activity was measured using a 5 nM p-nitrophenyl phosphate (4-NP)
colorimetric assay. The procedure was according to the manufacturer’s in-
struction (Sigma-Aldrich, St. Louis, MO, USA). Briefly, 80 µl of sample solu-
tion was combined with 20 µl of buffer (0.5 M 2-amino-2methyl-1-propanol).
A standard curve was prepared with serial dilutions of 4-NP, in a range of
0-25 nmol. Next, 100 µl substrate solution (5 nM p-nitrophenyl phosphate)
was added to the samples/standards and incubated for 60 min at 37◦C. The
reaction was stopped by adding to each well 50 µl 0.3M NaOH and the ab-
sorbance of samples was measured at 405 nm using an ELISA microplate
reader (EL800, BioTek, Abcoude, the Netherlands). ALP activity was nor-
malized for corresponding cellular dsDNA amount.
5.2.3.3 Calcium deposition
Calcium deposition was measured using the orthocresolphtalein complexone
assay (OCPC; Sigma Aldrich, St. Louis, MO, USA), which is based on
a colorimetric reaction between o-cresolphthalein complexone and calcium.
The assay was performed according to the manufacturer’s instruction. For
the standard curve, serial dilutions of calcium stock (CaCl2) were prepared
(range: 0-100 mg/ml). Next, 10 µl of sample or standard was used, to
which 300 µl OCPC solution was added to complete the reaction. After
the incubation of the plate for 10 min at room temperature, the absorbance
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was measured at 570 nm using an ELISA microplate reader (EL800, BioTek,
Canada).
5.2.4 Analysis of osteogenic molecules
5.2.4.1 RNA isolation and reverse transcription
To analyze gene expression profiles of selected genes, cellular RNA was iso-
lated using Tryzol method in combination with the Genelute Mammalian
Total RNA Miniprep Kit (Sigma-Aldrich). Samples were collected (at days
0, 14, 28 and 35) in 1 ml trizol lysis buffer and subsequently stored at −80◦C
until RNA extraction. After extraction, RNA was quantified using a spec-
trophotometer (Nanodrop Technologies, Wilmington, DE, USA). For reverse
transcription (cDNA synthesis), an iScript
TM
cDNA kit was used (Bio-Rad,
Hercules, CA, USA), and for each cDNA reaction 1 µg of RNA was used.
The samples were stored at −20◦C until use.
5.2.4.2 Real-Time Polymerase Chain Reaction
For real-time polymerase chain reaction (RT-PCR), qPCR Master Mix Plus/
SYBR Green I (Eurogentec; Seraing, Belgium) was used. RT-PCR was com-
pleted with 40 amplification cycles. The sequence of applied primers is given
in Table 5.3. The raw data were normalized to the expression of Ribosomal
Protein Large P0 (RPLP0 housekeeping gene) within the same sample/RNA
[29]. Gene expression level and fold changes were calculated according to
Livak & Schmittgen (2−∆∆Ct) relative subsequently to AT-MSCs or BM-
MSCs at the day 0 [30]. The genes of interest were Osteocalcin (OCN),
Bone Morphogenetic Protein 2 (BMP2), Runt-related Transcription Factor
2 (RUNX2), and Collagen type 1 (COL1).
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Table 5.3: Primer sequences for RT-PCR
Gene name Sequences
RPLP0 Forward- TTCTTCTTTGGGCTG GTCAT
Reverse- TTGGGTAGCCAATCTGCAGA
RUNX2 Forward- TCTGGCCTTCCACTCTCAGT
Reverse- GACTGGCGGGGTGTAAGTAA
BMP-2 Forward- CCCAGCGTGAAAAGAGAGAC
Reverse- GGAAGCAGCAACGCTAGAAG
COL1 Forward- GGTGTAAGCGGTGGTGGTTAT
Reverse- AGGTTCCCCGTTCTCACTTT
OCN Forward- GGCGCTACCTGTATCAATGG
Reverse- GTGGTCAGCCAACTCGTCA
5.2.5 Histological analysis & immunohistochemistry
Samples for histological analysis and IHC were collected at day 7 and 28,
fixed at 10% formalin, decalcified in 4% EDTA for ∼ 2 weeks, and regu-
larly checked with X-ray for the level of remaining mineral content in the
constructs. After complete demineralization, samples were dehydrated in
a graded series of ethanol (70-100%) and embedded in paraffin. Simulta-
neously, human bone chips (obtained from the Department of Maxillofacial
surgery, Radboudumc, Nijmegen, the Netherlands; after written informed
consent), were processed as a control for all stains. Sections with a thickness
of 6 µm were prepared using a standard microtome (RM2165; Leica, Nuss-
loch, Germany). To analyze cell distribution in hydrogels, every 10th slide
was stained with hematoxylin/eosin (HE). To identify phosphate groups in
mineralized matrix, separate slides were prepared for Von Kossa staining,
which were stained first with 5% silver nitrate (AgNO3), washed with distilled
water, dehydrated again, and fixed with 5% sodium thiosulfaat (Na2S2O3).
Next, continuous tissue sections were used to monitor osteogenic differen-
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tiation of cells in hydrogels. As an osteogenic marker, osteocalcin (OCN,
rabbit anti-mouse osteocalcin) protein was cheeked by IHC. Sections were de-
paraffinised, rehydrated and rinsed in PBS. Next, samples were fixed for 10
min in 10% hydrogen peroxide (stock)/methanol solution. Afterwards, sam-
ples were pre-incubated for 10 min with 10% normal donkey serum (NDS)
and then incubated with the primary antibody (1:1600) overnight at 4◦C.
Subsequently, sections were washed 3x with PBS, and incubated with sec-
ondary antibody, anti mouse IgG (host donkey) conjugated with biotin (Jack-
son Immuno-Research, West Baltimore Pike, West Grove, PA, USA) for 60
min. After washing, the peroxidase conjugates were visualized with 3’3 di-
aminobenzidine (DAB) substrate (Envision kit; Dako Cytomation) for 10 min
at room temperature, and nuclei were stained for 10 sec with hematoxilin.
5.2.6 Statistical analysis
Data are presented as mean ± standard deviation. Statistical analysis was
performed based on N=3 (for all experimental groups) with Graphpad Prism R©
5.03 software (Graphpad Software Inc, San Diego, CA, USA). Quantitative
results were analyzed using a one-way ANOVA with a Posthoc Dunnett test
(using nHA/COL=0/1 either day 7 [for biochemical assays] or day 14 [for Q-
PCR analysis] as control). Differences were considered significant at p< 0.05.
All experiments were repeated 4 times.
5.3 Results
The results of FACS analysis showed that both cell types (AT-MSCs and BM-
MSCs) were 99% positive for expression of stem cell surface markers CD73,
CD90 and CD105, whereas both these cell types were completely negative
for the hematopoietic marker CD45 (data not shown).
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5.3.1 Cell morphology
Light microscopy analysis showed that both AT-MSCs and BM-MSCs were
able to survive in nHA/COL constructs (Figure 5.1).
2. Day 3 AT-nHA/COL=1/1 3. Day 3 AT-nHA/COL=2/11. Day 3 AT-nHA/COL=0/1
5. Day 3 BM-nHA/COL=1/14. Day 3 BM-nHA/COL=0/1 6. Day 3 BM-nHA/COL=2/1
Figure 5.1: Cell morphology of AT-MSCs or BM-MSCs monitored with in-
verted light microscopy in different nHA/COL constructs, after 3 days of
culture
Both cell types showed an elongated, spindle-shaped morphology in these
constructs, but from 3 days of culture onward, AT-MSCs visually appeared
at higher cell density than BM-MSCs. After 7 days, hydrogels changed their
shape and morphology, becoming dense and no longer transparent for light
microscopy evaluation. The constructs shrunk drastically by changing diam-
eter size about 2-fold (from ∼11mm to ∼4-5mm).
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5.3.2 Cell behavior
5.3.2.1 Cellular DNA content
AT-MSCs showed a gradual increase in cell proliferation until day 14 (Fig-
ure 5.2). A significant temporal increase in cellular DNA content (relative
to day 7) was observed for AT-nHA/COL=0/1 at day 14 (p<0.05), AT-
nHA/COL=1/1 at day 14, 28, 35 (p< 0.001), and AT-nHA/COL=2/1 at
day 14, (p< 0.001). Relative to AT-nHA/COL=0/1, at day 7, a significantly
lower cellular DNA content was observed for AT-nHA/COL=1/1 (p< 0.05)
and AT-nHA/COL=2/1 (p< 0.01). BM-MSCs (Figure 5.2), showed limited
cell proliferation over the entire culture period. Relative to day 7, a significant
increase in cellular DNA content was observed only for BM-nHA/COL=2/1
at day 14 (p< 0.05).
5.3.2.2 ALP activity
AT-MSCs showed a gradual increase in ALP-activity (early marker for os-
teogenic differentiation) until the end of the culture period, irrespective of
construct type (Figure 5.3). A significant increase in ALP-activity (relative
to day 7) was observed for AT-nHA/COL=0/1 and AT-nHA/COL=1/1 at
day 28 and 35 (p< 0.001), and AT-nHA/COL=2/1 at days 28 (p< 0.01) and
35 (p< 0.001). Relative to AT-nHA/COL=0/1, no significant differences
were observed for AT-nHA/COL=1/1 and AT-nHA/COL=2/1. In contrast
to AT-MSCs, very low ALP-activity was observed for BM-MSCs (Figure 5.3)
over the entire culture period, which was significantly decreased (relative to
day 7) until the end of culture in all experimental constructs. Relative to
BM-nHA/COL=0/1, no significant differences were found between different
constructs.
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Figure 5.2: Cellular behavior of MSCs in different nHA/COL constructs. (A)
Cellular DNA content of AT-MSCs, (B) Cellular DNA content BM-MSCs.
The ∗ indicates significantly different compared to nHA/COL=0/1 control, at the same
time point (p-values: ∗p <0.05, ∗∗ p<0.01, ∗∗∗ p<0.001), # indicates significantly different
compared to day 7 (p-values: #p <0.05, ## p<0.01, ### p<0.001).
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Figure 5.3: Cellular behavior of MSCs in different nHA/COL constructs.
(A) ALP-activity of AT-MSCs,(B) ALP-activity of BM-MSCs. ∗ indicates
significantly different compared to nHA/COL=0/1 control, at the same time point (p-
values: ∗p <0.05, ∗∗ p<0.01, ∗∗∗ p<0.001), # indicates significantly different compared to
day 7 (p-values: #p <0.05, ## p<0.01, ### p<0.001).
5.3.2.3 Calcium deposition
Calcium deposition results (Figure 5.4 A,B) were normalized for non-cellular
constructs, which were treated similarly as cellular constructs. The miner-
alization level for both cell types was generally low. Relative to day 7, AT-
MSCs showed a temporal increase in calcium deposition for AT-nHA/COL=1/1
128 Chapter 5: Effect of nano-HA/Collagen Composite Hydrogels
at day 28 (p< 0.05), and at day 35 (p< 0.001) for all experimental constructs.
Figure 5.4: Ca deposition of MSCs in different nHA/COL constructs. (A)
Ca deposition of AT-MSCs, (B) Normailzed Ca deposition of AT-MSCs. ∗
indicates significantly different compared to nHA/COL=0/1 control, at the same time
point (p-values: ∗p <0.05, ∗∗ p<0.01, ∗∗∗ p<0.001), # indicates significantly different
compared to day 7 (p-values: #p <0.05, ## p<0.01, ### p<0.001).
BM-MSCs generally showed a decrease in mineralization (relative to day 7)
starting at day 14 until the end of the culture period (Figure 5.5A,B). Only
for BM-HA/COL=0/1, an increase in mineralization was observed at day 35
(p< 0.001). Relative to BM-nHA/COL=0/1, a significantly increased min-
eralization was observed for BM-nHA/COL=1/1 and BM-nHA/COL=2/1
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(p< 0.001) at day 7.
Figure 5.5: Ca deposition of MSCs in different nHA/COL constructs. (A)
Ca deposition of BM-MSCs, (B) Normailzed Ca deposition of BM-MSCs.
∗ indicates significantly different compared to nHA/COL=0/1 control, at the same time
point (p-values: ∗p <0.05, ∗∗ p<0.01, ∗∗∗ p<0.001), # indicates significantly different
compared to day 7 (p-values: #p <0.05, ## p<0.01, ### p<0.001).
5.3.3 Gene expression
BMP2: AT-MSCs showed a gradual increase in BMP2 expression until day
28, and decrease again until day 35, irrespective of construct type (Fig-
ure 5.6A).
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Figure 5.6: Gene expression profiles of BMP2 (A) in AT-MSCs and (B) in
BM-MSCs. ∗ indicates significantly different compared to nHA/COL=0/1 control, at
the same time point (p-values: ∗p <0.05, ∗∗ p<0.01, ∗∗∗ p<0.001), # indicates significantly
different compared to day 7 (p-values: #p <0.05, ## p<0.01, ### p<0.001)
Relative to day 14, significantly higher BMP2 expression was observed for
AT-nHA/COL=0/1 at day 28 (p< 0.01) and 35 (p< 0.05), for AT-nHA/COL=1/1
at day 28 (p< 0.001) and 35 (p< 0.05), and for AT-nHA/COL=2/1 at day
28 (p< 0.01) and 35 (p< 0.05). Relative to AT-nHA/COL=0/1, signifi-
cantly higher BMP2 expression was observed for AT-nHA/COL=1/1 at day
28 (p< 0.05). BM-MSCs showed a gradual increase in BMP2 expression
until day 28 and thereafter a decrease until day 35 (Figure 5.6B) for BM-
nHA/COL=1/1 and BM-nHA/COL=2/1. Relative to day 14, significantly
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higher BMP2 expression was observed for BM-nHA/COL=1/1 and for BM-
nHA/COL=2/1 at day 28 (p< 0.001). Relative to BM-nHA/COL=0/1,
significantly higher BMP2 expression was observed for BM-nHA/COL=1/1
and for BM-nHA /COL=2/1 at day 28 (p< 0.01).
RUNX2: AT-MSCs showed an upregulation of RUNX2 expression after day
14, irrespective of construct type (Figure 5.7A). Relative to day 14, signifi-
cantly higher RUNX2 expression was observed for AT-nHA/COL=1/1 at day
28 (p< 0.05) and for AT-nHA/COL=2/1 at day 28 (p< 0.01). BM-MSCs,
showed high levels of RUNX2 expression at day 14 irrespective to construct
type, which further increased only for BM-nHA/COL=1/1 (Figure 5.7B).
Relative to day 14, significantly higher RUNX2 expression was observed for
BM-nHA/COL=1/1 at day 28 (p< 0.05). Relative to BM-nHA/COL=0/1
significantly higher RUNX2 expression was observed for BM-nHA/COL=1/1
at day 28 (p< 0.001) and for BM-nHA/COL=2/1 at day 14 (p< 0.001).
OCN: AT-MSCs showed an upregulation of OCN expression starting at day
28 until day 35, except for AT-nHA/COL=2/1, for which the expression of
OCN was downregulated after day 28 (Figure 5.8A). BM-MSCs, showed high
expression of OCN at day 14, which was downregulated toward the end of the
culture period, irrespective of construct type (Figure 5.8B). Relative to day
14, significantly lower OCN expression was observed for BM-nHA/COL=0/1
at day 35 (p< 0.05), for BM-nHA/COL=1/1 at day 28 (p< 0.01) and 35
(p< 0.001) and for BM-nHA/COL=2/1 at day 28 and 35 (p< 0.05). Relative
to BM-nHA/COL=0/1, an upregulation of OCN expression was observed for
BM-nHA/COL=1/1 at day 14 (p < 0.05) and 28 (p< 0.01).
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Figure 5.7: Gene expression profiles of RUNX2 (A) in AT-MSCs and (B) in
BM-MSCs. ∗ indicates significantly different compared to nHA/COL=0/1 control, at
the same time point (p-values: ∗p <0.05, ∗∗ p<0.01, ∗∗∗ p<0.001), # indicates significantly
different compared to day 7 (p-values: #p <0.05, ## p<0.01, ### p<0.001)
COL1: AT-MSCs showed an upregulation of COL1 expression starting at
day 28 (Figure 5.9A), irrespective of construct type. Significantly higher
COL1 expression (relative to day 14) was observed for AT-nHA/COL=0/1
at day 28 and 35 (p< 0.001), for AT-nHA/COL=1/1 at day 28 (p< 0.01)
and 35 (p< 0.001), and for AT-nHA/COL=2/1 at day 28 (p< 0.01) and
35 (p< 0.01). Relative to AT-nHA/COL=0/1, the expression of COL1 was
significantly higher for AT-nHA/COL=1/1 at day 35 (p< 0.001) and for AT-
nHA/COL=2/1 at day 28 and 35 (p< 0.01). BM-MSCs showed high expres-
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sion of COL1 at day 14, after which the COL1 expression was downregulated
until the end of the culture period (Figure 5.9B). Relative to day 14, signifi-
cantly lower COL1 expression was observed for BM-HA/COL=0/1 at day 28
(p< 0.05), for BM-HA/COL=1/1 at day 28 and 35 (p< 0.01) and for BM-
HA/COL=2/1 at day 28 and 35 (p< 0.01). Relative to BM-HA/COL=0/1,
significantly higher COL1 expression was for BM-HA/COL=1/1 at day 14
(p< 0.01) and for BM-HA/COL=2/1 at day 28 (p< 0.01).
Figure 5.8: Gene expression profiles of OCN (A) in AT-MSCs and (B) in
BM-MSCs. ∗ indicates significantly different compared to nHA/COL=0/1 control, at
the same time point (p-values: ∗p <0.05, ∗∗ p<0.01, ∗∗∗ p<0.001), # indicates significantly
different compared to day 7 (p-values: #p <0.05, ## p<0.01, ### p<0.001)
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Figure 5.9: Gene expression profiles of COL1 (A) in AT-MSCs and (B) in
BM-MSCs. ∗ indicates significantly different compared to nHA/COL=0/1 control, at
the same time point (p-values: ∗p <0.05, ∗∗ p<0.01, ∗∗∗ p<0.001), # indicates significantly
different compared to day 7 (p-values: #p <0.05, ## p<0.01, ### p<0.001)
5.3.3.1 Histological analysis & Immunohistochemistry
HE stain: HE-stained histological sections of all experimental construct as
well as HE stained sections of human bone (positive control) are presented
in (Figure 5.10A).
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Figure 5.10: (A) HA staining of different group of nHA/COL constructs
after 7 and 28 days of culture, (B) Von Kossa staining of different group of
nHA/COL constructs after 28 days of culture.
Results of AT-MSC constructs showed that at day 7 as well as at day 28,
cells were distributed throughout the entire construct. At the periphery of
constructs, the cellular density was apparently higher compared to the centre
of constructs (high density cell populations are indicated with arrows in Fig-
ure 5.10A 1, 2, 3, 5). The distribution of BM-MSCs in nHA/COL constructs
was different at different time points. At day 7, cells were homogeneously
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distributed throughout the entire construct (Figure 5.10A-7, 8, 9). How-
ever, at day 28 cells were mainly located at the periphery of constructs, and
only few cells were detectable in the central region (Figure 5.10A-10, 11, 12).
Von Kossa stain: To monitor the mineral deposition inside the constructs,
Von Kossa staining was used (Figure 5.10B). Mineral deposition was only
detectable for AT-nHA/COL=1/1 and AT-nHA/COL=2/1 at day 28.
IHC-OCN stain: AT-MSCs showed detectable OCN expression at day 28,
especially for AT-nHA/COL=0/1 (Figure 5.11- 4, 5, 6).
Figure 5.11: Immunohistochemical staining of OCN, in different group of
nHA/COL constructs, after 7 and 28 days of culture
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OCN protein was homogeneously distributed throughout the entire con-
struct. AT-MSCs were observed in these constructs with an elongated,
spindle-shaped morphology (highlighted with arrows in Figure 5.11-4, 5,
6). BM-MSCs showed high OCN expression at day 7, especially for BM-
nHA/COL=1/1 and for BM-nHA/COL=2/1 (Figure 5.7-8, 9). At day 28,
the OCN was still detectable for BM-nHA/COL=0/1 and BM-nHA/COL=1/1,
but not for BM-nHA/COL=2/1 (Figure 5.11-10, 11, 12).
5.4 Discussion & Conclusions
The aim of this study was to comparatively evaluate the in vitro effect of
biomimetic nHA/collagen based composite hydrogels (with different con-
centrations of nHA) on the behavior of MSCs, isolated from adipose tis-
sue (AT-MSCs) and bone marrow (BM-MSCs). We hypothesized that (i)
nHA/collagen based hydrogels promote the osteogenic differentiation of MSCs
in nHA concentration dependent manner, and that (ii) AT-MSCs will show
higher osteogenic capacities compared to BM-MSCs, because of their intrinsic
proliferation and osteogenic differentiation potential in 2D in vitro cultures.
This study indicated that AT-MSCs show high proliferation, differentiation
and mineralization in nHA/COL constructs, irrespective of nHA concen-
tration, whereas BM-MSCs showed only marginal cell proliferation and os-
teogenic differentiation in all experimental nHA/COL constructs. Based on
the results of ALP activity and OCN protein level, the osteogenic differen-
tiation of BM-MSCs started in the beginning of the culture period and for
AT-MSCs at the end of the culture period. At a molecular level, both cell
types showed high expression of osteogenic markers (BMP2, RUNX2, OCN
or COL1) in both a nHA concentration and time dependent manner.
At a cellular level, the material properties (different nHA/COL ratio) did not
show any remarkable effect on cellular behavior of AT-MSCs or BM-MSCs.
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However, apparent differences were observed between cell types, i.e. the
source for MSCs. AT-MSCs showed higher proliferation and osteogenic dif-
ferentiation compared to BM-MSCs. This phenomenon corroborates several
earlier studies [21, 23], but this study demonstrates that the cellular behav-
ior of AT-MSCs does not change in a nHA concentration dependent manner.
High proliferation levels of AT-MSCs could potentially provide faster cell-
cell interaction compared to BM-MSCs, and this cellular interaction in 3D
micro-environment could promote subsequent AT-MSC osteogenic differenti-
ation [23, 31]. Remarkably, BM-MSCs started to proliferate and differentiate
already within the first week of culture, irrespective of nHA concentration,
whereas AT-MSCs started to differentiate only after the third week of cul-
ture. Early osteogenic differentiation of BM-MSCs can be explained with
faster osteocyte formation. The signaling mechanisms involved in osteo-
cyte formation could be activated at different time points in AT-MSCs and
BM-MSCs, because AT-MSCs and BM-MSCs were cultured in different (PL
or FBS supplemented) osteogenic media with different content of signaling
molecules [32].
Molecular analysis of osteogenic markers, i.e. BMP2 (osteoblast differenti-
ation marker), RUNX2 (essential element for osteogenic differentiation and
skeletal morphogenesis), OCN (later stage osteogenic differentiation marker)
and COL1 (crucial element of connective tissue) [33, 34, 35] showed that the
material properties (nHA concentration) have an effect on the gene expres-
sion pattern of these molecules. It is known that nHA play a functional role
in integrin-mediated cell adhesion and signaling [36]. Cell adhesion to ECM
is mediated by transmembrane receptors [37]. This initiates intracellular
signals, and focal adhesion kinase activation [38], which play crucial role in
activation of downstream signaling. This signaling cascade can stimulate the
activation of transcription factors and subsequent signal transduction [39].
For AT-MSCs, the expression of BMP2, RUNX2 and COL1 was promoted by
AT-nHA/COL=1/1 constructs, whereas the expression of OCN and COL1
was promoted by AT-nHA/COL=2/1 constructs.
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For BM-MSCs the expression pattern of BMP2, RUNX2, OCN and COL1
was remarkably higher in BM-nHA/COL=1/1 constructs, especially in the
beginning of the culture period (at day 14). This observation proved that
the osteogenic differentiation of BM-MSCs starts at an earlier time points
compared to AT-MSCs. Moreover, already at day 7, BM-MSCs expressed
high levels of OCN, which also indicates early osteogenic differentiation of
BM-MSCs. Next, AT-MSCs and BM-MSCs showed a similar pattern of
BMP2 expression. It has been shown that AT-MSCs can respond to BMP2
signals and express other osteogenic markers (e.g. OPN and RUNX2) [40],
which indicates that AT-MSCs are a reliable cell type for future use in cell-
based bone regenerative strategies.
In conclusion, AT-MSCs demonstrated higher osteogenic potential in nHA
/COL based 3D micro-environments compared to BM-MSCs, in which pro-
liferation and osteogenic differentiation were highly promoted. The prolifer-
ation and osteogenic differentiation pattern of AT-MSCs and BM-MSCs was
regulated in a time dependent manner, irrespective of nHA amount in the
constructs. On the other hand, nHA/COL ratios differently affected gene
expression profiles of AT-MSCs and BM-MSCs. The fact that AT-MSCs
showed high proliferation and mineralization is appealing for their applica-
tion in future (pre-)clinical research as an alternative cell source for MSCs.
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CHAPTER 6
Effect of Calcium Phosphate Ceramic Substrate
Geometry on Mesenchymal Stromal Cell Organization
& Osteogenic Differentiation
6.1 Introduction
One of the most challenging aspects in tissue regenerative research is to
find an appropriate material for bone regeneration therapy. Because of high
osteoinductive and osteoconductive capacities and hence clinical efficacy, au-
tologous bone grafting is still the most frequently applied material for bone
regenerative treatments [1]. However, bone grafting is an invasive proce-
dure, associated with high morbidity due to a second surgery site, and the
often limited amount of available bone [2]. In view of this, it has become a
scientific challenge to find effective alternatives for autologous bone grafts.
Calcium phosphate (CaP) based biomaterials have become the most fre-
quently utilized synthetic alternatives for autologous bone, for their chem-
ical composition strongly resembling the inorganic part of bone tissue [3],
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and their high bioactive and osteoconductive capacity [4]. Multiple in vitro
studies showed that CaP ceramics (e.g. HA and tricalciumphosphate, TCP)
promote proliferation and osteogenic differentiation already at the cellular
level [5, 6]. The efficacy of CaP is nowadays also exploited for clinical ap-
plication as bioactive coatings for the surface of new generation implants.
Such coatings were shown to stimulate osseointegration resulting in firm fix-
ation between implant and bone [7]. Another factor that is known to play
a crucial role for osseointegration is surface topography [8, 9]. Several stud-
ies have indicated that micro- and nano-scale surface topography of CaP
ceramics strongly influences cell adhesion, proliferation and differentiation
[10, 11, 12]. By combining topographical and chemical properties of im-
plants, several studies have investigated the osteoinductive effect of (repet-
itive) surface concavities on bulk CaP ceramics and CaP-coated titanium
implants [13, 14, 15]. The authors demonstrated that the presence of sur-
face concavities can provide osteoinductive capacity of the ceramic material,
concluding that topographical and chemical properties of implants can mu-
tually steer biological responses and (bone) tissue formation in vivo [13].
We recently studied the concept of mineralization within surface concavities
and showed that cell-independent mineralization in simulated body fluid is
strongly controlled by concavity dimensions [16]. Among the concavities in
different CaP ceramics, the mineralization process started preferentially in
small concavities (∼440 µm hemispheres) of hydroxyapatite (HA) disks sin-
tered at 1200◦C, where the mineralization was increased 124-fold compared
to medium ( 800 m hemispheres), and 10-fold compared to large concavities
(∼ 1800 µm hemispheres) [16]. It is known that physical factors, such as ge-
ometrical properties of surface, mechanical forces, and extracellular matrix
texture, have strong influence on MSC behavior. In response to extracellular
stimulation, cells activate their internal signaling pathways and subsequent
mechano-transduction, which both control MSC behavior [17]. However, ex-
perimentally little is known about the behavior of MSCs, cultured on pure
HA based scaffolds, which are covered with different size surface concavities.
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To evaluate the effect of surface concavities of CaP ceramics on cellular be-
havior of MSCs, human adipose tissue derived mesenchymal stromal cells
(AT-MSCs) were cultured on CaP ceramic scaffolds with different surface-
concavity sizes. The outcome parameters included analyses on cellular or-
ganization, cell proliferation, and osteogenic differentiation. We hypothe-
sized that compared to planar controls, surface concavities would promote
cell proliferation, cellular organization within the concavities, and osteogenic
differentiation of cells, because of mineral (CaP) nucleation in concavities
and a more 3D microenvironment [16]. Additionally, we hypothesized that
MSC proliferation and osteogenic differentiation would increase with smaller
concavity size due to more rapidly occurring 3D cell-cell interactions and
subsequent molecular cross-talk.
6.2 Materials & Methods
6.2.1 Substrate preparation & characteristics of disks
HA powder (Merck, Darmstadt, Germany) with a Ca/P molar ratio of 1.67
was used in this study. The powder was uniaxially pressed at 103 MPa
(15,000 psi) for 10 min in a cylindrical steel mold (internal diameter ∼ 21
mm). Subsequently, cylindrical HA ceramics were heat-treated in a furnace
at 800◦C for 6 h (1.67◦C min−1) to provide suitable strength to the ceramic
to withstand the stresses applied during the machining process. Thereafter,
heat-treated HA cylinders were cut into disks (thickness 4 mm, diameter 21
mm). Drill tips with different diameter sizes (2.1, 1.0 and 0.5 mm; Horico
Dental, Berlin, Germany) were used to prepare hemispherical concavities at
the disk surfaces. Subsequently, the disks were sintered in a furnace for 6
h (1.67◦C min−1) at 1200◦C, by which disk dimensions were reduced to 3
mm thickness and 16 mm diameter and cavities sizes to diameters of 440
µm (small concavity; SC), 800 µm (medium concavity; MC) and 1800 µm
150
Chapter 6: Effect of Calcium Phosphate Ceramic Substrate
Geometry
(large concavity; LC). Afterwards, the disks were prepared based on the
experimental setup.
For imaging, the heat-treated HA disks were divided (without cutting) in
three different regions, each containing a specific cavity size/diameter (SC
→ 440 µm, MC→ 800 µm or LC→ 1800 µm) with total of 6 cavities in each
size. The flat surface in the center of the disk was used as a planar control
(Figure 6.1A).
A
B
Figure 6.1: Schematic representation of disk surface topography employed in
the study. (A) Schematic distribution of the concavities at the surface of the disks for
confocal microscopy; 6 concavities of each size (small cavity (SC)’440 m, medium cavity
(MC)’ 800 m; and large cavity (LC)’ 1800 m) were prepared on the surface of the disks,
and the center to center distance was kept the same (SC=2.1, MC=2.5, LC=2.8 mm). The
planar surface in the centre of the disk was considered as a control planar surface (PS).
(B) Schematic distribution of the concavities at the surface of the disks for biochemical
assays. Disks were completely covered with each size of concavities (SC, MC, LC) center
to center distances SC=0.6, MC=1.2 and LC=2.7 mm
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For the evaluation of cellular behavior and gene expression, the heat-treated
HA disks featuring concavities of the same size, were cut in 4 pieces (n=4,
Figure 6.1B). The total number of hemispherical concavities in each disk was
148 for SC, 42 for MC, and 36 for LC, resulting in a total surface area of
respectively 2.23 cm2 (SC), 2.22 cm2 (MC) and 2.92 cm2 (LC). As a control
group, planar disks (PS) were used with a total surface area of 2.01 cm2
(Figure 6.1B). Before cell seeding, disks were autoclave-sterilized.
6.2.2 AT-MSC isolation, expansion & characterization
AT-MSCs were isolated from fat tissue of healthy donors (Department of
Plastic Surgery, Radboudumc, Nijmegen, the Netherlands) after written in-
formed consent, following a previously described AT-MSCs isolation proce-
dure [18, 19]. Harvested cells were cultured in proliferation medium, consist-
ing of alpha Minimal Essential Medium (α-MEM; Gibco R©, Life Technologies,
Grand Island, USA) supplemented with 5% platelet lysate (PL, (Sanquin
Blood Bank, Nijmegen, the Netherlands), pooled from 5 different donors,
100 U/ml penicillin (Gibco), 10 g/ml streptomycin (Gibco R©), and 10 U/ml
heparin (LEO Pharma, Amsterdam, the Netherlands) at 36◦C in a humid
atmosphere with 5% CO2. Medium was changed twice a week. Cells were
passaged upon reaching ∼ 80% confluency using 0.25% w/v trypsin/0.02%
EDTA (Gibco R©). Prior to MSC characterisation, harvested cells, from the
first passage, were examined by fluorescence-activated cell sorting (FACS)
for positive expression of CD73, CD90 and CD105 (eBioscience, San Diego,
USA) and negative expression of CD45 (R& D system, Abingdon, United
Kingdom). Next, MSCs from passage 3 were examined with three biochemi-
cal assays i.e. DNA assay for proliferation capacity, and osteogenic differen-
tiation and Ca deposition assay for later stage of osteogenic differentiation.
The cells from passage 4 were used for this study. The experiment was re-
peated three times.
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6.2.3 Biochemical assay for cellular DNA content
AT-MSCs were cultured on disks, using 10.000 cells/cm2 as the seeding den-
sity (relative to PS). Cells were cultured in the osteogenic medium consist-
ing of α-MEM supplemented with 5% PL, 100 U/ml penicillin, 10 µg/ml
streptomycin, 10 U/ml heparin, 0.2 mM L-ascorbic acid-2-phosphate (Sigma-
Aldrich, St. Louis, MO, USA), 2mM L-glutamine (Gibco R©), 10−8M dexam-
ethasone (Sigma-Aldrich) and 0.01 M β-glycerophosphate (Sigma-Aldrich),
at 37◦C in a humid atmosphere with 5% CO2. Cell proliferation was evalu-
ated with a DNA assay. Samples were collected at 3 time points relative to
cell seeding (i.e. day 3, 14, 28). Prior to sample preparation, cell layers were
washed twice with PBS, 1 ml MilliQ was added, and the sample was stored
at −80◦C. After two repetitive freeze/thaw cycles, samples were used for
DNA assay. The cellular DNA content was measured using a QuantiFluor R©
dsDNA System Kit (Promega, Madison, Wisconsin, USA). For the standard
curve, serial dilutions of dsDNA stock (range: 0-2000 ng/ml) were prepared.
Next, 100 µl of either sample of standard solution was added into the wells,
followed by 100 l of working solution. The plate was incubated at room
temperature for 5 min, and then the absorbance of samples/standards was
measured at 504 nm excitation and 541 nm emission, using a fluorescence
microplate reader (FL600, BioTek, Canada).
6.2.4 Immunofluorescence & quantitative cell measure-
ments
For the immunofluorescence and quantitative cell measurements, at selected
time points (3, 14, 21 and 28 days), samples were collected by washing 2x in
phosphate buffered saline (PBS, Gibco R©), fixation in 2% paraformaldehyde
(PFA, Sigma-Aldrich) for 20 min, permeabilization in PBS containing 0.25%
Triton X100 (Koch, Light-Laboratories, Colebrook, UK) for 10 min, washed
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again 2x in PBS and blocking with 1% BSA (Sigma Aldrich) for 1 hour.
Thereafter, cells were washed 2x in PBS and stained as follows:
1. For visualization of nuclear dsDNA, cells were stained with DAPI (In-
vitrogen, Molecular probes) for 1 min, in a dilution of 1:2500. After-
wards, cells were washed 2 x 5 min in PBS,
2. For visualization of cytoskeletal morphology, the filamentous F-actin
was stained with Alexa Flour R© 568 phalloidin (Invitrogen, Molecu-
lar probes, Eugene-Oregon, USA) for 2 hours, in a dilution of 1:250.
Afterwards cells were washed 2 x 5 min in PBS,
3. For visualization of the osteogenic marker osteocalcin, cells were stained
with a monoclonal osteocalcin antibody conjugated with Alexa Flour R©
488 (Novus Biologicals, Cambridge, UK) for 2 hours in a dilution of
1:1000. Afterwards, cells were washed 2 x 5 min in PBS.
Subsequently, the samples were mounted with Mowiol R© 4.88 solution (Merk
Millipore, Darmstadt, Germany), covered with cover-glasses, and stored at
+4◦C for fluorescent imaging.
For visualization of calcium embedded within the extracellular matrix, at
the same time points (3, 14, 21 and 28 days), separate samples were stained
with 2% w/v Alizarin Red S 598 (ScienCell Research Laboratories, Carlsbad
CA, USA) for 15 min. Subsequently, samples were washed 5x with PBS for
1 min and stained with DAPI for 1min in a dilution 1:2500. Afterwards,
the samples were washed and mounted with Mowiol R© 4.88 solution (Merk
Millipore, Darmstadt, Germany), covered with cover glasses, and stored at
+4◦C for fluorescent imaging.
The substrates were analyzed with a fluorescence microscope (Axio Imager
Microscope Z1, Carl Zeiss Micro imaging, Gottingen, Germany). The exci-
tation and emission wavelength for a filamentous F-actin was 568 and 603
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nm, for dsDNA (DAPI) 405 and 428 nm, for osteocalcin 495 and 519 nm,
and for alizarin red 590 and 617 nm, respectively. The images were captured
with a 20x/0.75 objective.
To obtain high-resolution 3D images for analysis of cellular organization
within the concavities, the samples (day 3, 14, 28) were analyzed by con-
focal laser scanning microscopy (CLSM; Olympus FV1000, Olympus, Tokyo
Japan). The images were captured with 20x/0.75 objective. In order to ob-
tain qualitative and quantitative data on concavity volumes, the images were
analyzed with ImageJ imaging software (Centre for Information Technology,
National institutes of Health, Bethesda MD, USA), using 3D object counter
plugin. For quantification of cell nuclei, an average of single cell immunofluo-
rescence intensity was measured (from the samples at day 3) and this average
intensity level was considered as a standard for cell quantification.
6.2.5 RNA isolation & reverse transcription
For RNA isolation, separate samples, collected at day 3, 14, 28, were washed
2x with PBS, treated 500 µl ’RNA’ lysis buffer from Genelute Mammalian
Total RNA Miniprep Kit (Sigma-Aldrich), and stored at −800◦C until RNA
extraction. RNA isolation was performed according to manufacturer instruc-
tions. The extracted RNA was quantified with a spectrophotometer (Nan-
odrop Technologies, Wilmington, DE). For reverse transcription (cDNA syn-
thesis), an iScriptTM cDNA kit was used (Bio-Rad, Hercules, CA, USA). For
each cDNA reaction, 15 µl RNAse free water containing 1 µg RNA, mixed
with 4µl 5xiScript reaction mix and 1µl reverse transcriptase was used. The
samples (cDNAs) were stored at −20◦C until use. Before use of samples
(cDNAs), they were diluted 5 times by adding 80 µl of nuclease free water.
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6.2.6 Real-time polymerase chain reaction
For real-time polymerase chain reaction (RT-PCR), qPCR Master Mix Plus/
SYBR Green I (Eurogentec, Seraing, Belgium) was used according to the
manufacturer’s instructions. Briefly, for each reaction 12.5 µl SYBR Green
Supermix, 3 µl of primer mix, 4.5 µl of nuclease free water and 5 µl di-
luted cDNA was used. RT-PCR was completed with 40 amplification cycles.
The genes of interest were Osteocalcin (OCN), Bone Sialoprotein (BSP),
Bone Morphogenetic Protein 2 (BMP2), Runt-related Transcription Factor
2 (RUNX2), and Collagen type 1 (COL1). The sequence of applied primers
is given in Table 6.1. The raw data for respective transcripts were normalized
to expression of 60S Acidic Ribosomal Protein P0 (RPLP0) within the same
sample/RNA. The gene expression and fold changes were calculated accord-
ing to Livak & Schmittgen (2−∆∆Ct) relative to control samples (collected
from PS) [20].
6.2.7 Statistical analysis
Data are presented as mean ± standard deviation. Statistical analysis was
performed based on N=3 (for all experimental groups) with Graphpad Prism R©
5.03 software (Graphpad Software Inc, San Diego, CA, USA). Quantitative
results were analyzed using a one-way ANOVA with a posthoc Tukey Multi-
ple Comparisons Test. A probability (p) value < 0.05 was considered statis-
tically significant.
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Table 6.1: Primer sequences for RT-PCR.
Gene name Sequences
RPLP0 Forward- TTCTTCTTTGGGCTG GTCAT
Reverse- TTGGGTAGCCAATCTGCAGA
RUNX2 Forward- TCTGGCCTTCCACTCTCAGT
Reverse GACTGGCGGGGTGTAAGTAA
BMP-2 Forward- CCCAGCGTGAAAAGAGAGAC
Reverse- GGAAGCAGCAACGCTAGAAG
Col type 1 Forward- GGTGTAAGCGGTGGTGGTTAT
Reverse- AGGTTCCCCGTTCTCACTTT
OCN Forward- GGCGCTACCTGTATCAATGG
Reverse- GTGGTCAGCCAACTCGTCA
BSP Forward- GACTGTGACGAGTTGGCTGA
Reverse- AGGTTCCCCGTTCTCACTTT
6.3 Results
6.3.1 Cellular behavior
During the first 14 days, MSCs showed the highest proliferation on PS disks,
and lowest proliferation on SC disk. However, after 28 days of culture, an
increased cell proliferation was observed on SC and MC disks compared to
PS disks (Figure 6.2a).Because of the differences in surface area of the disks
(PS→2.01 cm2, SC→2.23 cm2, MC→2.22 cm2 and LC→2.92 cm2), the re-
sults of DNA content were normalized for surface area (Figure 6.2b). After
normalization, MSC proliferation patterns remained similar, showing at day
14 a significantly lower DNA-content for SC (p< 0.001), MC (p< 0.001), and
LC (p< 0.05), and at day 28 significantly higher DNA-content values for SC
(p< 0.01) and MC (p< 0.01) compared to PS.
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Figure 6.2: (a) Cellular DNA content/proliferation level during 28 days of
culture. (b) DNA content normalized for surface area of the disks. (p-values: ∗p <0.05,
∗∗ p<0.01, ∗∗∗ p<0.001) compared to control planar surface (PS); indicate significant
differences compared to PS control at the same time point. ND means not determined.
6.3.2 Cellular organization
6.3.2.1 Immunofluorescence results
The samples for immunofluorescence were stained with 3 different dyes, i.e.
DAPI (in blue) for nuclear visualization, actin (in red) for visualization of the
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cytoskeleton, and osteocalcin (in green) for late osteogenic differentiation.
After each staining, the samples were observed by means of fluorescence
microscopy (Figure 6.3).
D 28 PS c
D 28 PS b
D 28 PS a
D 28 SC c
D 28 SC a
D 28 SC a
D 28 MC c
D 28 MC b
D 28 MC a D 28 LC a
D 28 LC c
D 28 LC b
Figure 6.3: Fluorescence microscopy images. For visualization of dsDNA in nuclei,
cells were stained with fluorescent DAPI (in blue); for cytoskeletal structure visualizations,
filamentous F-actin (in cells) was stained with Alexa Flour 568 phalloidin (in red); for
visualization of osteocalcin, cells were stained with a monoclonal osteocalcin antibody,
labeled with Alexa Flour 488 (in green).
At day 28 osteocalcin-positive signal (green) was mainly detected in SC and
MC. In SC, osteocalcin was distributed within the entire concavity volume,
while in MC osteocalcin was only detected on the edges of the concavities
(Figure 6.3). To visualize the mineralization pattern of AT-MSCs, separate
samples were stained with Alizarin Red S 598 (Figure 6.4). During 28 days
of culture, a gradual increase of calcium positive staining was observed on
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the surface of the experimental scaffolds in presence of cells. Contrary, no
positive Alizarin staining could be observed in the cell-free control at day 28.
Day 14 Day 21Day 3
Day 28 neg. 
control
Day 28
Figure 6.4: Qualitative evaluation of calcium deposition during 28 days of
culture. Samples were stained with Alizarin Red S 598 (in red)
6.3.2.2 Qualitative results of cellular organization
Confocal microscopy showed that after 3 days of culture only few cells were
situated inside of the concavities independent of the size (Figure 6.5). How-
ever, several differences in cellular organization were detectable. In SC and
MC, cells were distributed already in a 3D multi-layer configuration, while
in LC cells generally covered the concavity walls (Figure 6.5).
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D3 SC D3 SC D3 SC
D3 MC D3 MC D3 MC
D3 LC D3 LC D3 LC
SC
MC
LC
A
Figure 6.5: Confocal microscopy images with 3D reconstruction of SC, MC
and LC. Cell nuclei were stained with fluorescent DAPI (in blue). Samples
with different concavity sizes after 3 days of culture.
Cell nuclei in the Figure 6.5 present an elongated shape due to the fact
that cells were viewed in a 3D environment and different angles were chosen
(Image J) for visualization. After 14 days of culture, for all concavity sizes a
substantial increase in the number of cell nuclei was observed. In SC and MC,
cells created an apparent multilayered cell sheet, covering the walls, and in
SC cells filling up the entire concavity volume (3D cellular organization). The
planar surface between concavities was also covered with a cellular multilayer.
In contrast to SC and MC, the cellular organization in LC was different,
day 14, still a gap between these two cell populations in LC was observed
(Figure 6.6).
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D 14 SC D 14 SC D 14 SC
D 14 MC D 14 MC
D 14 LC
SC
MC
LC
B
D 14 MC
D 14 LC D 14 LC
Figure 6.6: Confocal microscopy images with 3D reconstruction of SC, MC
and LC. Cell nuclei were stained with fluorescent DAPI (in blue); filamen-
tous F-actin (in cells) was stained with Alexa Flour 568 phalloidin (in red).
Samples with different concavity sizes after 14 days of culture.
After 21 days of culture, very densely distributed cell nuclei were observed
in SC and MC. In SC, cells homogenously distributed within the entire con-
cavity volume. In MC, the cellular organization was different from SC with
a less dense cell population in the center compared to the edges. The cellular
organization in LC at day 21 was similar to the LC at day 14 with a separa-
tion in two cell populations (on the concavity walls close to surface area of
the disk and at the bottom of the concavities), and still a gap between those
populations (Figure 6.7).
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D 21 SC D 21 SC
D 21 MC
D 21 LC D 21 LC
SC
MC
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C
D 21 SC
D 21 MC D 21 MC
D 21 LC
Figure 6.7: Confocal microscopy images with 3D reconstruction of SC, MC
and LC. Cell nuclei were stained with fluorescent DAPI (in blue); filamen-
tous F-actin (in cells) was stained with Alexa Flour 568 phalloidin (in red).
Samples with different concavity sizes after 21 days of culture.
After 28 days of culture, cells in SC and MC were homogenously distributed
within the entire concavity volumes. At day 28 in SC and MC cells already
reached the highest deepness within the concavity volume. However, in LC
the cellular organization was still different from SC and MC, with still the
existence of two separated cell populations, but the distance between those
populations was smaller compared to day 21 (Figure 6.8).
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D28 MC
D28 SC D28 SCD28 SC
D28 LC
SC
MC
LC
D
D28 MC D28 MC
D28 LC D28 LC
Figure 6.8: Confocal microscopy images with 3D reconstruction of SC, MC
and LC. Cell nuclei were stained with fluorescent DAPI (in blue); fila-
mentous F-actin (in cells) was stained with Alexa Flour 568 phalloidin (in
red).Samples with different concavity sizes after 28 days of culture.
6.3.2.3 Quantitative results of cellular organization
Cell nuclei were quantified in PS, SC, MC and LC at all time points (Figure
6.9). The number of nuclei for SC, MC and LC was normalized for the
concavity volume and the number of the nuclei for PS was normalized with
the volume of one layer (L=0.75; B=0.75; H=0.01mm). In the first 3 days no
significant differences were found in SC, MC, and LC compared to PS control.
After 14 days, an increase in cell nuclei was observed for all groups, with the
highest number of cell nuclei in PS. At day 14, the number of cell nuclei
was significantly lower in SC (p< 0.05), MC (p< 0.01), and LC (p< 0.01)
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compared to PS. At day 28 the number of cell nuclei was significant high
in SC (p< 0.001) and in MC (p¡0.05) compared to PS. Cell nuclei numbers
at day 28 in LC could not be determined due to large data information and
software limitations.
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Figure 6.9: Results of quantitative analysis of the number of cell nuclei within
the concavities normalized for concavity volume. P-values (p-values: ∗p <0.05, ∗∗
p<0.01, ∗∗∗ p<0.001) indicate significant differences compared to PS control at the same
time point. ND means not determined.
6.3.3 Gene expression profile of selected molecules
To determine gene expression of selected genes, RT-PCR analysis was per-
formed only at day 28 of culture. The samples collected at day 3, and 14 were
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excluded from analyses because of insufficient extracted RNA. From selected
molecules OCN expression showed an upregulation (up to ∼2.2 fold) in SC
compared to PS control (p=0.0181). BMP2 was also upregulated in LC (up
to 3 fold) compared to PS control (P=0.0088). Similar gene expression levels
were observed for BSP, RUNX2 and COL1 (p> 0.05) (Figure6.10).
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Figure 6.10: Gene expression of OCN, BSP, BMP2, RUNX2 and COL1 genes
at 28 days of culture. * indicates significant different value compared to PS control
(p-values: ∗p <0.05)
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6.4 Discussion & Conclusions
The aim of this chapter was to evaluate the effect of surface concavities on
CaP ceramic scaffolds on mesenchymal stromal cell organization, prolifera-
tion, and osteogenic differentiation. We hypothesized that compared to pla-
nar control surfaces, surface concavities would promote cell proliferation and
cellular organization within the concavities and osteogenic differentiation of
cells, because of a 3D microenvironment and mineral (i.e. CaP) nucleation
in concavities [16]. Additionally, we hypothesized that MSC proliferation
and osteogenic differentiation would increase with smaller concavity size due
to more rapidly occurring 3D cell-cell interactions and subsequent molecu-
lar cross-talk. The main findings of this study were that surface concavities
promote cell proliferation, in a concavity size dependent manner. At day 28,
SC increased cell proliferation to a larger extent compared to MC and LC.
Next, different size concavities regulated the distribution of cells and 2D/3D
cellular organization. Finally, the concavity size influenced osteogenic differ-
entiation of cells, showing an upregulation of OCN expression in SC (mRNA
level) and OCN protein product detected in SC and MC.
Our study indicated that surface concavities promote cell proliferation, which
was proven by quantification of both integral cellular DNA content and 3D
cell nuclei. In addition, the proliferation pattern promoted by different con-
cavity sizes was different. In SC, proliferation increased to a larger extent,
because at day 28 the highest cell number (nuclei) and the highest amount
of DNA content was found in SC. The quantitative analysis of cell nuclei
showed that cell proliferation can be increased inside the concavities com-
pared to PS and that the proliferation potential of cells is high inside SC,
possibly due to cell proximity and faster cellular communication [21], because
the cell-cell interaction and cellular communication is based on exchange of
secreted molecules, which can activate appropriate signals in cells [22, 23].
In addition, cells are able to adhere to the surface, recognize its geometrical
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properties, and respond to geometrical stimuli [24, 25]. This phenomenon is
called adhesion-mediated signaling, which provides cells information about
extracellular microenvironment, including geometrical and chemical charac-
teristics of the substrate [26]. Based on the proliferation and differentiation
results, cells seem to recognize the geometrical properties of the surface.
The fact that CaP-based biomaterials with specific surface geometry can pro-
mote bone formation in vivo was proven by others [27, 28, 29, 30]. However,
little is known about the influence of CaP-based biomaterials combined with
geometrical properties (e.g. size, shape) on cellular organization and cell dif-
ferentiation [11]. In this study, we found that concavity size can influence
cellular organization, because already on day 3 cells were distributed in a
3D-like manner in SC and MC, whereas in LC cells were distributed still as
a monolayer. This observation can be explained by the fact that cells rec-
ognize geometrical properties of the surface and respond differently to their
cellular organization ([24, 25]). Next, mineralization results of cells on the
surface of experimental scaffolds (featuring different size concavities) showed
a gradual increase in Ca deposition, which indicates that cells can proliferate
as well as differentiate on the surface of CaP-based biomaterials. However,
the method to visualize Ca deposition (Alizarin Red S staining) was not
suitable for the quantification of mineralization within different concavity
sizes. Therefore, for the analysis of osteogenic differentiation/mineralization
within the concavities, the secretion of several osteogenic markers, i.e. osteo-
calcin (osteogenic differentiation marker), BSP (component of mineralized
tissue), BMP2 (osteoblast differentiation marker) and RUNX2 (essential el-
ement for osteogenic differentiation and skeletal morphogenesis), were ana-
lyzed ([31, 32, 33]). We observed that concavity size influences osteogenic
differentiation of MSCs, because higher levels of OCN protein (OCN immuno-
staining) were found in SC and MC compared to LC and PS. Moreover,
RT-PCR results showed that OCN was overexpressed in SC compared to
PS. These results indicate that extracellular stimulation factors (e.g. geo-
metrical properties, cell-cell communication, and local calcium nucleation)
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can provide specific signal activation and osteogenic differentiation of MSCs.
However, the expression of BMP2 showed opposite results, where a signif-
icant high expression of BMP2 was observed in LC, which indicates that
possibly alternative signaling pathways are involved in osteogenic differen-
tiation of cells in different size concavities. Additionally, it is known that
the BMP signaling is not a crucial pathway for osteogenic differentiation of
AT-MSCs [34, 35]. Other osteogenic genes did not show significant differ-
ences between the groups. This observation can be explained by the fact that
all experimental samples were obtained from cultures in osteogenic medium
containing 5% PL, which promotes osteogenic signaling.
In conclusion, CaP disks covered with different surface concavities (in size)
were able to direct MSCs behavior in terms of proliferation and osteogenic
differentiation. The results of this study suggest a correlation between con-
cavity size, cell proliferation, cellular 3D organization and osteogenic differ-
entiation of cells within the concavities. Further, the effect of a concavity
on the behavior of MSCs will disappear above a certain dimension threshold
(i.e. between MC and LC, corresponding to concavity diameter of 800 and
1800 µm, respectively); beyond this threshold, MSCs do not recognize the
hemispherical volume in which they are cultured.
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CHAPTER 7
Summary, Closing Remarks and Future Perspectives
Due to the ageing of the world population, healthcare professionals are con-
tinuously searching for new or improved treatment approaches for a large
variety of medical problems, like e.g. genetic, developmental, and traumatic
skeletal disorders [1]. The challenge in the treatment of bone defects is to
find a technology that can replace the use of autologous bone grafts. In
this context, tissue engineering and regenerative medicine, which both aim
to replace damaged tissues, have raised major expectations [2]. Tissue engi-
neering strategies combine the knowledge of (stem) cell biology and bioma-
terial development. The promise to use stem cells for tissue regeneration is
appealing, although the exact way to implement stem cells toward tissue re-
generation remains unclear. Characterization of adult stem cells in the form
of mesenchymal stromal cells (MSCs) or pericytes [3], isolated from different
tissues, e.g. bone marrow and fat tissue, showed promising future for bone
tissue engineering and regenerative medicine, but still the actual progression
of MSC-based therapies toward clinical application remains at a slow pace
[4]. It is anticipated that by guiding the activation of adequate osteogenic
signals in these stem cells, upon loading in a properly designed biomaterial
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scaffold, an effective contribution to bone regeneration becomes feasible [5].
This thesis aimed to evaluate specific cellular and molecular aspects of cell-
cell and cell-biomaterial interactions for tissue engineering applications. In
more detail, the research described in this thesis focused on the effect of MSC
origin, nutritional additives to the culture medium, properties of biomate-
rial scaffolds, and co-culture with angiogenic or hematopoietic cells on the
behavior and osteogenic differentiation of MSCs. Following specific subaims,
the main findings of the research efforts are summarized below.
Chapter 1 provides a brief introduction on bone tissue regeneration strate-
gies, especially cell-cell and cell-biomaterial based strategies, their clinical
need and scientific achievements so far. Each following chapter discusses
a separate study. This summary addresses the aim described in the first
chapter in successive order:
Subaim 1 (Chapter 2): Which signaling pathways are involved in osteogenesis
and how can the knowledge on these signaling pathways be applied to improve
the success of bone regenerative medicine?
Chapter 2 describes a review of the scientific literature to pinpoint the differ-
ent signaling pathways involved in osteogenic differentiation of MSCs/ osteo-
genesis and their potential to be used in bone regenerative treatment. MSCs
play a crucial role in natural bone regeneration and remodeling processes,
during which their differentiation is regulated by specific signaling pathways.
The understanding of this molecular machinery will be a crucial point for the
development of bone regenerative treatments, as differences in culture pro-
tocols, biomaterial scaffold properties, and interactions with resident cells
will lead to changes in MSC behavior, osteogenic differentiation, and hence
their contribution to bone regenerative processes. Detailed knowledge about
signaling mechanisms, will help to regulate the osteogenic signals in MSCs,
which will provide controlled mechanisms, for the designing cell-based tis-
sue engineering constructs. Fundamental screening of osteogenesis-related
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complete gene profiles could help to increase the quality of newly designed
biomaterials with superior performance in terms of osteoinductivity and os-
teogenicity. Fundamental knowledge about cell signaling mechanisms can
be effectively implemented in bone regenerative treatments, by incorporat-
ing signaling molecules via loading or via genetic modification of stem cells,
which will help to control cell-cell and cell-biomaterial interactions.
Subaim 2 (Chapter 3): To what extent do cell culture nutritional supple-
ments affect osteogenic differentiation of human BM-MSCs and AT-MSCs?
Based on the fact that cell culture nutritional supplements affect the in vitro
mineralization of MSCs [6], it become important to analyze the activation of
signaling pathways that promote the osteogenic differentiation of BM-MSCs
and AT-MSCs.
Chapter 3 we evaluated osteogenic mechanisms in BM-MSCs and AT-
MSCs, cultured with different nutritional supplements (i.e. platelet lysate
[PL] and fetal bovine serum [FBS]). The osteogenic differentiation and re-
lated gene expression profile of common osteogenic genes in different MSCs
(i.e. BM-MSCs and AT-MSCs) were the major focus of this study.
In view of mineralization, BM-MSCs showed a significantly higher calcium
deposition when cultured in FBS- compared to PL-supplemented media,
while AT-MSCs showed opposite results of mineralization i.e. high level of
mineralization in PL supplemented media. Gene expression results showed
that BM-MSCs in PL-supplemented medium highly express BMP2, BMP4,
Wnt1, Runx2, and osterix in contrast to AT-MSCs, which only highly ex-
pressed Runx2. Additionally, a high level of parallelism in BMP2, BMP4 and
Wnt1 gene expression was observed, irrespective of MSC origin or nutritional
supplement. The results of this study showed that (i) the osteogenic gene
expression profile is dependent on the origin of the MSCs and nutritional sup-
plements (i.e. FBS or PL), which differently affect cell signaling pathways
and related osteogenic differentiation, and (ii) AT-MSCs have high potential
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as an alternative to BM-MSCs in application of subsequent (pre-)clinical re-
search, because of their rapid proliferation and high mineralization capacity,
especially in PL supplemented media.
Subaim 3 (Chapter 4): How does co-culture of human AT-MSCs with en-
dothelial or hematopoietic cells affect osteogenic signaling and differentia-
tion?
Cell-based bone regeneration is generally pursued based on single cell type
approaches, for which MSCs are most frequently used. Because multiple cell
types are involved in physiological bone regeneration, including those related
to blood vessel formation and inflammation,
Chapter 4 we evaluated the osteogenic differentiation of AT-MSCs upon co-
culture with endothelial cells or macrophages in a direct or indirect in vitro
co-culture set-up. We assumed that (i) endothelial cells and macrophages
would stimulate AT-MSCs proliferation and osteogenic differentiation, and
that (ii) these two cell types will more profoundly affect osteogenic differen-
tiation of AT-MSCs in a direct compared to an indirect co-culture set-up,
because of the possibility for both cell-cell interactions and effects of secreted
soluble factors. The results of this study showed that the osteogenic differen-
tiation of AT-MSCs was indeed stimulated by endothelial cells, particularly
in the direct co-culture set-up. Although initial numbers of AT-MSCs in co-
culture with endothelial cells were 50% compared to monoculture controls,
equal levels of mineralization were achieved. In contrast to endothelial cells,
macrophages showed a variable effect on AT-MSCs behavior for indirect co-
cultures and a negative effect on osteogenic differentiation of AT-MSCs for
direct co-cultures, the latter most likely related to the difference in species
from which the cells derived. The results of this study demonstrated potential
for the use of cell-cell combination strategies in bone regenerative therapies
involving cell-based concepts.
Subaim 4 (Chapter 5): To what extent does the amount of HA nano-crystals
179
in a composite nHA/collagen hydrogel system affect the osteogenic differen-
tiation of different MSCs?
Hydrogels represent a versatile group of biomaterials with promising proper-
ties for bone regenerative research and therapy. Natural hydrogels (i.e. col-
lagen, fibrin) have the advantage of being non antigenic and having intrinsic
cellular interaction capacities. Toward biomimetic scaffold systems.
Chapter 5 is focused on the combination of collagen (COL) hydrogels with
nano-sized hydroxyapatite (nHA; Ca10(PO4)6(OH)2), to comparatively eval-
uate the in vitro effect of biomimetic nHA/COL based composite hydrogels
(with different ratios of nHA and COL) on the osteogenic differentiation
of human mesenchymal stromal cells (MSCs), isolated from either adipose
tissue (AT-MSCs) or bone marrow (BM-MSCs). We hypothesized that (i)
nHA/COL composite hydrogels will promote the osteogenic differentiation of
MSCs in an nHA concentration dependent manner, and that (ii) AT-MSCs
will show higher osteogenic potential compared to BM-MSCs, because of
their intrinsic higher proliferation and osteogenic differentiation potential in
2D in vitro cultures. The results indicated that AT-MSCs have high prolifer-
ation, differentiation and mineralization capacities in nHA/COL constructs,
irrespective of nHA concentration, whereas BM-MSCs only showed marginal
cell proliferation and osteogenic differentiation in all experimental nHA/COL
constructs. Based on the results of ALP activity and OCN protein level, the
osteogenic differentiation of BM-MSCs started in the beginning of the culture
period and for AT-MSCs at the end of the culture period. At a molecular
level, both cell types showed high expression of osteogenic markers (BMP2,
RUNX2, OCN or COL1) in both an nHA concentration and time dependent
manner. In conclusion, AT-MSCs demonstrated higher osteogenic potential
in nHA/COL based 3D micro-environments compared to BM-MSCs, in which
proliferation and osteogenic differentiation were highly promoted in a time
dependent manner, irrespective of nHA amount in the constructs. The fact
that AT-MSCs showed high proliferation and mineralization is appealing for
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their application in future pre-clinical research as an alternative cell source
for BM-MSCs.
Subaim 5 (Chapter 6): Do surface features of CaP-based ceramics affect cel-
lular organization and osteogenic differentiation of AT-MSCs?
With improved osteogenic capacity of AT-MSCs in HA/collagen based 3D
scaffolds (previous chapter)
Chapter 6 is focused on the evaluation of AT-MSC behavior on CaP ce-
ramic scaffolds either or not endowed with micro-scale surface features. In
brief, AT-MSCs were cultured on CaP disks featuring hemispherical concavi-
ties of various sizes (i.e. 440, 800 or 1800 µm diameter). It was hypothesized
that (i) surface concavities would promote cell proliferation, cellular organi-
zation within the concavities, and osteogenic differentiation, as a result of
a more pronounced 3D micro-environment and CaP nucleation in concav-
ities. MSC (ii) proliferation and osteogenic differentiation would increase
with smaller concavity size due to more rapidly occurring 3D cell-cell inter-
actions. We found that indeed, concavity size affects cell proliferation, i.e.
440 µm concavities significantly increased cell proliferation in comparison to
planar surface and to 800 and 1800 µm concavities. Additionally, concavity
size demonstrated to influence 3D cellular organization within the concavity
volume, because already after three days cells, in different size concavities,
were distributed differently, i.e. 3D-like manner in SC and MC, and 2D
monolayer on the in LC. This means that cells can recognize geometrical
properties of the surface and respond differently to their cellular organiza-
tion. Next, concavity size promoted osteogenic differentiation of cells, as
evidenced by increased osteocalcin gene expression in 440 µm concavities,
and exclusive osteocalcin staining for 440 and 800 µm concavities, but not
for 1800 µm concavities and planar surface controls.
‘
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Closing remarks and future perspectives
The research described in this thesis aimed to study cellular and molecular
aspects of the natural bone regeneration process and to create new concepts
in cell-based bone tissue engineering strategies for future application in bone
regenerative medicine. To achieve this goal, cellular and molecular aspects
of MSC osteogenic potential were analyzed.
Molecular analysis of MSCs from different origin (i.e. bone marrow and adi-
pose tissue), showed that the osteogenic gene expression profile is dependent
on the origin of MSCs and nutritional supplements, which can differently af-
fect signaling pathways and the subsequent cell proliferation and osteogenic
differentiation. This phenomenon of maximized mineralization capacity of
AT-MSCs in PL-supplemented and BM-MSCs in FBS-supplemented media
still remains elusive. Rapid proliferation and high mineralization activity of
AT-MSCs, especially in PL supplemented media, seems appealing for their
use in subsequent (pre-)clinical applications. AT-MSCs in the presence of en-
dothelial cells showed a positive effect in terms of osteogenic differentiation
and mineralization, which means that endothelial cells apparently interact
with AT-MSCs and promote their osteogenic differentiation via cellular cross-
talk and exchange of signaling molecules [7, 8]. The stimulated osteogenic
differentiation and mineralization of AT-MSCs makes co-culture systems at-
tractive for future (pre-)clinical work. The next step in the search to the
potential of co-culture systems will be the investigation of cell behavior in
3D scaffold systems, where cellular interaction can be analyzed in the pres-
ence of multiple cell types.
Further, our studies showed that AT-MSCs demonstrated enhanced osteogenic
potential in nano-HA/collagen based 3D hydrogel constructs compared to
BM-MSCs. Th observation fact that AT-MSCs demonstrated a higher pro-
liferation and mineralization profile can be used as an alternative cell source
for BM-MSCs. In addition, the studies indicated that this effect can be
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increased further by introducing concavities in the scaffold surface. A cor-
relation was found between concavity size, cell proliferation, cellular 3D or-
ganization and osteogenic differentiation. Evidently, AT-MSCs are able to
recognize the geometrical and chemical properties of the surface and respond
to these geometrical and chemical stimuli [9, 10].
In summary, current strategies in cell-based bone regenerative research are
not ideal yet, but tissue engineering approaches hold promise to achieve this
goal. Advanced bone tissue engineering requires consideration of many cru-
cial factors, including cellular behavior, cell-cell interaction, material prop-
erties, their proper interaction and controlled intracellular signals. Com-
plete screening of the molecular mechanisms (e.g. via microarray and RNA
sequencing), controlling cellular behavior and osteogenic differentiation of
MSCs will provide a closer look into their molecular machinery. This will
enable external control over cellular behavior (into osteogenic lineages) via
environmental changes, such as topography, 3D cellular scaffolding or influ-
ence with other cell types. However, after each change of external stimuli,
cellular behavior needs to be analyzed at the molecular level to understand
possible changes in osteogenic signaling pathways. With controllable cel-
lular behavior, it would be possible to modify or develop new engineered
tissue constructs (using collagen in combination with other macro-molecules,
HA nano-crystals, inorganic elements which are present in bone), which can
more closely mimic the bone micro-environment. To analyze cell-cell, cell-
biomaterial 3D interaction in the same construct, different cell types, as
co-culture system, can be encapsulated in new engineered construct. How-
ever, these in vitro observations do not warrant successful translation into
(pre-)clinical work. The biological response to new engineered constructs at
the cellular as well as molecular level need to be analyzed an in vivo level,
in order to understand and to control osteogenic signals in the living organ-
ism, where many factors (such as blood supply, interaction of different cell
types, immunological response) are influential. Better understanding of in
vivo biological response to new engineered constructs will help to improve
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their structure for future (pre-)clinical applications.
7.1 Samenvatting, Eindopmerkingen en
Toekomstperspectieven
Als een gevolg van de steeds ouder wordende populatie, zijn gezondheidszorg
professionals steeds op zoek naar nieuwe of verbeterde behandelingsmetho-
den om een variteit aan medische problemen aan te pakken. Een voorbeeld
daarvan zijn de genetische botziekten, de botziekten die ontstaan tijdens de
ontwikkeling en de traumatische botproblematiek [1]. The uitdaging in de
behandeling van botdefecten is het vinden van een technologie die het gebruik
van autoloog bot kan vervangen. In deze context, hebben specialismen bin-
nen de gebieden van weefselontwikkeling en regeneratieve geneeskunde, welke
beiden als doel hebben om beschadigd weefsel te vervangen, hoge verwachtin-
gen geschapen [2]. Weefselontwikkelingsstrategien combineren de kennis van
(stam)celbiologie en de ontwikkeling van biomaterialen. De belofte om stam-
cellen te gebruiken binnen de weefselregeneratieve geneeskunde is aantrekke-
lijk, echter blijft de precieze aanpak om stamcellen te implementeren in weef-
selregeneratieve methoden onduidelijk. Karakterisatie van volwassen stam-
cellen in de vorm van mesenchymale stromale cellen (MSCs) of pericyten
[3], gesoleerd uit verschillende weefsels, bijvoorbeeld beenmerg en vetweefsel,
toonden verwachtingsvolle toekomstperspectieven op het gebied van botweef-
selontwikkeling en binnen de regeneratieve geneeskunde. Echter, tot op
heden gaat de progressie van op MSCs gebaseerde therapien tot aan klin-
ische toepassing nog langzaam [4]. Verwacht wordt, dat doormiddel van het
begeleiden van de activatie van adequate osteogene signalen in deze stam-
cellen, en het combineren van deze stamcellen met een gedegen ontwikkeld
biomaterial, een effectieve bijdrage kan worden geleverd aan de botregen-
eratieve geneeskunde [5] . Dit proefschrift heeft als doel het evalueren van
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specifieke cellulaire en moleculaire aspecten van cel-cel en cel-biomateriaal in-
teracties voor toepassing in de ontwikkeling van weefsel. In detail ligt de focus
van de onderzoeken binnen dit proefschrift op het effect van MSC afkomst,
toevoeging van voedingsstoffen aan het celkweek medium, eigenschappen van
de biomaterialen en co-kweek met angiogene of hematopotische cellen op het
gedrag en de osteogene differentiatie van MSCs. Op basis van de specifieke
doelen van dit proefschrift worden hieronder de belangrijkste resultaten per
hoofdstuk samengevat:
Hoofdstuk 1 geeft een korte introductie ten aanzien van botweefsel re-
generatieve strategien, voornamelijk cel-cel en cel-biomateriaal strategien,
hun klinische relevantie en de wetenschappelijke prestaties op dit gebied tot
op heden. Elk volgend hoofdstuk bespreekt een afzonderlijke studie. Deze
samenvatting richt zich met opeenvolgende deeldoelen tot het uiteindelijke
hoofddoel beschreven in het eerste hoofdstuk:
Deeldoel 1 (Hoofdstuk 2): Welke signalerings routes zijn betrokken bij de os-
teogenese en hoe kan de kennis van deze signalerings routes toegepast worden
om het succes van botregeneratieve geneeskunde te verbeteren?
Hoofdstuk 2 geeft een review op basis van de wetenschappelijke literatuur
betreffende de verschillende signalerings routes die betrokken zijn bij osteo-
gene differentiatie van MSCs/osteogenese en hun potentie om gebruikt te
worden in botregeneratieve behandelingen. MSCs spelen een cruciale rol in de
natuurlijke botregeneratie en in het remodelleringsproces, waarbij gedurende
dit proces hun differentiatie wordt gereguleerd door specifieke signalerings
routes. Begrip van deze moleculaire mechanismen zal een cruciaal punt zijn
in de ontwikkeling van botregeneratieve behandelingen. Verschillen in celk-
weekprotocollen, eigenschappen van biomaterialen en interacties met resi-
dente cellen zal leiden tot veranderingen in het gedrag van MSCs, osteogene
differentiatie, en als een resultaat in hun bijdrage aan het botregeneratieve
proces. Gedetailleerde kennis van signaleringsmechanismen, zal bijdragen
aan het reguleren van osteogene signalen in MSCs, wat zal leiden to gecon-
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troleerde mechanismen, voor het ontwikkelen van op cellen gebaseerde weef-
selconstructies. Fundamentele screening van osteogenese-gerelateerde, com-
plete genprofielen kunnen bijdragen aan een toename van de kwaliteit van
nieuw ontwikkelde biomaterialen met een superieure prestatie op het gebied
van osteoinductiviteit en osteogenese. Fundamentele kennis van celsigna-
leringsmechanismen kunnen effectief gemplementeerd worden in botregener-
atieve behandelingen, door middel van het incorporeren van signaalmoleculen
via lading of via genetische modificatie van stamcellen, wat zal bijdragen aan
het cotroleren van cel-cel en cel-biomateriaal interacties.
Deeldoel 2 (Hoofdstuk 3): In hoeverre benvloeden de voedingssuplementen in
celkweken de osteogene differentiatie van humane BM-MSC’s en AT-MSC’s?
Uitgaande van het feit dat voedingssuplementen in celkweken de in vitro min-
eralizatie van MCS’s benvloeden, is het belangrijk geworden de activatie van
signaleringsmechanismen die osteogene differentiatie van BM-MSC’s en AT-
MSC’s bevorderen, te analyseren.
In Hoofdstuk 3 is de osteogene differentiatie van BM-MSC’s en AT-MSC’s,
gecultiveerd met verschillende voedingssupplementen (d.w.z. plaatjes lysaat
[PL] en foetaal serum van bovine origine [FBS]) gevalueerd. De osteogene
differentiatie en gerelateerde genexpressie profielen van de veelvoorkomende
osteogene genen in de verschillende MSC’s (d.w.z. BM-MSC’s en AT-MSC’s)
waren hoofdfocus van deze studie. Met betrekking tot de mineralizatie, toon-
den BM-MSCs een significant hogere calciumdepositie wanneer gekweekt in
FBS- in vergelijking tot PL-media, terwijl AT-MSC’s tegenovergestelde re-
sultaten lieten zien, d.w.z. een hoger niveau van mineralisatie in de PL-
gesupplementeerde media. Resultaten van onderzoek naar genexpressie toon-
den dat BM-MSC’s in PL-gesupplementeerde media een hoge expressie hebben
van BMP2, BMP4, Wnt1, Runx2 en osterix in tegenstelling tot AT-MSC’s,
welke alleen een hoge expressie lieten zien van Runx2. Bovendien, werd
een hoog niveau van parallelisme gezien van BMP2, BMP4 en Wnt1 genex-
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pressie, onafhankelijk van de origine van de MSC of van het voedingssup-
plement. De resultaten van deze studie laten zien dat (i) het osteogene
expressie profiel afhankelijk is van de origine van de MSC’s en de voed-
ingssupplementen (d.w.z. FBS of PL), welke de cel signaleringsroutes en de
gerelateerde osteogene differentiatie op een verschillende manier benvloeden,
en (ii) dat er een hoge verwachting is van AT-MSC’s als alternatief voor
BM-MSCs wanneer toegepast in (pre-)klinisch onderzoek, vanwege de snelle
proliferatie en hoge mineralisatie capaciteit van AT-MSC’s, met name in de
PL-gesupplementeerde media.
Deeldoel 3 (Hoofdstuk 4): Hoe benvloedt co-celkweek van humane AT-MSC’s
met endotheelcellen of hematopotische stamcellen de osteogene signalering en
differentiatie?
Op cellen gebaseerde botregeneratie is in het algemeen gebaseerd op toepassin-
gen met enkele cell types, waarbij MSC’s het meest gebruikt worden. Omdat
echter meerdere cel types betrokken zijn bij de fysiologische botregeneratie,
waaronder ook de cel types gerelateerd aan vaatformatie en inflammatie, werd
in Hoofdstuk 4 de osteogene differentiatie van AT-MSC’s in co-celkweek
met endotheelcellen of macrofagen in een directe of indirecte in vitro co-
celkweek opzet gevalueerd. We veronderstelden dat (i) endotheelcellen en
macrofagen de proliferatie en osteogene differentiatie van AT-MSC’s zouden
stimuleren, en dat (ii) deze twee cel types duidelijker de osteogene differenti-
atie zouden benvloeden in een directe co-celkweek opzet dan in een indirecte
co-celkweek opzet, vanwege de mogelijkheid voor zowel cel-cel interacties als
effecten op de gesecreteerde oplosfactoren. De resultaten van deze studie
tonen aan dat de osteogene differentiatie van AT-MSC’s inderdaad werd ges-
timuleerd door endotheelcellen, met name in de directe co-celkweek opzet.
Ondanks dat het initile aantal AT-MSC’s in de co-celkweek met endotheel-
cellen 50
Deeldoel 4 (Hoofdstuk 5): In hoeverre benvloedt de hoeveelheid HA nano-
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kristallen in een nHA-collageen hydrogel systeem de osteogene differentiatie
van de verschillende MSC’s?
Hydrogels vertegenwoordigen een veelzijdige groep van biomaterialen met
veelbelovende capaciteiten voor onderzoek naar botregeneratie en therapie.
Natuurlijke hydrogels (d.w.z. collageen, fibrine) hebben het voordeel dat
ze niet antigeen zijn en intrinsieke cellulaire interactie capaciteiten hebben.
Ten aanzien van biomimetische scaffold systemen, focust Hoofdstuk 5 op de
combinatie van collageen (COL) hydrogels met nano hydroxyapatiet (nHA;
Ca10(PO4)6(OH)2), om het in vitro effect van biomimetische nHA/COL
hydrogels (met verschillende ratio’s van nHA en COL) op de osteogene dif-
ferentiatie van humane mesnechymale stromale celeln (MSC’s), geisoleerd
uit of vetweefsel (AT-MSC’s) of beenmerg (BM-MSCs) vergelijkend te kun-
nen evalueren. De hypothese was dat (i) nHA/COL hydrogels de osteogene
differentiatie van MSC’s zouden promoten afhankelijk van de nHA concen-
tratie, en dat (ii) AT-MSC’s een hogere osteogene potentie zouden laten zien
in vergelijking tot BM-MSC’s, vanwege de hogere intrinsieke proliferatie en
osteogene differentiatie potentie in 2D in vitro celkweken. De resultaten
indiceerden dat AT-MSC’s over hogere proliferatie, differentiatie en mineral-
isatie capaciteiten beschikken in nHA/COL constructies, onfahankelijk van
de nHA concentratie, terwijl BM-MSC’s alleen een marginale cel prolifer-
atie en osteogen differentiatie lieten zien in alle experimentele nHA/COL
constructies. Gebaseerd op de resultaten van ALP activiteit en OCN eiwit-
niveua, begon de osteogene differentiatie van BM-MSC’s in het begin van de
celkweek periode en voor AT-MSC’s aan het einde van de celkweek periode.
Op moleculair niveau toonden beide cel types een hoge expressie osteogene
markers (BMP2, RUNX2, OCN of COL1), zowel afhankelijk van de nHA
concentratie als tijdsafhankelijk. Concluderend laten AT-MSC’s een hogere
osteogene potentie zien in op nHA/COL gebaseerde 3D micro-omgevingen
in vergelijking tot BM-MSC’s, waarbij proliferatie en osteogene differentiatie
zeer bevorderd werden door de tijd, onafhankelijk van de hoeveelheid nHA
in de constructies. Het feit dat AT-MSC’s een hoge proliferatie en mineral-
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isatie laten zien maakt AT-MSC’s interessant voor toepassing in toekomstig
pre-klinisch onderzoek als een alternatieve cel bron voor BM-MSC’s.
Deeldoel 5 (Hoofdstuk 6): Beinvloeden oppervlakte eigenschappen van CaP
keramieken de cellulaire organisatie en osteogene differentiatie van AT-MSC’s?
Hoofdstuk 6: Met het oog op de verbeterde osteogene capaciteit van AT-
MSC’s in HA /collageen 3D scaffolds (voorgaand hoofdstuk), focust hoofd-
stuk 6 op de evaluatie van het gedrag van AT-MSC’s op CaP keramieken scaf-
folds met of zonder micro-geschaalde oppervlakte eigenschappen. In het kort:
AT-MSC’s werden gekweekt op CaP schijfjes met verschillende grootte hemis-
ferische concaviteiten (d.w.z. 440, 800 of 1800 m in diameter). De hypothese
luidde dat (i) oppervlake concaviteiten de cel proliferatie, cellulaire organ-
isatie in de concaviteiten en osteogene differentiatie zouden bevorderen, als
een resultaat van een meer geprononceerde 3D micro-omgeving en CaP nu-
cleatie in de concaviteiten en dat (ii) met kleinere concaviteiten de MSC pro-
liferatie en osteogene differentiatie zouden toenemen ten gevolge van snellere
3D cel-cel interacties. We vonden inderdaad dat de grootte van de con-
caviteiten de cel proliferatie beinvloedt, d.w.z. concaviteiten met een grootte
van 440 m verhoogden significant de cel proliferatie in vergelijking tot vlakke
oppervlakten en in vergelijking tot concaviteiten met een grootte van 800 en
1800 m. Ook werd aangetoond dat de grootte van de concaviteiten de 3D cel-
lulaire organizatie in het concaviteiten volume benvloedde, omdat al na drie
dagen, cellen in verschllende grootte concavitetien, verschillend waren gedis-
tribueerd, d.w.z. op een 3D manier op SC en MC en in een 2D monolaag
op LC. Dit betekent dat cellen geometrische eigenschappen op de opper-
vlakte kunnen herkennen en verschillend kunnen reageren ten aanzien van
hun cellulaire organizatie. Ten tweede werd aangetoond dat de grootte van
de concaviteiten de osteogene differentiatie van cellen beinvloedt, als bewezen
door een verhoogde genexpressie van osteocalcine bij de 440 m concaviteiten
en exclusieve osteocaline kleuring bij de 440 en 800 m concaviteiten, maar
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niet bij de 1800 m concaviteiten en de vlakke oppervlakten.
Eindopmerkingen en toekomstperspectieven Het onderzoek beschreven in dit
proefschrift doelde op het bestuderen van cellulaire en moleculaire aspecten
van de natuurlijke botregeneratie processen en om nieuwe concepten te cr-
eren op het gebied van op cellen gebaseerde botweefsel ontwikkelingsstrate-
gien voor toekomstige toepassing in de botregeneratieve geneeskunde. Om
dit doel te bereiken, werden de cellulaire en moleculaire aspecten van de os-
teogene capaciteit van MSC’s geanalyseerd. Moleculaire analayse van MSC’s
van verschillende origine (d.w.z. beenmerg en vetweefsel), toonde dat het
osteogene genexpressie profiel afhankelijk is van de afkomst van de MSC’s
en van de voedinssupplementen, welke op een verschillende manier de sig-
naleringsroutes en opeenvolgend de celproliferatie en osteogene differenti-
atie kunnen benvloeden. Dit fenomeen van gemaximaliseerde mineralisatie
capaciteit van AT-MSCs in PL-gesupplementeerde en BM-MSC’s in FBS-
gesupplementeerde media blijft tot op heden onvatbaar. Snelle proliferatie
en hoge mineralisatie activiteit van AT-MSC’s, met name in PL- gesupple-
menteerde media, lijkt aantrekkelijk voor gebruik in opeenvolgende (pre-)
klinische toepassingen. In de aanwezigheid van endotheelcellen laten AT-
MSC’s een positief effect zien ten aanzien van osteogene differnentiatie en
mineralisatie, wat betekent dat endotheelcellen blijkbaar interactie vertonen
met AT-MSC’s en hun osteogene differentiatie bevorderen middels cellulaire
cross-talk en middels uitwisseling van signaleringsmoleculren [1, 2]. De stim-
ulatie van de osteogene differentiatie en mineralisatie van AT-MSC’s zorgt
ervoor de co-celkweek systemen aantrekkelijk zijn voor toepassing in toekom-
stig (pre-)klinische werk. De volgende stap in de zoektocht naar de potentie
van co-celkweek systemen zal zijn het onderzoeken van gedrag van cellen in
3D scaffold systemen, waarbij de cellulaire interactie kan worden geanaly-
seerd in de aanwezigheid van meerdere cel types.
Verder toonden onze studies dat AT-MSC’s een verbeterede osteogene ca-
paciteit hebben in op nano-HA/collageen gebaseerde 3D hydrogels, in vergeli-
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jking tot BM-MSC’s. De observatie dat AT-MSC’s een hoger proliferatie en
mineralisatie profiel laten zien, betekent dat zij gebruikt kunnen worden als
alternatieve cel bron voor BM-MSC’s. Daarbij indiceren deze studies dat
dit effect verder kan toenemen door het toevoegen van concaviteiten aan de
oppervlakte van de scaffold. Een correlatie werd gevonden tussen de grootte
van de concaviteiten, celproliferatie, cellulaire 3D organisatie en osteogene
differentiatie. Klaarblijkelijk zijn AT-MSC’s in staat de geometrische en
chemische eigenschappen van de oppervlakte te herkennen en te reageren op
deze geometrische en chemische stimuli [1, 2]. Samenvattend zijn de huidige
strategien in op cellen gebaseerde botregeneratief onderzoek nog niet ideaal,
maar zijn weefselontwikkeling benaderingswijzen veelbelovend om dit doel te
bereiken. Vooruitstrevende botweefselontwikkeling vereist het in ogenschouw
nemen van vele cruciale factoren, inclusief cellulair gedrag, cel-cel interactie,
materiaal eigenschappen, hun gepaste interactie en gecontroleerde intracel-
lulaire signalen. Complete screening van moleculaire mechanismen (bijv.
via microarray en RNA sequencing), het controleren van cellulair gedrag en
osteogene differentiatie van MSC’s zal een beter beeld geven van de molecu-
laire machine. Dit zal controle van cellulair gedrag via veranderingen van de
omgeving, zoals topgrafie, 3D cellulaire scaffolding? of invloed van andere
celtypes, mogelijk maken. Echter, na elke verandering van externe stimuli
zal cellulair gedrag geanalyseerd moeten worden op moleculair niveau, om
mogelijke veranderingen in osteogene signaleringsroutes te begrijpen. Wan-
neer controleerbaar cellulair gedrag mogelijk is, is het ook mogelijk om weef-
selconstructies (waarbij collageen gebruikt wordt in combinatie met ander
macro-moleculen, HA nano-kristallen, inorganische elementen die aanwezig
zijn in bot) aan te passen of the ontwikkelen die de micro-omgeving van
bot beter kunnen imiteren. Om cel-cel, cel-biomateriaal en 3D interactie in
dezelfde constructie te kunnen analyseren, kunnen veschillende celtypes, als
co-celkweek systeem, ingegoten worden in een nieuw ontwikkelde constructie.
Echter, deze in vitro observaties garanderen geen succesvolle translatie tot
(pre-)klinisch werk. De biologische reactie op nieuw ontwikkelde construc-
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ties op zowel cellulair als moleculair niveau dient te worden geanalyseerd in
vivo, om osteogene signalen in een levend organisme te kunnen begrijpen
en controleren, waarbij vele factoren (zoals bloedvoorziening, interactie van
verschillende cel types, immunologische reactie) van invloed zijn. Een beter
begrip van de in vivo biologische reactie op nieuw ontwikkelde constructies
zal bijdragen aan het verbeteren van hun structuur voor toekomstige (pre-)
klinische toepassingen.
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